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SYNTHESIS OF MESO IONIC NUCLEOSIDES AS POTENTIAL ANTINEOPLASTIC AGENTS. 
Shanaz H. Tejani, P h.D., Nedical College of Virginia, Virginia C01Il!non­
wealth University, 1983. 
Advisor: Dr. R. A. Glennun 
During the past few decades, analogs of purine nucleosides have 
been described that are modified either in the heterocyclic base� sugar 
moiety or both, and many of these modified nucleosides display antivi-
ral and/or antineoplastic activity. The Class II meso ionic purinones 
are isosteric with their non-meso ionic purinone counterparts. It is 
conceivable that the mesoionic purinone nucleosides might constitute an 
entirely novel class of modified nucleosides vlith potential chemothera-
peutic activity. That the meso ionic heterobases are bioisosteric as 
well as isosteric \vith non-mesoionic purinones was realized by demon-
strating that certain mesoionic xanthine derivatives, sueh as Anhydro-
8-ethyl-5-hydroxy-7-oxo-l,3,4-thiadiazolo[3,2-a]pyrimidinium hydroxide 
and Anhydro-6-p-chlorobenzyl-8-ethyl-5-hydroxy-7-oxo-l,3,4-thiadiazolo 
[3,2-a]pyrimidinium hydroxide were comparable in potency to test com-
pound, theophylline as inhibitors of adenosine binding at the Al site. 
Three different types of meso ionic nucleosides vlere subsequently 
designed and synthesized as potential antineoplastic agents. Mesoionic 
thiadiazolopyrimidine nucleosides, i.e. Anhydro-6-ethyl-8-(2',3',5'-tri-
O-acetyl-D-ribofuranosyl)-5-hydroxy-7-oxo-l,3,4-thiadiazolo[3,2-a)pyri-
midinium hydroxide and Anhydro-8-(2',3',5'-tri-O-acetyl-D-ribofuranosyl) 
-5-hydroxy-7-oxo-l,3,4-thiadiazolo[3,2-a]pyrimidinium hydroxide were de-
xiii 
signed to serve as potential pro-drugs of 2-amino-I,3,4-thiadiazole 
mononucleotid e which has been reported to be a potent inhibitor of ino­
sine monophosphate dehyd rogenase. The O-ac ylated derivatives of the 
target compound s were prepared by the acid catalyzed condensation of 
D-ribose with 2-ATD followed by protection of the hydroxyl groups and 
subsequent cyclization to the meso ionic produ�ts; anomeric separation 
was achieved by column chromatography. All attempts to deprotect the 
hyd roxyl groups of the meso ionic nucleosid es resulted in hydrolytic 
ring-opening of the mesoionic heterobase. The O-ac etyl derivatives of 
the meso ionic thiadiazolopyrimidine nucleosid es were evaluated for anti­
neoplastic ac tivity but were found to be inac tive. The meso ionic thia­
zolinopyrimid ine nuc leoside, i.e. Anhydro-6-ethyl-8-(D-2'-deoxyribo­
furanosyl-5-hydroxy-7-oxo-2,3-dihyd rothiazolo[3,2-a]pyrimid inium hydrox­
id e, prepared in a similar fashion to the mesoionic thiadiazolopyrimi-· 
dine nuc leosid es, was designed as a potential inhibitor of the enzyme 
thymidylate synthetase. The Inesoionic thiazolinopyrimidine nucleoside, 
was obtained as the a. anomer and was not evaluated for antineoplastic 
activity. The mesoionic imidazothiazine nucleoside, i.e. Anhydro-l­
(2',3' ,5'-tri-O-ac etyl-D-ribofuranosyl)-5-hyd roxy-7-oxoimid azo[2,1-b] 
thiazinium hyd roxid e was prepared as a potentially useful agent, due to 
its structural and isosteri.c similarity w·ith purine nuc leosides. The 
mesoionic imid azothiazine nucleoside \.;ras prepared by a cyclization re­
action between the tri-O-ac etyl-D-ribofuranosyl imidazole-2-thione and 
carbon suboxid e. The meso ionic imidazothiazine nucleosid e \vas not sta­
ble at room temperature or in aqueous solution. \.Jhile the results of 
this study on the chemotherapeutic utility of meso ionic nucleosides was 
rather discouraging, knowled ge has been gained that might be of value 
\. 
xiv 
for the future design and synthesis of useful mesoionic nucleosides. 
xv 
I. INTRODUCTION 
Nucleic acid molecules can be envisioned as polymers constructed 
from four major nucleoside components; adenosine, guanosine, cytidine 
and uridine make up the ribonucleic acid (RNA) polymer and deoxyadeno­
sine, deoxyguanosine, deoxycytidine and thymidine make up the deoxyri­
bonucleic acid (DNA) p olymer . The basic structures of these individual 
nucleosides can be modified at specific locations by addition or substi­
tution of various groups, and such naturally occurri.llg structural modi­
fications are referred to as minor, odd or rare nucleosides (1). 
These are not the only knmm modified nuc leosides. During the past 
few decades, a.na1ogues of purine nucle osides have been described that 
are modified either in the hete rocyclic base or sugar moiety or both, 
and a large number of these modified nucleosides have generated a great 
deal of interest. Recently, modifiednucleosides with interesting anti­
viral and antineoplastic activity have been reported. 
Nucleoside antibiotics are another diverse group of modified nuc1e­
osides that are structurally similar to the purine a1.1d pyrimidine 
nucleosides, and have aided in studying complex processes such as RNA 
and DNA biosynthesis, and enzymatic mechanisms. Certain antimetabo­
lites a re also considered as modified nucleosides; hecause of their 
structural resemblance to purine and pyrimidine nucl.eosides and nuc1eo­
tides, they have been useful as structural analogs �n biological sys� 
terns. For example, the antineoplastic agent 7-deazainosine has been 
reported to inhibit the ribophosphorylation of ino'sine and adenosine, 
and thus serves as an antimetabolite (2). 
1 
In recent years, there has b een increased interest in modified 
nucleosides in which the sugar moie ty is attache d at the N3 position of 
the p urine ring. Thes e nucleos ides are nmv commonly called "isopurinel1 
nucleosides. Interest in isopurine nucleosides was st imula t e d  when 
�orrest et aI, in 1961, isolate d  3-ribosyluric acid and the corr e spond­
ing nucleotide from b eef erythrocytes. The isopurine nucleosides can 
be envisioned as being bicyclic nuc leo sides with the ribo furano sy1 
moiety residing in the pyrimidine ring; some of these modified nuc1eo­
sides have been reported to exhibit interesting biological a ctivity such 
as an tiviral and antitumor properties . 
Coburn et a1 (3-6) and Glennon et al (7-1 1) have reported that mes­
oionic purinones bear an isosteric rel at ionsh ip with non-mesoionic puri­
nones, hence, it might be intere s t ing to investigate me soionic purinone 
nuc1eoside s .  Mesoionic nucleosides may be envisioned as a novel elass 
of modified nucleosides that show struc tural and isost:eric similarity 
to other chemotherapeutically useful nu cleoside s and� thus , may serve as 
potentially useful chemothe rapeutic a gents. 
2 
II. BACKGROUND 
A. Five�Membered Ring Me soionic He t erocycles 
In 1949 , B aker and Ollis (12) rec ognized that N-phenylsydnone could 
only b e  rep resen ted as a resonance hybrid of s everal dipolar canonical 
forms (Fig 1) , and the term l'me soion iclt was suggested by Bake r et al 
(13) t o  des crib e  this type of he tero cycle. Although the name I'sydnone" 
has nearly be come s ynonymous with l'mesoionicl', there are, in fact, num-
Figure 1: Resonance hybrid structures for N-phenylsydnone. 
erQu.s five�membered ring JIlesoionic he t e ro cy cles. The chemistry of these 
me soion i c  he terocycles has b e en the subje c t  of several reviews (14-16). 
In 1975, Ollis and Rams den (15) re-de fine d a mes oionic compound a s  fo1-
lows: "A compound may b e  appropria t ely c alled mesoionic if it is a 
five-JIlembered heterocycle ,·rhich cannot be r epresented sa tisfactorily by 
any one covalent or polar st ructure and possesses a sextet of electrons 
in ass o c iation with the five atoms compris ing the ring," The (+) 
(F ig 2) symbolizes a delocalizat ion of �-ele c trons within an electron-
deficien t heter ocyclic ring; this is balanced by an ele ctron-rich exo-
cyclic group. 
If the atoms a-f in the general stru cture below are chosen from 
3 
suitably substituted C,N,O or S atoms, then 228 different mesoionic ring 
Figure 2: General representation of a five-membered ring mesoionic 
heterocycle. 
systems can be formulated; of these , · 56 ring systems have been synthe-
sized (16). 
Mesoionic compounds have attracted the attention of many medicinal 
chemists. The first report that the sydnones might possess properties 
as amino acid antagonists was by Brookes et al (17) in 1957. A number 
of sydnones have been exa,.-uined for antitumor activity; for example, 
Daeniker and Druey (18) reported such activity for the ethylene homolo g 
l (n=2) , and Greco et al (19) reported carcinostatic activity in mice 
for 3-(4-methoxybenzyl)sydnone. There have also been several reports 
�o 
1 
that sydnone derivatives exert antibacterial, antimalarial, antiparasi� 
tic, antiinflammatory, analgesic and other biolo gical activities (20-
23). Sydnone derivatives have been incorporated into several penicil-
lins and cephalosporins (e.g. !:..a and 2b resp ectively) that exhibited 
4 
antistreptococcal and antistaphylococcal activities in vivo (24,25). 
Two sydnone imines, sydnofen (�a) and sydriocarb (�b) have undergone 
H H R1W+ CH2-CONH"f---Y=tS 
N8 - ,J-�-- ' o 0 eOOH 
2a 
�b 
clinical trials as antidepressants (26,27). Recently) a mesoionic 
1,3,4-thiadiazolidine-2--thione (LU2443) (�) has been reported to exhi-
bit antiepileptic activity (28) . Several older reviews describing the 
biological activities of various five-membered mesoionic heterocycles 
are available (16,29). 
Since the term "mesoionic" w'as coined, rapid progress has been made 
in heterocycl ic chemistry and several novel related ring systems have 
been reported; this has required a broader interpretation of the defini-
tion. According to Ollis and Ramsden (16), use of the term !'mesoionic" 
should be restricted to five-membered heterocyc les of the general type 








su ch a s ,.2. , for example, be called mesomeric betaines. 
5 
C oburn (3) ,however, had earlier extended the original. definition 
to include any hetero cycl i c  rin g  system which showed extensive 7r-elec-
tron delocalization and where no s ingle dipolar or covalent structure 
could be drawn to indicate true mol e cular s t ructure. Alt]lOu gh some in-
vestigators prefer to describe six�membered mesoionic compoun ds as mes-
omeric betaines (16,30,31).the exclusion o f six-membered! rings from the 
6 
defini t ion o f  "meso ionic" app ears unwarranted ( 3 2) . 
B .  S ix-Nemb e red Ring Nes o ionic Heter() cycles 
The fir s t  s ix-memb ered r ing mono cyclic mesoio n ic heterocyc le ( i . e .  
mes o ion ic 4 , 6-dioxopyrimidine .2) 'was rep orted by Kapp e e t  al ( 33) in 
19 71 ; P o t t s  e t  al ( 3 4 , 35) have also rep orted the syn thes is o f  s everal 
related derivatives . Mes o ionic 4 , 6-dioxo-l , 3-thiazines ( i . e . �a) ( 36)  
and mes oioni c  4 , 6-dioxo- l , 3- oxazines (�b) ( 3 7 , 3 8) (Fig . 3 ) have also been 
prep ared . The aza analog o f  l, i . e .  2, is als o known . None o f  the s e  
o 
&�R1 O���R , 2 
F igur e 3 :  General s tructures for mo no cyclic s ix-memb ered m e s o io n i c  
hetero c ycles . 
monocy clic s ix-membered ring heterocycles have been evalua ted fo r any 
b iol ogical ac t ivity ; ho'tvever , the chemis try o f  thes e  r in g  sy s tems has 
recen t ly been reviewed ( 3 2) . 
Ring-fus ed s ix-memb ered mes o ionic het e ro cy cl es have als o  been re-
p orted . Coburn e t  al (39)  rep o r ted the synthes is o f  s evera l mes o ion ic 
pyrida z inopyrimidines ,  !!..,a ,  and pyrida z inotriazines , 4b , which ,,,ere 
screened for ant ibacter ial act ivi ty . Greco e t  a 1  (40) des c r ib ed their 
e f fo r t s  to prepare examples o f  meso ionic pyrimido triazines , !!..,c ,  and 
thei r  mon othione derivatives . Po tts  et al ( 3 1) s tud i e d  the synthes is 
and reac t ions of mes o ionic pyridopyrimidines , !!..,d ,  and pyr imidopyr imi-
dines , 4e .  Kappe et a l  ( 4 1) prepared monocyclic , b icyc1 i c  and tricy-
c lic mes oionic 1 , 3- thiazine derivatives e . g .  !!..,f - 4 i .  Hagemann e t  a1 
( 42) rep orted the synthes is of a fused r ing derivative of mes o ion ic 
7 
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Figur e 4 ;  Examp l e s  o f  f u s ed s ix-m emb ered r ing meso ionic 
he t er o cy c l e s and r e l a t ed compound s . 
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1 , 3� thia z ine 2, i . e , 4j .  A numb er of mes o ion ic 1 , 3-oxa zine derivat ives 
such as 4k , �l ,  have been prep ared and their chemis try s tudied ( 37 , 3 8) . 
The s t ructu res o f  thes e s ix�memb ered mono , bi  and tricyc l i c  mes o io n i c  
he terocycle s  i s  shmvn i n  Figure 4 .  
In 19 7 5 , Coburn and cowo rkers ( 3 , 4 )  p os tula ted a hyp o the t i cal clas s 
o f  mes o ionic p urinones ; these s t ruc tures c an b e  either a f ive-memb ered 
mes o ionic heter ocyc le fused to a s ix-memb ered r ing , or a s ix-membered  
meso ion ic heterocyc le fused  t o  a f ive-memb ered r ing . S everal such r ing 
sys tems have now been syn thes ized . Thes e mes o ioni c purinones may be 
viewed as a sp e c ial typ e o f  fused five o r  s ix-membered mes o ion ic com­
pound , and vlil l  be discu ss ed in the f ol loHing s e c tion . 
C .  Meso ion ic Pur inones : General Introduc t ion 
C obura and cO\vorkers (3 , 4) repo r te d the formulat ion of a large clas s 
of mes o ionic he terocyc les that are isoelec tronic and is os teric with non­
mes o ionic purinones ; th es e mes oionic comp ounds have been formal ly 
divided into tHO cla ss es . Tho se  mes o ionic purin ones derived f rom a 
five-memb ered mes o ionic ring s tru c ture are referred to a s  Class I ,  while 
C la s s  II deriva t ives are derived f rom s ix-membe red r ing mes o ionics . The 
mes o ionic p urinone s  c an b e  fur ther divided into s everal sub c l as ses : 
meso ionic hyp oxanthine s ,  me s o ionic xanthines and mes o ionic 2-purinones 
(Fig 5) .  The atoms X ,  Y and Z can b e  varied amongs t C ,  N ,  0 and S s o  
long a s  the resul tant s t ructures p os s es s a � -electron sys t em that is 
isoelec tronic H ith that of the ir non-mes o ionic co unt e rp ar t .  In this 
way , ove r  one hundred meso ionic r ing sys tems can be theore ti cal ly con­
s truc ted that are isoelectronic w'ith the purinones .  
Mes o ionic compounds undoub tedly derive s ome o f  the ir s tab ili ty as a 
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F igur e 5 :  Meso ionic hypoxanthine (a , d ) , xanth ine (b , e) and 
2- pur inone ( c , f ) analo g s . 
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in s pe c t ion ,  i t  can b e  seen tha t s eve ral p o s s ib l e  res on ance hyb r i d s  can 
be drawn f o r  a C la s s  I mes o i onic hyp oxanthin e  an alo g  ( F ig 6)  and for a 
C la s s  I I  me s o ion i c  xan th ine anal o g  (Fig 7) . Thu s , i t  migh t b e  mis lead­
ing to dep i c t  the s e  s tructures as a s ingle d ip o lar en t i ty . S everal dif­
f er en t  me tho ds have now b e en emp loy e d  to des c rib e the s tru c ture s  o f  
the s e  c omp ounds . W i t h  res p e c t  t o  the C la s s  I mes o ion i c  hyp oxan t h ines , 
the s truc ture shmm. in F igure 8 a  is p erhap s the most c ommon ; however , 
thi s  s tru c ture fa ils to t ake in t o  ac count e le c tron del ocal i zat ion in the 
s ix-membered ring . Alterna t ive s tru ctures are tho s e  shown in F i gures 8b 
and 8 c . The Cla s s  II mes o io n i c  xan thine an alo gs have b een rep r e s en t e d  
as shown in F igu re 9 .  B e cause F igure s  Bc and 9c imp ly ar oma tic charac­
ter (which thes e comp o unds do d is p lay) , s ugge s t  e l e c t r on delo ca l iza t io n , 
and re adily iden t i fy and c ontra s t C la s s  I ve rsus Clas s  I I  analogs , s�ch 
s truc tural rep r e s en t ations will b e  us ed herein . 
B e f ore cont inuing , it should b e  mad e  clear that th ese mes o  ionic 
d e r iv a t ives are n o t  s a l t s ; they s imp ly s u f f e r  from our inab i l i ty t o  
s a tis f a c tor ily dep i c t  their s truc tures us ing s tand ard " cova len t" me th­
o d s . In f a c t , s ome o f thes e c ompo unds do exis t as the i r  c or r e s p ond ing 
s a l t s ; f o r  examp le s everal C la s s  I I  mes o i on i c  1 , 3-dialkylhypoxanthine 
deriva t ives have b e en p rep ared by treatmen t of 1 , 3-d ialkylhyp oxanthi­
n ium hal ides wi th base (43) , and guan o s ine can be methyla ted 'vith 
methyl iodide to a f f ord 7 -methylguan o s inium io d id e  ( 4 4) . Th is \v ill be 
discu s sed fur ther und er the app ropr i a t e  hea d ings . 
S ome of the mes o  ioni c hetero cycles t o  b e  d e s c r ibed bel ow p o s s e s s  
numb e r ing sys t ems tha t d if f er from tha t o f  pur in e . Fo r the s ake of 
s imp l ic ity and f or ease of dis cus s ion , the purine number ing sys tem will 
b e  used when dis cu ss ing the s e  hetero cycles in genera l ( as , f o r examp le , 
1 1  
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F igur e 6 :  R e s o n a n c e  s tr u c t ur e s  f o r  an exampl e o f  a Cl as s I 
meso io n i c  hypo xanthine analo g . 
1 2  







I I R R 
o 
O:C)) N ... I k R 
F igur e 7: Resonance structures f o r  an exampl e  o f  a Cl ass I I  
meso ionic xanthine analog .  
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Figur e 8 :  No t a t ions emp l o y ed to r epr e s en t  a C l a s s  I 
meso io nIc hypox an thine anal o g . 
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F igur e 9 :  No t a t ions empl o yed t o  r ep r e s ent a Cl a s s  I I  
m e s o  io nic �anth ine analo g .  
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in the B ackground s e c t ion) .  H owever , \vhen individual mes o ionic he t e r o­
cy cle s are des crib e d  or discus sed , the ir correct IUPAC numbering sy s tem 
\,1ill be used . 
Various mes o ion ic purine ring sys tems have been fo rmula ted and s tu­
d ie d  f rom a quantum chemical s tandp o int , but relatively f e\v comp ounds 
h.sv e b een p repared syn the t i ca lly ( 3 , 4) . In the C las s I hyp oxan th ine 
ana l ogs , the e le c tron den s i t ies on the t\vO n it r o gen a toms in the s ix­
memb ered r ing are nearly equal , while in the C la s s  I mes o ionic purin-2-
one analogs , the den s i ti e s  a t  N3 exceed tho s e  at Nl . In b o th c a s e s , 
the ele ctron dens ity on the exocyc l ic oxygen is increased  as compared t.o 
its non-meso ionic counterp ar t . In the Class I hyp oxan thine s er i e s , the 
p ur ine I-p os i t ion b e c omes ele c t ron r i ch ,  wh ile the p ur ine 8-p o s i t ion is 
e le c tron def i c ient . In b oth the Clas s I me so ion ic hyp oxan thine and 
pur in-2-one s e r i es , the s ix-memb ered r ing is ele c t ron r i c h  and the f ive­
membered ring is s trongly ele c tr on d e f ic ient . When the charge d en s i t ies 
of a C la s s  I xanthine ana log i s  c omp ared \vith xanthine , it is f o und 
that the s ix-memb ered ring in the me s o ion i c  series is only s l igh t ly el e c­
tron de f i cient , c ompare d t o  xanthine . 
Quan tum chemical s tudies have also been comp le ted on the Cla s s  I I  
ana lo gs and the ir electr onic s truc tur es have b een compared with tho s e  o f  
their covalen t  non-me s o ion i c  c oun terp a r t s  ( 4) . F o r  a l l  C lass I I  hyp ox­
an th ine ana logs , nucle oph ilic a t tack ,vas pred ic ted to o ccur a t  the 
purine 2-p osition , and e l e c t rophilic attack was p referred at e i ther the 
purine 7 ,  8 or 9-p os it ion ,  depending on the sub s tituen t s  p r e s ent . When 
compared with hyp oxanth ine , there is a s ign i f i cant in creas e in e l e c tron 
dens ity in the five-memb ered r in g  of the mes o ioni c  hyp oxan thine anal og . 
This is in dire c t  contras t with a C la s s  I hyp oxan thine in \vh ich the 
15 
f ive-membered ring is electr on-defi cient . 
With Cla s s  II purine-2-one anal ogs , nucleophilic at tack 'va s predict­
ed t o  occur a t  the purine 6-·p o s i t ion and elec trophili c  a t tack wa s p r e­
d ic ted to o c cur a t  the purine 3-p o s it ion in mo s t  cas e s , The Class I I  
p urine-2-ones show very s imilar p suedo carb onyl charge dens it ies and bond 
orders when compared to the ir c ovalent ana logs . 
Comp ari son o f  the quantum chemical s tudies comp leted  on C la s s  I I  
mes o ionic xanthine analogs t o  xanthine i t s e lf has r evealed s everal com­
mon features ; nucleophill,c attack wa s p redic ted to o c cur at the t\vO 
psuedocarbonyl group s  and electr oph ilic a t tack was predicted t o  take 
p lace at the purine I-pos i tion . The results of these s tud ies indica te 
the close s imilar i t ies  in ground s t a te p roper t ies of thes e mes oionic 
analog s and the purinones themse lves .  In addit ion , with re s pe c t  to any 
ant icip ated b io chemi cal p rope r t ie s  of thes e mes o :i.oni c  analogs . i t  migh t  
be exp e c ted that the general increas e  in e le c tron a f f inity may be o f  
imp o r t ance . espe cially s ince the na tura l ly occurring purinones f unc t ion 
as elec tron ac cep tors during nuc leic a c id bas e inte rac tions in b iol ogi­
cal sys tems . 
D .  Nucleos ides and Mod if ied Nucleos ides 
The term P nu cleos ide" . intro duced by Levene and Jacob s  in 1909 ( 45 ) , 
wa s or iginal ly app l ied t o  the purine-c arbohydrate d e r ivatives i s ola ted 
from alkal ine hydrolysa tes of yeas t r ibonuc leic ac id s . Even though the 
term nucleos ide , in the s tricte s t  sens e , is reserved fo r g lyco syl 
purines and pyrimidines derived from nucleic acids , it ha s now g radually 
come to inc lude bo th natura l  and synthetic glycosy l  amin e s  ill which the 
amine is a heterocyc l ic base . 
There are f our kinds of  known nucleo s ides : N-glycos ides ,  C-glyco-
1 6  
s ides and S- o r  O-glyco s ides ( 4 6 ) . The mo s t  common are the N-g l yc o s id e s  
i n  which the D-r ib o s e  o r  D-2 ' -deoxyrib o s e  is a t t ached through C I ' t o  
either a purine or pyr imidine b a s e . In the ca se of C-glyco s i d e s , the 
sugar is  a t t ached t o  a he t ero cyc l ic base via a C-C bond , \-lhil e  an 0 or 
S-glyc o s ide has t h e  sugar mo iety connec t ed t o  the he t erocyc l ic base b y  
an O-C bond o r  a S - C  b o nd , re s p e c t ively . S t ru c ture s o f  a ll four kind s 







F igur e  1 0 :  Examp l e s  o f  an N-glyc o s id e  ( a ) , C-glyco s id e  ( b ) , 
O-glyco s ide (c ) , and S-glyc o s ide ( d ) . 
Cons iderable e f fort ha s b een d ir ect ed toward s  the synthes i s  o f  nu-
cleo s i d e s , par t ly a s  a compl ementary method to degradation studies t o  
help elucidate s t ructur e s  o f  naturally o c cu r r ing c ompound s , and also 
partly t o  p rov id e analogs for t h e  interpre t a t ion of b io log ica l action 
in terms of chemic al s t ructure . Recentl y ,  isolat io n  of  nucle o s id e  ant i-
b io t ic s  a s  wel l as abnormal o r  "mod if ied" nucleosides as p o t ent ial che-
1 7  
mo therap eu t ic agen t s  ag a ins t neo p las t ic d is eases has in tens ified this 
e f f o r t  and has led to d evel opment of me tho d s  by which many nucle os ides 
may be synthe s i z e d . The s e  metho d s  fall into three genera l  cla s s es : 
1) a p r e f ormed h e t er oba s e  is treated wi th a pro te c ted or unpro t e c t ed 
sugar . 
2 )  elab orat ion o f  a N.,-g ly co sy l p r e cu r s o r . 
3) nlOdif i cat ion of a p refo rme d nucleo s ide e ither in the s ugar moie ty 
or the heterobase . Several reviews have covered in de tail the conven-
tional metho d s  of pur ine nu cleo s ide syn the s is ( 47-4 9 ) . T o d ay rqo s t  pyr i-
mid ine nu cle os id es and s ome purine nucleos ides are almos t exc lus ively 
p rep ared us ing the Vorb r�ggen mod i f icat ion ( 50-5 2)  o f  the H ilbert 
Johnson procedure ( 53) .  A r eview by D ekker and Goo dman (49) summa r i zes 
nucl e o s ide chemi s try thr ough 19 70  and a r eview by Wa lker and coworkers 
( 5 4)  dis cus s e s the syn thes is and chemic al reac t ions o f  nu cleos id e s  
� 
through 19 7 9 . B e s ides these , s eve ra l o ther re feren c e s  and textbooks 
are ava ilable on the s ubj e·c t  of nu c l eo s i de s and nucl e o t id e s  ( 45 , 55- 5 7 ) . 
B e f ore 1950 , each o f  the known cla s s e s  of nu cl e i c  ac ids was though t 
t o  consis t o f  only f our bas i c nucl eo s i de monomer s . To day , thi s concep t  
ha s proven to b e  quit e  naive s in ce many addit ional comp onents have now 
been discovered b o th in RNA and DNA . Mod if ied nucleos ides have been 
found in almo s t  a l l  ma j or clas s e s  o f  nuc le ic ac ids j.nc lud ing mess enger 
RNA (mRNA) and rib o s omal RNA , ( 5 8 , 5 9 )  a l though the g r e a t e s t numb er and 
s tructura l var iations p er mo le cule have been f o un d to o ccur in t r an s fer 
RNA ( tRNA) . 
The p re s en ce o f  mod if ied nuc l e o s i d e s  in nucl eic a c ids \-73 S real i z e d  
in 1 9 /+ 8  when Hotchkiss ( 60) d e t e c ted the firs t knO'�m modif ied. comp on ent 
of a nu c l eic ac id , i . e . , 5 -me thyl� 2 ' - d e oxycy t o s ine , in a s ample o f  calf-
1 8  
thymus DN.A. . S irlce that t ime , five modified nucleos ides in DNA , and more 
than thir ty modified nuc leos ides in RNA have been identif ied . 
5 -Me thyldeoxycy t id ine is one o f  the only mod if ied comp onent s tha t 
has been detec ted in the DNA o f  p lan t and mammalian t is sues . The 
5-methyl sub s tituent does not seem to affect  normal base pair ing , but it 
c ould p erturb the se co ndary s truc tur e of DNA . Even th ough the ind ivi dual 
DNA mo le cule inte.racts \olith o the r mo lecules during the course of r ep l i� 
cat ion and t r an s c r ip tion , the bas ic chemic al reac t ions are r ep e t it ive . 
I t  therefore seems that DNA does no t have much need f or mo d ify in g group s .  
The mRNA do es no t app ear t o  contain many modif ied nu cle o s id e s ,  al­
though data on this are somewhat s p a r s e . S everal reas ons have b e en 
given as to why extens ive mo d i f ica t ions o f  mRNA are not l ikely t o  o cc ur . 
The mo st imp ortant reason is that , after the mRNA mo le cule is s equen­
t ia lly synthes ized on the corresp ond ing DNA molecule , any s tru c tural 
changes could affect  the e f f ic ien cy of t r ansmi s s ion of the mes s a ge . L os s  
o f  n ormal c oding p r oper t i es resulted ,,,hen guanos ine res idues o f  syn the­
tic ol ig onucleotides were rep laced by 7-me thyl gu anos ine res idues ( 61) . 
Rep lacement of ur idine res idues wi th 5 , 6-d ihydrourid ine in ol igonuc leo­
t ide trip lets  resulted in loss of template a ct ivity . The mRNA of mo u s e  L 
cells is f ound to be methylated in bo th the base and r ibo s e  mo ie tie s  v ia 
S-adeno sy lme thion ine , a l though the variety of methyl ated bases in mRNA 
is more limited than in r ibo somal RNA ( 6 2 , 63) . 
Mo s t  of  the resear ch on nucleic ac id s tru c tur e has cen tered around 
tRNA s ince the tRNA mo le cule i s  rela t ively smal l ,  and ind iv idua l  molecu­
lar species can be more readily is ola ted and iden tif ie d . Tran s f er RNA 
is p erhap s the mo st vers atile of known c la s s es of nucleic ac ids in t e rms 
o f variety and complexity o f  the chemical reac t ions in which i t  par t i ci-
19 
p a t e s . Ea ch tRNA mo lecu le carr i e s  a s peci f i c it y f or a p ar t icu lar amino 
ac id , re c o gn i z e s the cor resp ond in g  amino acy l  synthe tase  and m a in t a ins 
its r e a d in g  f ide l i ty f or the codon . 
S ome mod i f i ca t ion s in the tRNA s t ru c ture ar e re l a t ively mo r e  e l ab o -
rate t han the ab ove men t io ne d  s imp l e  mod if i c a t ions and resul t from the 
a t ta chment of a more c omp lex s ide cha in . Not only does the p r e s enc e of 
a larger s ide cha in create bul k , but these s i de cha ins may al so be f unc-
tional ized . It is fo r thes e re as ons that s uch nuc le i c a c id c omp on en t s  
are ca l led " hyp ermod i f i e d  nucle o s i d e s . "  S ix such nuc leos ides , � - f 
( Fig 11) have b een d e t e c ted in tRNA .  These modify in g  comp onen ts h ave 
been found to occur in the ant i c od on loop adj acen t to the 3 '  end of the 
an t i c o d on of tRNA mo le cul e s ( 6 4 ) . 
Compounds s u ch a s  l la- I ld r ep r e s ent tRNA compenen t s  in whi ch a rela -
t ive ly lar ge s ide chain p r o trud e s  f r om the b a s i c  polynu c l e o t ide b ackbone . 
Thes e  f unc t ional ized s ide cha ins mus t c on f e r  s ome un ique p rop ert ies on 
the sur r ounding o l igonucl eo t ide r e g i on . The al ly l i c , hy droxyl , and ca r-
boxy l group s  o f  t he s e m o d i f ied comp ound s c ou ld very read ily bond c ova-
lently wi th o ther mo lecu les and coul d therefore cons titu t e  r e a c t ive cen-
ters o f  high s p e c i f i c ity . 6 - I s opent eny ladeno s ine ( 6-IPA) ( lla) and 
o th e r  ana lo gs have s t imul ated i n t e re s t  by the ir p o t en t ial app l i ca t.ion a s  
immuno- sup p re s s ive agen t s , the p r imary e f fe c t of which h a s  b e en s u g ge s t -
e d  to b e  in t e r f erence with RNA and p r o t e in s yn the s i s  ( 65 ) . 
Ano ther unique ly mo d i f ie d nucl eo s id e  des ignat ed as nu cleo s ide Q 
o ccurs in the f irs t p o s i t io n  o f  the ant icodon o f  E . c oli tRNATyr , 
H ; s Asn Asp ( ) tP�lA � , tRNA and tru�A ( 6 6 ) , and in r a t  l iver t RNA 6 7 . More 
re cent ly , nucleo s ide Q has been fo und in tRNA ' s from various o rg an isms , 
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Figure 11: Na turally o c c u r r ing hy p ermo d if ied nu c l eo s id e s . 
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hag f is h  and in ,,,heat germ ( 6 8 ) . S t r u c ture e lu c id a t ion has ind icated 
nu cleo s id e  Q to b e  7 � ( 4 , 5 -d.s - d ihyd r oxy- I-cyclop enten�3-yl-amino 
me t hy l) - 7-dea z aguano s ine (�) . 
8 
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Mo s t  of the se s o-ca lled mod if ied nucle o s ides have s imp le mod if ica­
t ions such as me thy lat ion ,  reduc t ion o f  a 5 , 6  doub l e  b ond of a pyrimid ine 
b a s e , rep lacement of a hy dr oxyl gr oup w i th a su lfur a t om ,  rep la cemen t of 
an amino group ,-lit h  a hydroxyl group , or var iat ion in p o s i t ion of sugar 
a t t achment ( e . g .  p s eudour id ine) . It is p o s s ib l e  that me thy la ted nuc leo ­
s id e s  c o u l d  have a pronoun ced inf luence o n  the s e c onda ry s t ruc ture . No t 
only can they crea te a bulk e f f e c t , bu t  t hey c ou ld a l so change the 
hydrogen-b ondin g  cap ab il ity and mo d ify the b a s e-s t acking p a t t e rn . Me th­
y la t ion app ear s  t o  be the mo s t  common form of mo d i f i ca t ion in tRNA ;  more 
than t" e.nty me.thy la ted nu cle o s i des have b een iden t if ied and thes e 
includ e me thyla t ion o f  bo th the he t e r ocyc l i c  b a s e and th e s ug ar mo iety . 
The p r ope r t i es of mo d i f ied nucl e o s id e s  c an d i f fer f rom tho s e  o f  the 
paren t nu cleo s id e . For examp le in d ihy d ro u r i d ine , there is a d e crea s e d  
n -ele c t r on overlap wh ich mo d if ies t h e  ne ighbor-n e i ghb o r  s t ac king in t er ­
a c t ions that are normal ly f ound i n  o l igonu cl e o t id e s  conta ining urid ine . 
P s eud ourid ine con t a ins an ac t ive hyd r o gen wh ich could p r ov i d e  a spec i f i c  
r e ac t ive s i t e  in the tRNA po lymer tha t y70 uld n o t  be p rov i d e d  b y  urid ine . 
Thus \Ve s ee ho,v th ese sub t le and s imp le mod i f i ca tions can c au s e  a c on­
s i d e r ab l e  change in the ch emi c a l  prop e r t i es of tRNA a t  the ir p o int of 
l o c a t ion . 
Nucl e o s ide s  and nucleo t id e s  have a t tr a c t e d  cons iderab l e  int e r e s t no t 
only b e c au s e  they are bui lding b l o cks o f  the nucl e i c  a c ids , DNA and Rl.'4A ,  
but a l s o  b e caus e they are co f a c t o r s  and al lo s te r i c  e f f e c t o r s f or many of 
the f undament al enzyma t i c  r e a c t ions . Nucle o s i d e  and nucleo t id e  analogs 
are wid e s pread in na tu re , and numerous syn the t i c  ana lo g s , tha t have ex­
h ib it e d  degre e s  of b iol og i cal p r oper t i es , have b e en p r o du c ed over the 
years . These ana lo g s  have imp o r t an t  app l i ca t ions in help ing e luc ida te 
s everal a sp e c t s  of  cel l  fun c t ion , int ermed iary metabo lism ,  en z�na tic 
me chan isms , b i o synthe s is and hormonal r e s p on s e . Analogs of na tural pur­
ine and py r imid ine nucleo s id e s  hav e p r oven t o  b e  quite effec t ive as 
an t ib a c t e r ial , ant iviral and ant icanc e r  a gents due to their r o l e s  a s  
e nzyme inh ib it or s  and ant agon is t s , 
Even th ough severa l unusual nu cleo s ide s ) s u ch as is oguanos ine 
( crotonos ide) ,ver e  is o la te d  in t he e arly 1 9 3 0 ' s ( 69) ,  it was not unt il 
much la t e r  that serious a t tent ion wa s d ir e c t e d  t owar d s  nucl eos ides a s  
p o t en tial d rugs , e s p e c i ally as an t i tumor agents . A maj o r  s t imulus f or 
the synthe s is of nucl e o s ide analogs wa s the obs erva t ion that p ur ine and 
2 3  
pyrim id ine analogs , such as 5-bromourac il , 8-azaguanine , and 6-mercap t o ­
pur ine p o sses s ed an t itumor ac tiv ity ( 70-7 2 ) . The repor t that nebularine 
( 9 �  -D-ribo furano sylpurine) was cy t o t oxic to mice , \.hi le the aglyc one 
was re la t ive ly non t oxic ,  s ugges ted that ribo syla t ion of a bas e may a f f e c t  
i t s  b io lo g i c a l  ac t iv i ty in v ivo ( 7 3) . 
In the p as t  f e", decaaes , there have been rep or ted a var ie ty o f  nu­
cleo s ide s that a r e  mo d if ied in the he t e r o cy c le portion , within the car­
bohydrate r ing , or  bo th .  Figur e 12 illu s t rates s ome examp les o f  p ur ine 
nuc leos ide s , mod i f i ed in the het ero cy cl ic po r t ion , tha t wer e  r ep o r t ed to 
exhib it intere s t ing b iological ac t ivit ies . The nucleos ide 2-a za-adeno­
s ine (Fig l2a) \.a s  found to be a potent inhibitor  of KB c e l l s  in c ul­
ture ( 7Lf) . Rep lacemen t of nitro gen with carbon in the imi da z o l e  r ing 
p roduced some p o tent nucleos ides ; among the s e are toyo camy c in ( F ig l 2 b )  
and sangivamyc in ( 2 , 75- 7 7 ) . Exchange of a c arbon for a nitro gen a tom 
in the imida z o le r ing provided 8-a z a  ana logs of na tural pu r ine s ; 8 -a za­
adenos ine (Fig 1 2 c) and 8-a z aguano s ine have demonst rated p o t ent inhib i­
t ory a c t ivity again s t  microbial and tumor c e l ls in vitro ( 78 , 7 9) . It 
was observed that \.hile the f) -anomer of 8-a za-aden ine arab inos ide ,.;ras 
ine f f e c t ive , the a-anomer of th is c omp ound wa s ac t ive as an an t in e op las­
tic agen t . Hore recently , 2 ,  4-dioxo- 8- (f) -D-r ib ofuran osyl ) pyrido 2 ,  3-d 
pyr imi dine ( 80) (Fig l2d) and o th er der ivat ives have shown inh ib it o ry 
ac t ivity agains t leukemia L12 l0 cells in cultur e . Two other modified 
nucleo s ides (Fig l 2 e , f) have r e cently been rep or ted t o  exhib i t  int e res t­
ing ant iviral and an t ineop la s t ic ac t iv ity ( 81) • 
The de novo syn thes is of p ur ines p r o ceeds via a number o f  imidazo le 
ribonucleot ides and it was sugges ted tha t imidaz ole derivatives be eval­
uated for activity . S ome of these  der ivat ives have p roven t o  be q u i te 
2 4  
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F igur e 1 2 :  Struc tural exampl es o f  b iolog icall y  ac t ive nu cleo s i d e s  
mod if ied in t h e  he tero cycl ic b a s e . 
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p o tent inhib itors o f  c e l l  gro,.;th . One examp le ( Ribavir in) , shmvn in 
F ig l2 g , was a c t ive agains t s everal exp er imen t a l  tumor s in v ivo ( 82.) . 
Re cent ly a large number o f  imidazo le nu cle o s ides has been syn th e s i z e d  
and s everal have shown bo th antivir a l and an t i tumor p rop e r t ie s  ( 83 ) . 
The s e arch f or p o t en t i a lly a c t ive nu c leo s ide ana lo gs has a ls o  led 
to mo d i f i ca t ion of the carb o hy dr a t e  r ing . F igu re 13 il lu s tra tes s ome 
examp le s of mod if ied nu c le o s ides . The c a rb o c y c l ic ana lo g o f  a d eno s ine 
(F ig l3 a) p roved to be a po t ent inhib i tor of b o th bac ter ial and mamma­
l ian c e l l  gro,.;th ( 84) . The 4 '  - thio analogs o f  purine nuc le o s i d e s  sub­
s ti tuted at the ir 6-p o s it ion \vith C l  o r  SH a ls o were a c t ive ( 85 )  86)  
(Fig 13b ) . 
The demons trati on tha t the ' I amino nu cleo s ide " ( Fig l 3 c )  had b iol ogi­
cal a c t ivi ty , p r omp t e d  synthes is of o ther nu c le os id e analo gs mo d i f ie d  at 
the 3-pos i t ion of th e carb ohydra te r in g  ( 8 7 ) . Dideoxy nu cl e o s i d e s  have 
also be en prep ared and 2 '  , 3 ' -d ideoxyadeno s ine ( F ig l 3 d )  inh ib ited gro,.;th 
of E . c oli ( 88 , 8 9 ) . More r e cent ly , a t r i-O-acetyl der ivat ive (Fig l 3 e) 
has demon s t r a t e d  a c tivity agains t Halke r carc inoma ( 9 0) . 
Anhydro or cyclonucleo s id e s  have p r eviously been prepared a s  syn­
the t ic int ermediates . In teres t  in these comp ounds a s  p o t en t ial ant itu­
mor ag en t s  \V'as s t imula ted ,.;hen pronoun ced antitumor ac t iv i ty wa s ob­
s erved fo r 2 . 2 ' - 0 - cyc l o cytidine ( F ig 1 3f) ( 91 ) . 
Acy c l i c  nuc leos i d e s  we re des igned as p o ten tial an t ineop las t i c  
agents ; Baker ( 9 2)  and S chaef fer (93)  h a d  in i t ially d emons t ra t e d  a c t iv­
ity for d e rivatives of p u r ines and pyr im id ines c ar ry ing a lky l or aryl 
group s at 9 -p o s it ion , This has led to the deve lo pmen t o f  agents  such a s  
acy c l ovir ( Fi g 1 3 g) with us eful an t ineop lastic and an t iv iral a c t ivity 
( 9 4) • 
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F igur e 1 3 : Exampl e s  o f  nu c1eo s ides mod if ied in the carbohydrate 
r ing . 
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The a t t achmen t  o f  the carb ohyd r a t e  mo i e ty in na tural nu c le o s ides is 
us ually at N l  f o r  p y r imid ine s an d at N9 f o r  purines . H oweve r ,  o th e r  
p os i t ion s  f or a t t acrunent o f  the s u g a r  mo i e ty wer e r e co gn i z ed ,,,h e n  r ibo sylu,­
ric a c id \vas is olated f r om b ee f  ery thr ocytes and the r ibo s y l  mo i e ty was 
shown t o  be at t ached at N3 , ra ther than N9 (95 )  ( F ig l 4a ) . The c or res ­
p ond in g  nucle o t ide , 3-rib osylur i c  5 " �p h o sphate 'va s a ls o  ob t a in e d  from 
n atural s o urc e s  ( 9 6 ) . Ha t f ie ld et al ( 9 7) purif ied the en zyme nucleo-
t i de pyrophosphoryl a s e  and demon s t r a ted that xanthine could be r ib o p ho s­
pho ryl ated to 3-rib osyl xanthine-5 ' -pho spha te by thi s  en zyme , S in c e  the 
rib osyl mo iety i s  a t t a ched in a manner th a t  corre s p ond s to n a tura lly 
o c curr ing p y r imid ine nucl eo s ide s , i t  was s ug ges ted that the synthe s is of 
t he s e  unique " is opurinetr  nu cl e o s id e s  and nucleo t ides was ca taly z ed b y  a 
pyrimid ine py rophosphory l as e  ( 9 7) . Sub s t r a t e  s p e c i f ic ity s tu d i e s  have 
sho\Vll that the en zyme is a 2 ,  6 - d ike t o  pyr imid ine ribonuc leo t i d e  p y r o­
pho sphoryla s e  ( 9 7 ) , wh i ch has the c ap ab il i ty o f  c onv er t ing u r ic a c id and 
xant h:ine , t o  their co r r e s p ond ing nu c l e o t id e s , when the sugar mo ie ty re­
s ides at N3 o f  th e p y r imidine p o r t ion of the he t ero cy cl e . 
Al though the b i o l o g i ca l  f un c t ion of  3 - r ib osyl urIc ac id is no t 
c l e ar , the i s o l a t ion o f  this c omp ound s t imulated a sur.ge o f  int eres t in 
the syn th es is o f  b icyc l i c  nu cleos ides with the r ib of ur anosyl mo i e ty re­
s i d ing in the pyrim i d ine rin g , and t h es e  " i sopurin e t r  n n c le os idcs we r e  
evalua t e d  for p o ten t ia l  b io l og ical ac t iv ity . F igur e ( 14a-f) ( 9 5 , 9 8-102) 
illus trates examp l es of s ome na tura lly o ccur r ing or syn the tica ll y p r e ­
pared i s op urine nuc le o s id e s . Leonard e t  al (103 , 104)  s yn thes i z e d  3 - i s o ­
adenos ine ( F ig l 4 g )  in o rder t o  compare it s b ehavior in chemi c a l  and 
b io lo g ic a l  sys tenls ,vi th adeno s ine to s e e  whe ther aden o s ine and 3 -isoade­
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F igure 14 : Modified nu c 1 eosid es , i n  which the s u g ar mo i e t y  
is a t t a ched at N3 o r  N7 . 
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3-Is oaden o s ine Ha s f ound to inhi,b it groW'th o f  var io us cell l ines 
in vitro and in vivo and shoHed ac tivi ty against  aden o I I I  virus in cul­
ture . The d i- and t r iphosphate deriva tives of 3-is oadeno s ine have been 
prep ared ( 105 )  and an NAD ana lo g containing 3-isoadenos ine in p lace of  
adenos ine has b een synthes ized . 3-l s o-ATP Has capable o f  rep la c ing ATP 
in hexokinase-ca talyz ed pho sphorylat ion of glucos e ,  and the NAD ana lo g , 
NHN-3-is o-AMP wa s reduced by various dehydr ogen as e  enzymes ( 105) . 
7-Is oadeno s ine (Fig l4h) \vas als o prep ared and comp ared to 3- is oadeno­
s ine and adeno s ine ( 106) . In c on t ra s t  t o  3- isoadenosine , 7-isoadenos ine 
did no t inhib it cell g roHth . Results o f  the s tudy by Leonard e t  al 
( 104) s ugges ted tha t 7- is oadeno s ine bears  l i t tle s imilar ity t o  adeno s ine � 
Hhereas 3- is oadeno sine b ears s truc tura l res emblance to ad eno s ine as a 
sub s trate in enzymatic  c onvers ions . 
From the preceeding examples , one can s e e  that b iolog ical ac t ivi.ty 
has b een obs erved Hi th a relat ive ly large number of 'mod if ied pur ine 
nucleos ides \"h ich vary widely f rom each other . I t  is quite clear that 
b e c aus e of  their varied b iological ac t ivity and varied s tr u c tural mod i­
f icat ions , the des ign and synthes is o f  o th er nove l modif ied nucle o s ides 
'''ill b e  fruit ful and may have a potent ial for bio lo g ical a c t iv i ty . 
E .  Mesoionic Purinones and Mes oionic  Purinone Nucleo s ides 
S ince meso ionic purinones are isos teric with non-meso ion ic pur i ­
nones , it is conceivable t h a t  mes o ionic pur inon e  nu c1eosides might con­
s t i tute a neH c lass of hetero cycl i c  ag ents \-lith chemo therapeut ic p o t en­
t ial as ant ineop lastic  or ant iviral agents . To dat e , this has no t y e t  
been explored . 
The term "mes o ioni c nucleos ide" was f irs t us ed by Glennon and c o­
\vo rkers ( 10 7 )  in 19 81 . However ,  a review of the l iterature reveals that 
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s ever al s u ch d e r i,va t i,ves have b e e n  known f o r  over thirty y ear s an d ,  in 
f ac t , that a f ew are even natura lly o ccurr ing . The fac t r emains that up 
t o  this t ime ,  the s e  c omp ounds have no t been r e c ogn i z e d  a s  bel ong ing to a 
mu ch larger c l a s s  of comp ound s that \ole nmv c a ll me s o  io n i c  nucl e o sides . 
Wha t f ol lows is a r ev i ew o f  t he l i t e r a ture on me s o io n i c  pur in on e s  
an d me s o io n i c  pur i,none nucleo s id e s  t h a t  have been rep o r t e d  to d a te . An 
a t temp t ha s been made t o  cla s s ify thes e nucle o s ide s , p r eviou s ly v i ewed 
a s  unu sual ind ividu al en t i t ie s , in t he s ame manner in wh i c h  the me s o io­
n i c  p u r inones have b een c la s s i f i e d . Th is r ev iew will c ons t i tu t e  the 
f ir s t  attemp t  t o  view mes o i,onic p u r inone nu cleo s id e s  as a s ing le large 
c la s s  o f  comp ound s . The r ea l i za t ion that thes e meso ion ic pur inone 
nucle o s id e s  a r e  m��be r s  of var i o us sub - c l as s es s hould a ll ow gen e r a l iza­
t ions to be made that migh t l e ad to a b e t ter unders t anding of the ir 
chemi cal and phy s i co-chemic a l  pro p e r t i es , and s hould al l ow f o r  the de� 
s ign and synthes is of nov e l  agents 'vi th p o t ent ial therapeut ic u t i l i t y . 
In 1 9 5 6 , Brederek e t  a l  ( 108 , 10 9 )  r ep or t e d  that t re a tment o f  guan o­
s ine with d imethyl sulf a t e  at pH 4 . 0  a f f o r d s  l�me thyl guanos ine . La ter , 
Lawley e t  al ( 110) n o t e d  tha t 7-me thylguanine 'va s a produ c t  when DNA was 
me thy l a ted with d ime thy l  su lf a t e  in a neutral aqueous so lu t ion . L awley 
e t  a l  ( 11 1) sugges ted tha t  guano s i,ne reac t e d  with d ime thy l sulf a te t o  
yie l d  a b e ta ine tha t wa s irr evers ib ly d e s troyed b y  a lkal i . Ha ines e t  a 1  
( l I Z )  a lky1 a ted Z ' , 3 ' , 5 ' - tr i-0-a c e ty lguano s ine with d iazome than e and 
p rovided eviden c e  f or the 7 -me thy lguano s ine s tr u c ture . In 19 6 3 , Dunn 
( 113)  is o l a t e d  nat ura lly·� o c cur r ing 7 -me thy lguano s ine f r om a c id hy d r o 1y­
sa t e s  of tRNA f r om p i,g l iver , yeas t c e l ls and the le aves of �s i ca 
ch inens is . 
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The e f f e c t s  of var ious a lky l a t ing agen ts und er mild co nd i t ions of 
pH 7 . 3 to 7 . 5  at 230C  on f ree ba s e s , nuc leo s id e s  and highly p o lymer i z e d  
DNA o f  ca lf thymus have been inve s t iga ted by Re ine r e t  a l  ( 1 14 ) . The ir 
s tudi es have indi c a t e d  tha t th ere is d if f er en t ial s e ns i t ivity amongs t 
the DNA b a s e s . Onl y the p u r in e  ba s e s o f  in t ac t  DNA mo lecules ap p e ar to 
be a t t a cked up on alky la t ion at r o om t emp era ture a n d  phy s io lo g ical pH . 
Comp l e t e  inac t ivat ion oc cur s only '-lhen one o f  the s e  b a s e s , guan ine ) has 
been a lkyla ted . Als o , the mo s t  r e a c t ive s i t e  w ith res p e c t  to alky la t io n 
app e ar s  to b e  the nitr ogen a t om a t  t h e  7 -p o s i t ion . 
Guan o s ine i t s e l f  has b een alky l a t e d  by o t h er alky la t ing agent s ,  s uch 
as d i e thyl s u l f a t e , 1 , 4-d ime than e s u l f ony loxybu tane , e thyl ene oxide an d 
b u t adiene d ioxide ( 11 5 ) . The maj o r  p ro du c t obta ined on ac id hy drolys i s  
,,,as 7 - a lkylguan ine , a g a in illus t r a t ing that the mo s t  l ikely s ite invo lved 
is the N 7  ni t ro gen ( 11 6 ) . 
Ini t ial s t ud ie s by B r e d e r ek e t  a l  ( 10 8 , 1 0 9 )  and the l a ter wo rk of 
Lawley e t  al ( 1 10 , 1 1 1 )  and Ha ines et a l  ( 1 1 2 )  iden t i f ied with c e r tainty 
that 7-me thyl guan o s in e  wa s the p r o duc t ob t a ined on me thy l a t ion o f  gua­
nos ine . When ino s ine and xantho s ine ,,,er e  me thy la t e d , the produc t s  ob­
ta ined ,,,er e  7-me thyl inos ine and 7-me thylxantho s ine , r e s p e c t iv e ly . 
Jones e t  a l  ( 4 4 )  la t e r  p o s tul a t e d  a b e t a in e  s truc tur e f o r  the s e  me thy­
la ted nucleo s id e s  on t he ba sis of t h e i r  p roper t i es . 7 -Hc thylguano s ine 
can n ow be represen t ed as shmm in s truc ture �, and p robably cons t i­
tu t es the f ir s t  examp l e  o f  wha t c an now be c al led a C l a s s I me s o ionic 
hypox ant h ine nuc leo s ide . 
Cla s s  I Hypoxanthine Der ivat ive s ,  Al though a fair ly large numb er of 
the s e  me s o ionic hyp oxanthine r ing sys t ems have been f ormu lated and s tu­
died f r om a quantum chemi c al s t and p o in t ( 3 , 4 ) , r e la t ive ly few examp le s  
3 2  
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have . b een syn t he t ica lly prep ar e d . Acke rmann and Lis ·t ( 11 7 )  iso l a t ed 
herb ip o lin ( 10) , a d imethylguan ine f r om Ne d i t e rranean sponge s . This 
na tural ly occurring me s o ionic 7 , 9-dimethylguanine de riva t ive was la ter 
synthes ized by B r e derek e t  al ( 1 18) . Thi s b is hydroxyethyl der i:vative 
( L e .  11) , ( 115) 7-me t hyl - 9- e thylgu anine 1 2  ( 1 1 9 ) , a s  we l l  as t.ne 
7 , 9 -d i sub s t i tu t e d  hyp oxanthine derivat ive 13 ( 120)  are also kno"m . 
I f  the N9 ( o r  N7) alkyl g r o up of a me s o  ionic hyp oxanthine is re-
p la c e d  by a sugar moie ty , the result is a mes oionic nucleos ide . Thus , 
7 -methy lguano s ine (1) may n ow be con s i d e r e d  as b e ing a Clas s I ae s o io -
nic hyp oxan thine nucleo s ide . 
The 7-e thy l ( 119 , 12 1) and benzy l ( 122) homologs � and 12 have a l s o  
been prep ared . Addit ional r e lated der iva tives a r e  kno\ffi , inclu d ing 
7-me t hy 1- ( 11 0 , 44 ) and 7-e thyl- ( 1 19) 2 ' -deoxyguano s ine 16  and l 7 , and 
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t he nu cle o t id e s , methy1guany1 i c  ac i d  18 , ( 11 5 )  7-methy1 and 7 - e thyl - 2 ' -
deoxyguany 1 i c  a c ids (12 ( 119)  and � ,  ( 1 1 9 ) , respe ct ively) , bu t non e o f  
the s e  has been a s  \ve 11 inves tigated a s  7-methy1guan o s ine . The mes o ionic 
ino s ine ana log �l ( 44 ,  123)  and the 2 ' , 3 ' - is o p r opy1 idine d e r iv a t ive o f  
7 -methy 1 inos ine , 2 2  ( 12 4 )  have als o  been p repared . 
He thy 1a t ion of nu c l e i c  a c ids ( 11 9 , 1 2 5 , 1 2 6) has att rac ted c on s idera-
b le at t en t ion over the year s . Ch emi cal me thylat ion of nucleic a c id s  is 
very c omp lex and therefore e arlier \"orkers cond u c ted the alky l a t ion s tu-
dies on s imp ler r ibo- and deoxy r ibonucle o s id e s  ( 11 2 , 1 19 � 1 2 5 ) . This 
initial p io ne e r ing work has led to an under s t anding of the rela t ive r e -
ac t ivit ies of t he more c ornmon purine b a s es and their p r in c ip a l  s i tes of  
alky la t i on . 
In DNA , the p r in c ip a l  pr o duc t , 7-a 1kyl- 2 ' - deoxyg uano s ine has b e en 
sho,Vl1 t o  b e  r e ad ily depurinat e d  and this c an le ad t o  b ackb o ne b reakage ; 
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It has also been found that 7�methy l�2 ' �deoxyguanos ine-S ' - triphosphate 
may be sub s t ituted for 2 ' -deoxyguanos ine-S ' - t r iphospha te in DNA po lyme-
ras e rea c t ion u s ing calf thymus DNA as th e template ( 128)  . Ad d i t io n al 
intere s t  in 7.-methy1guanos ine has arisen s ince it ap p e ar s  t o  have a 
higher turnover rate than o ther methylated bases in intac t animals ( 129) . 
One o f  the f irs t sys tematic s tud ies on the alkylation o f  guanos ine � 
includ ing product identif ication � was that by Ha ines et  al ( 1 1 2 )  who 
treated an aqueous solut ion of guanos ine with e ither diazome th ane or 
d imethy l  sul fate at pH 4 . 0  and 1 . 0. Hhen Jones et  al ( 4 4) methyla ted 
guanos ine \vith me thy l iodide in N , N-dime thy1a cetamide a t  30oC ,  they re-
ported high y ie lds of 7-me thy1guan o s ine (1) . The maj or s ite of a1ky 1a-
t ion o f  guano s ine in ac idic or neutr a l  med ia is N7 , wh i le in alkaline 
so lu t ion , a lkylat ion o ccur s a t  N1 . On occas ion ,  it has b een dif f i cul t 
t o  s ep ara te the me so ion ic c ompound from i t s  s a l t . For examp le , me thy1a-
t ion of 7-methylguan o s ine (1) \vith me thy l iod ide yields 1 ,  7 - d ime thy lgua-
nos in ium iodide (Q) ( 4 4 ) ; B r ookes et al ( 12 2 )  reac ted guanos ine w"ith 
b enzyl bromide to  a f ford a mixture o f  mes o ionic 7-benzy1guanos ine ( 15 )  
and 7-benzy1guanos inium b romi d e  ( 2 4) . 
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Although 7 -me thy 1guano s ine (1) is s t ab l e indef initely when s t ored 
at room temp erature , 7-me thy l ino s in e  ( 2 1) slowly decomp oses to 7 -me thy l-
hyp oxanthine . 7-Me thy lguano s ine and o ther Class I mes o ionic hyp oxan-
th ll1 e analogs exh ib it p ro p e r t ies that ind ica t e  a general ele c tron d ef i -
ciency i n  the im ida z o le r ing . The somewhat greater s tab ility of 
7-methy1guanos ine (1) over 7-me thy 1 ino s ine ( 2 1) h a s  b een interp reted as 
being due to the e le ctron d ona ting amino gr oup a t  the purine 2-posit ion . 
Hydro lysis s tudies a l s o  support the idea  of an electron def icient f ive-
lllelllbered ring . Me t hy la t ion of either 7 - or 9-methylguanine aff ords the 
ident ical me s o ion ic 7 , 9-d ime thy lguan ine der iva t ive ; the effec t of alky l 
3 6  
var�at ion on s tability has been s tud ied ; In genera l ,  7 , 9�dia1ky 1gua� 
n �nes are relatively s table at a pH of b e low 8 . 5 ;  however , alkal ine 
( pH > 8 . 5 ) hydro lys is resul t s  in r ing opening of the imidazole r ing t o  
g ive 5 , 6�d iaminopyrimid ine derivat ives .  Heating 7-a 1ky1pur ine nu c1eo� 
s�des in d ilute ac ids resul t s  in a r ap id (usually le.ss than 3 0  minutes ) 
and quantita t ive conver s ion t o  th e 7�a1ky1pur ine . Thus , the g ly co s id ic 
b ond is les s s tabl e than in the correspond ing non-me s o  ionic nu cleo s ide . 
7�A1kylpurine nuc1eo s ides are also rap idly decomposed by aqueous alkal i ;  
at neu tral or alkal ine pH , 7�methy1guano s ine (�) und ergoes r ing op en ing 
to yield the 2-amino-4-hydroxy- 6-ribo furanosy1aminopyr imid ine ( 25 ) , and 
Hall ( 130)  has isol ated 25 from an enzymatic  hydro lys ate of yeast  tP�A . 
The 2 '  , 3 ' - isopropylidene der ivat ive of  7-me thy l ino s ine , i . e .  � ,  under­
goes  a s imilar base ca taly zed r ing opening reac t ion . The rate of r ing 
opening f or.  7-benzy1guanos ine ( 15 )  was f ound to be s imilar to that  of 
7-methyl guanosine (�) .  Under c ondit ions of acid hyd ro lys is , there is 
little  diff erence in glyco s id i c  bond s t ab i l ity when 7-e thy 1guano s ine 
( 14 )  wa s c omp ared lvi th 7-methy1guano s ine (2.) , ( 122)  hmvever the glyco­
s id i c  bond of 7-a1ky1guanos ines are approximately 15-20  t imes mo re s t a­
b l e  than that of  me so ionic 1 , 7-d ia1ky1guanos ines ( 12 5 ) . S tudies o f  the 
gly c o s idic cle avage of the mes o ionic 7-a1kylpurine nucleos ides may b e  
useful in a s  much as they m�ght s erve as model s  f or s tudying th e a c id 
c ataly zed hyd rolys is of na tural nuc 1eos ides and s ugges t that a c id 
hydrolys is of such natural nucleos ides may involve an ini t ial p ro t ona­
tion at Nr 
Methylat ion o f  2 ' �deoxyguano s :tne mo iet ies of D N A  has been repor ted ; 
Nrme thylat ion 1ab ilizes the g ly co s id i c  b ond and the me thy la ted ba s e ,  
7-methylguanine , is readily split out o f  the nucle i c  a c id . Ac cording 
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t o  Lawley e t  aI , ( 111) it s e ems p r ob ab l e  the 7-me thy l-2 1 -d eoxyguan o s ine 
may o n ly have a t emporary ex is tence under the s e  cond i t ions . Jon e s  e t  a 1  
( 4 4 )  have me thy la t ed 2 ' -d e oxyguano s in e  d ir e c t ly t o ' af ford the mes o ionic 
7-me thyl- 2 ' -de oxyguano s ine ( 16 ) , and Lmvley e t  al ( 119)  have p r ep a r e d 
b o th 16 and 7-ethyl-2 ' - deoxyguano s ine (12) , a s  "ell a s  7-me thyl- and 
7-e thy l-2 ' -deoxyguanos ine-S ' -monoph o s phate , 19 and 2 0 , respe c t ively . 
The 5 ' -me thyl hydr o gen p h o s phate e s te r  of 16 h a s  been prep ar e d  by 
Khorana ( 12 7 ) . 
Comp ar is on s tu d i es o f  the s t ab i l i t ie s  o f  7 -me t hy lguano s ine (�) and 
7-me t hy l- 2 ' -deoxyguanos ine ( 16)  r eve a ls tha t  the mes o ion i c  2 ' -deoxy 
derivat ive is very un s table and d e c omp o s e s  a lmos t s p ont aneously to g ive 
7-met hy1guan ine (119) . Compar isons of the r at e s  of hydr olys is of 7-
methyl- and 7-e thy l- 2 ' -d eoxyguan o s ine ( 16 and 1 7 , r e sp e c t ive ly) and 
- -
7...,me thy 1- and 7-e thy l-2 ' - deoxyguanos ine- 5 ' .... m onopho spha t e  (.!.2. and 2 0 , 
respe c t ive ly) a t  neutral pH , and over the r ange o f pH 5-10 , show's that 
the methyl ated nu cleos ide and nuc l e o t id e  �'le re l e s s  s tabl e than their 
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corresponding e thylated derivatives ( 11 9 ) . It  has a l s o  b e en rep orted 
that a t  pH 9 , 7-methy l-2 ' �deoxyguanos ine- 5 ' -monopho sphate ( 19 )  undergoes  
open ing o f  the imidazole r. ing , a react ion that apparently compe t es with 
hydr olys is of the glyco s id ic bond . Hm.,ever ,  at pH > 9 ,  r. ing op ening 
app ear s to be the predominant reaction ( 119) . 
Michelson e t  al ( 131)  have methylated p olyguanylic a c id and p o ly ino­
s inic acid , us ing techniques that avo ided degradation of the s e  p o lymer s ,  
and ,,'ere  successful in isolating the corresp onding mes o ion ic p o lynucleo­
tides . Ac id hydro lys is of the s e  products  gave the correspond ing methy­
la ted purine c omp onent , i . e . , 7-methylguanine and 7-me thylhypoxan thine . 
Alkaline hydrolys i s  f ollowed the same p ath previous ly descr ibed  f or hy­
dro ly s is o f  the nucleo t ide ( Ill) . B o th p o lymers wer e resis tant t o  the 
ac t ion of  rat tlesnake venom d ie s t erase ( 131) . 
As previous ly s tated , s ome o f  the s e  mes o ionic nucleo s ide der iva t ives 
are naturally o ccurring . In 1 9 6 3 , Dunn is olated 7 -methylguanos ine (2..) 
from acid hydro lysates of  tRNA from p ig liver , yeas t  cells and the 
leaves of Bras s ica chinensis  ( 113) . There is also evidenc e  that 9 may 
be a comp onent o f  calf and rat liver tfu�A ( 1 13 ) . Kemenes et al ( 13 2 )  
have hypo thesi zed that a modified nucleos ide , such a s  �, might s tabilize  
cer tain regions of  the  tRNA s tructure . The observa t ion that  9 is no t 
reduced by so dium borohydride is  per t inent to theore t .i c a l  mod el s of the 
three-dimens ional  s tructur e  of tRNA ( 132) . I t  may be reasonable t o  
as sume that these  mesoionic nucleos ides are involved in defining the 
mo lecular conformation of cer tain par ts  of tRNA s t ructure . 
RNA from viral s ources contains 7-methylguanos ine (�) as p ar t  o f  
the 5 ' - terminal cap s t ructure which is thought to p lay an imp ortant ro le 
in translation ( 133-13 7) . Ant ibodies sp ecif ic for 9 have been des c r ibed 
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( 13 8-140) . Thes e  an t ib o d :i,es hav e been emp loyed to d e t e ct the p r es en c e  
of  2. in synthe t i c nucle ic a c id p olymer s  and to f r ac t iona te o l igonu c l eo­
t id e s  conta in ing me thyl ated b a s e s . 7-Methylguan o s ine an t ib o d i e s  dis­
p lay s p e c if ic ity f o r  methy la t e d  purines over non-me thylat e d  pur ine s , and 
d is t ingu ish b e tween 1 , - 3- and 7 -monome thy l  derivat ives ( 138) . Although 
the an t ib o die s c an recogn:i, z e  7 -me thy lguano s ine in the RNA cap , the de­
gree of r e act ivity o b s erved in le s s  than with f ree 7-me thy l guan o s ine . 
Th i s  has been s ug ges ted as r e f l e c t ing a c ons tra ine d  conf igura tio n  f or 9 
as it  ex is t s in t he cap . P r o t on NMR s t ud ies ind i cat e the 7-me thy1 gua ­
no s ine o c cur s in a s ta cked c on f igur a t i on with res p e c t  t o  the adj acent 
b a s e , w'hich may p r event maximum re cogni t ion by the an t ib o dy ( 1 4 1 , 14 2 ) . 
Re lat ive ly few rea c t i ons invo lving the s e  me so ion ic nu c 1 e o s i des have 
been rep o r ted . For examp le , 7-methylguanos ine (2.) , a C la s s  I me s o ionic 
hypoxanthine derivat ive , can be readily converted by t r ea tment Hi th 
ni trous ac id to 7-me thylxan tho s ine ' (.?:,i) ,  a Cl a s s  I me s o ion i c  xanthin e  
analog ( 44) . Comp ound 2. has als o been me thy la t e d  t o  a f f ord l , 7-d ime­
thylguano s inium :i, od ide ( 12 2) .  At temp t s  to der :i,vat ize 1 by s ilyl a t ion 
. \vi th B STFA resul t s  in oxygen in s e r t ion to g ive what is b e l ieved to be 
2 7  (14 3 ) . 
Cla s s  I Xanthine Derivat ive�. Brederek e t  al ( 1 44)  re p or t e d  the p r epa­
rat ion o f  7 , 9-dime thy1xanthine ( 28) ,  which now ,  by def in i t ion 1 is a 
Clas s I me so ionic xanthine ana lo g , Jon e s  e t  al ( 120) by independent 
methylat ion of 7- and 9-me thy l  xan thine established the s t ru c ture of 2 8 . 
Comp ound '� was also ob t a ined up on t r e a tment of 7 ,9-d imethylguanine 
( 10) \'li th ni trous a c i d  ( 44 ) . 
S enga e t  al ( 145)  have rep or t e d  t h e  synthes i s  o f  the 1 , 2 , 3- thiad ia­
zolo [ 4 , 5- d ] pyr imidine derivative �, ' wh ich is ano ther examp le of a 
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7 -Methylxanthos ine ( 26) , the f ir s t  examp le of a Clas s I me s o ion ic 
xanthine nucleoside , wa s ob t a ined by trea t ing the mes o ion ic 7-me thy lgua-
4 1  
nos ine (�) \.;r it h n it r ous a c i d  ( 44 ) . At r o om temp era t ur e � s lm.;ly dec oP.1-
p o s e s  t o  7 -me t hy lxanthine ; 2 6  r ap id ly de comp o s es in aque ou s alkal i to 
a f f ord s eve r a l  r ing- o pened produ c t s  s imilar t o  th a t  ob served for 7-meth-
ylguanos ine ( 4 4 ) . Up on trea tmen t vrith a c id , 2 6  i s  hyd r oly z e d to 
7 -me thy lxanthine ( 4 4) . 
C la s s  I 2-Purinone Derivat ives . To d a t e , no ex amp les of Clas s I mes o io-
nic 2-purinones or 2-purinone nu c l e o s ides have b een r e p o r ted . 
Cla s s  I I Hypoxanth ine Der ivat ives . Clas s II mes o ion i c  an al o g s  may b e  
f ormula t e d  by t h e  fus ion of a five-memb er e d  r in g  t o  t h e  ex o c y c 1 i c  n i tro-
gen of a hyp o thet ical imino der iva t ive of the mes o ion i c  l , 3 - d is u b s t i-
tuted pyr imidin- 4 , 6 - d i one 1. i . e .  3 0 . Re su l t s  o f  a quantum chemical s tudy 
sugges t tha t there are b o t h  d i f f er en c e s  and s imil ar i t ie s  be tvreen the s e  
me s o ion i c  r ing sy s t ems and the ir non-me s o ion i c  coun t er pa r t s , ( s e e S e c t io n  
I I C )  . 
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In 1 9 6 2 , Town s end and Rob ins repor ted the syn the s i s o f  3-me thylgua-
nine and sugges ted , ba sed on obs erved chemical p roper t ies ,  tha t 31 and 
32 mus t  be s ignif ican t  resonance c on t r ib u t o r s  ( 14 6 ) . Albert u s ed a 
s imilar argument t o  exp l a in s ome of the pr oper t i es o f  s t r u c tura lly re-
la ted 3 -me thyl- 8�a z apurin� 6-ones ( 14 7 ) . S t ructur e s  such as 3 1  and 32 
d o  no t a dhe r e  to the def in it ion of me s o  ionic in t hat this comp ound c an 
b e  represented by a s ing l e  covalent s t ruc ture , i . e .  }l.. Thus it wa s of 
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intere s t ,  from a theoret ical s tandpoint , to  fur ther inve s t iga te thes e  
s tructures . On the bas is o f  quantum chemical cal cu lations , Pu llman p r e -
dicted tha t  the "mesoionic" 3-me thy 1guanine would be about 50 Kca1 /mole 
le s s  s t able than the usual tautomers of guanine , and concluded tha t the 
7H- tautomer 33 would b e  the mos t s table ( 14 8) . Indeed , Ab o l a  e t  al 
( ILI 9 )  have demonstrated b y  X- r ay crys t a ll ographic me th ods tha t 11. p re-
d om ina t e s  in the crys tal s tate . 
0 















Coburn and Carapello t t i  p r ep ared the f ir s t  examp les of t rue Cla s s  
II mesoionic hyp oxanth ines , i . e .  1i .. (150)  • In contrast to the salts 
34a (X==Br , I) which darken rap idly up on exp os ure t o  a ir , the me soion ic 
comp ounds exis t as wh ite crys tals tha t are s table to heat and ligh t in 
air . The chemis try o f  these comp ounds 'vas no t s tud ied ; however , i t  
was found tha t  3 4  ( R==R ' = b enzy l) underg oes s low c onversion , up on tr eat-
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ment w i th 5% aqueous s o d ium b icarbona te , t o  the r ing-op en product 
N-b enzyl- 5  (4)  - ( N-benzy lformamid o)  imida z o le-4 (5 )  -carb ox,'3lTl ide ( 150) . 
T o  d a t e , no C l as s  II me soionic hypoxanthin� nuc l eo s id e s  have b e en 
r epor ted . 
Clas s I I  Xanthine Der ivat ives . Th is is p erhap s the bes t s tu d i e d  of the 
three Clas s I I  sub clas s es , and y e t , of th e thirty-six po ss ible  het ero cy-
c l ic ring sys tems that are is oe lectronic and isos ter ic with xanthine , 
examp l e s  of less than a do zen have been synthes ized . Of th e s e , only one 
or two ring sy s tems have been s tud ied in any detail . Clennon et al (9)  
have p rep ared several examp les o f  mes o ionic  imida z opyrj.mid ine and 1 , 2 , 4 -
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been exp l ored . Examp l es o f  a 1 , 3 , 4- oxad iazo lopyr imid ine , '}2, and a 
1 , 2 , 4- thiad iaz ol opyrimidine 3 8 , have also been rep o r ted ( 5 ) . Coburn and 
Glennon ( 1 5 1) r ep o r t e d  the f ir s t s yn t h es i s  of me s o  ion ic thiazolopyr imi­
d in e s , �, and 1 , 3 , 4-thiadiazolopyrimidine s ,  4 0 ,  and a large s e r ies o f  
such d e riva t ives have s ince been prepared and evalua t e d  f or the ir an t i­
mi cr ob ial a c t iv i ty ( 5 , 6) and f or their ab ility to  inhibit cyc l i c  AHP 
p h o s phod ie s t e ra s e  ( 8 , 10 , 1 1 , 15 2 ) . S ever a l  su ch deriva t iv e s  p rodu ced hy­
p o t ens ive e f f e c t s in ra t s  s imi la r  to that p rodu ced by the xanth ine der i-
vative t he ophylline ( 11) . 
For the mo st p a r t , deriv a t ive s o f  3 9  and 1,0 have been prepared by 
the cy c l i z a t ion of an ap propr iately s ub s t i tuted mn ino deriva t ive o f  a 
f ive-membe red he t er ocyc le with e i ther a t r ichlo r ophenylmalona te e s t e r , 
( 5- 1 0 , 15 1 , 1 5 3 )  sub s t ituted mal onyl d i chlo r ide s (41) , ch lo ro carb ony l 
ke tenes ( 15 4 )  or carb on sub o xide ( 1 5 1 )  (Fig 15) . In f a c t , mos t  of  the 
Cla s s  II  me s o i o n ic xanth ine ana lo gs have b een prepared by the mal on a te 
c ondens at ion me tho d  of Kap p e  and Lub e ( 3 3 ) . 
Deriva t ive s of 3 9 and If 0 are ordinarily stab le to heat and l ight in 
a ir ,  a r e  r e ad ily recr y s tall izab le f r om or ganic so lv ent s ,  p o s se s s  minimal 
aque ou s s o lub il i ty and d isp lay typ i c al he t er o ar oma t i c  p rop er t ie s . D e r i­
va t iv e s  o f  4 0  o r d inar ily me l t  w'ith d e c omp o s i t io n ,  wh ile der ivat ives o f  
3 9  d o  not . The s p e c tral charac t e r i s t i c s  o f  s uch c ompound s , inclu d ing 
infrare d , ( 1 5 1) p r o t on nmr , ( 15 1 )  l 3C_nmr , ( 155)  u l t ravio l e t  an d mas s 
spec t ra , ( 15 1 , 1 5 6 )  have b een examin ed . 
Der ivat iv e s  o f  3 9  tha t are unsub s t ituted a t  the purine I-p o s it io n  
a r e  p rone to  e l e c t r oph ilic a t t ack ( 15 1 )  and have been demon s t ra t ed t o  
unde rgo , for examp le , b r omina t ion and n itrat i o n  t o  y ie ld , in a ccor dance 
wi th predic t ions based on quantum chemi cal s tudies , ( I, )  the cor r e s p o n d-
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F igure 1 5 : Pr epar at io n  o f  C l a s s  II  m e s o  io nic  xanthine anal o g s  by d i f f er ent cycl i za t io n  
pro cedur e s . 
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ing p ur ine I- sub s t ituted d e r iv a t ives 4 l a  an d 4 lb .  S ub s t ituted der iva-
t ive s o f  l2. are only mod e ra t e ly s en s i t ive t o  a c id ;  several c omp ounds 
have b een r ec ry s t all ized from 5% hydr o chlor ic ac id , although prolo ng ed 
hea t ing with 5 - 1 0% hydro ch lo r i c  ac id resul t s  in r ing op ening to af f ord 
a 2-a lkylaminothiazole 42 and t he corresp ond ing malonic a c id derivative 
( 6 , 1 5 1 )  ( F ig . 1 6 ) . 
Comp ounds such as 3 9  are p r e s ulliably a t t a cked by hy droxide and a lko-
xide at the br idgehe ad carb on t o  g ive c omp l ex m ixtures of p r oducts ( 1 5 1 ) . 
Conc omi t tant a t tack may a l s o  o ccur a t  one o f  t he p s eudo carb onyl po s i-
t ions ; this phenomenon has not been thoro ughly inve s t igated . Attack by 
amines o c curs , ini t ial ly , a t  the pur ine 6 -p o s it ion f o ll owed , und e r  mo re 
v igo rous cond i t ions , by a t t ack at the p ur ine 2 -p o s i t ion to give r ing 
open p r o du c t s ( 6 , 15 1 , 15 7 ) . This i s  normally a s t ep\vise p r o c es s ; gentle 
he a t ing of an ethan o l ic s o lut ion o f  39 "lith b enzylamine or phenethyl a-
mine will a f f o r d �, while he at ing a s o lut ion o f  l2. in p hene thy lamine 
at r e f lux will a f f or d  4 2 . A t t ack by amin e s  is hind e r e d  by the p res ence 
of alkyl s ub s t i tuen t s  a t  the pur ine I-p o s i t ion and is f ac il ita ted by 
e l e c t ron vl;lthdrawing sub s t ituents  on the s ix-memb ered r ing ( 1 5 8 ) . Com-
p ound 2.2. also undergoes d ip o lar cy cl oadd i t io n  reac t ions with d imethyl-
ac e t y lene d icarb oxyla te to a f f ord 44 ( 1 5 1 ) ,  ( F ig 1 6 ) . , -
l-Aza analogs o f  3 9  and 4 0 , i . e .  45 and 4 6 , respec t ively , have b een 
rep o r t ed ( 15 9 , 1 6 0 ) . D e r iv a t ives of 4 5  and � p o s s e s s  only limited s ol u-
b i l i ty in wa ter and mo s t  organ ic solvents ;  they are l e s s s table and mo re 
pr one to r ing opening t han the ir c orresp onding deaza p arents l2. and 4 0 . 
Several nuc le o s ide s  of Cl ass  II  me s o ion ic xan thine analogs have b een 
rep or ted . For examp le , G lennon and c o  .... workers have prep ared the II and 
S -anomer s of comp ound 47 (R = H ,  C2H5) , as wel l a s  their 2 '  , 3 ' , 5 ' - tr i-O-
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F igur e 1 6 :  Typ ical r e a c t ions o f  meso  io nic th iazo1o pyr imid ines . 
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acety l derivatives ( 10 7 ) . 
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Prisbe and cO-Horker s ( 161) conver ted  1- ( 2  , 3-0- is opropylidlene-13 -D-
rib ofurano syl) imidazo [ 1 , 2-a ] -1 , 3 , S-tria z ine-2 , 4- ( lH , 3H) -dione to � by 
treatment with me thy ltr iphenoxypho sphonium iod ide . Hm"ever , \.(!hen the 
co rresponding 6- thio analog Has subj ec ted to s imilar cond it ion s , the 
l-aza mes o ionic xanthine nucleos ide 49 was iso l a ted . 
48 49 
49 
Class I I  2-Pur inone De r ivatives . The f irs t examp les o f  a Clas s I I  mes o-
ion ic 2-pur inone r ing sys t em ,  5 0 , were re cently rep or ted (1 62) ; no nu-
cleos ide d e r ivat ive s  have been p rep ared to date . Compound 5 0  can exis t 
as any one of several t au t omers and each tau tomer may be represented by 
a numb e r  of d ipolar c anon i cal s truc tures . On the bas is  o f  pro t o n  and 
l3C-nmr s tudies , Coburn and Taylor have conc luded tha t these me s o io n i c  
c ompounds exis t predominant ly as  the C 7-H t automer 51 ( 16 2 ) . Der iva-
t ives of 51 Here found to be prone to hydro ly t i c  ring open ing reac t ions . 
Although 5 1  ( R  = CH3) .. las s t ab le i n  Ha ter a t  r oom temp er a ture , heat ing 
at re f lux , or treatment Hith s o d ium hydroxide , af forded comp ound 5 2 . 
Re act ion o f  5 1  ( R  = phenyl) \vi th d ime thylacety lene dicarb oxylate (DMAD) 
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When one consider s the number of hyp o the tical Cl a s s  I an d C la s s  I I  
me s o io n i c  r ing s ys tems tha t are p os s ible , no t t o  men t ion the variety o f  
der ivat ive s result ing f r om the a t t achment o f  var ious s ub s t ituent s , the 
number of p o t en t ia l mes o ionic nucleos ide s is eno rmous � Wha t f o llmvs is 
the f ir s t  synthesis  o f  me s o  ion ic nucleos ides based o n  r a t io na l  d e s ign 
f o r  p o s s ible chemotherapeut ic ut il i ty . 
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I I I . RAT IONALE AND DISCUS S I ON OF SYNTHES IS 
The work to b e  des cr ib e d  here in d e a l s  �vith C l as s  II mes o ioni c  xan­
thine nu c l e o s i de s ; b a s e d  on the wo rk o f  G lenn on e t  aI , ( 8 , 10 , 1 1 , 15 2 )  the 
synthe s is o f  su ch comp ound s ce r t ain ly app e ar s  f e a s ib l e . Howeve r ,  b e f o re 
under t aking t he ra t ional des ign and s yn the s i s  of s u ch nu cleo s ides , it 
would b e  r ea s sur ing , and , in f act , p ru d en t , t o  det ermine if the me so ionic 
he terob a s e s  p os se ss ed a b io i s o s t er i c  r e l a t ion s h ip with the i r  non -m e s o io­
nic coun t e rp ar t s . If thi s could b e  demons t r a te d , there wo uld then b e  a 
gre a t e r  p r obab il ity tha t the mes o i on i c  nu cleo s id e s  might b e  cap able o f  
mimicking a non-mes o ion ic nuc l eo s ide and/ or nu cl eos ide an t ime tab o l it e . 
In the s e c t ion t ha t  imme d ia t e ly f o ll O\vs , ev idence will b e  p r ov ided tha t 
d emon s tr a t e s  that the mes o ionic he t e r ob a s e s  d o , indeed ,  p o s s e s s  a b io­
iso s te r i c  r e la t ionship �vi t h  the ir non-mes o ionic counterpar t s  (a t  leas t 
in the sys t ems s tud ie d) . The nex t  thr ee s e c t ion s \vil l then d e s crib e  the 
des ign and s ynthes is of three d i f f e r ent types o f  mes oion ic nu cl e o s ides 
as p o tent ial chemotherap eutic agents . The me s o ion ic nu cleos ides wer e  
d e s igned a s  p o t e nt ial inh ib i t o r s  o f  en zyma t i c  p athways . The me s o ion ic 
thiad i a z o lo py r im id ine nucleo sides , 9 3  and � were de s igned as p r o - drug s 
o f  2-amino- l , 3 , 4- thiad ia z ol e  (2-ATD) mononu c le o t ide Hhi ch has b e en re­
p o r ted t o  inhib it the en zyme , ino s ine monop hosphate dehydro genase ( IMP 
dehydrogenase) (Sect ion I IIE ) . The mes o ion ic thiazo l inopy r imid ine nu� 
cle os ide l:,.13 ,vas d e s igned as  a p o te nt ial inhib itor o f  the enzyme thymi­
dy la t e  synthe t a s e  ( S e c t ion l I IC) , while the me s o ionic imid a z o thi a z ine 
nucleo s ide ill may inhib it tho se en zyme s that u t i l i ze ll1P as a s ub s tra te 
in p ur ine b io syn thes is ( S e ct ion I I ID ) . The s t ructur e s  of th e s e  targ e t  
52 
mes o ionic nucleo s id e s are shmvn in Figure 17 . 
A .  B io is o s te r ic Re lat ions h ip 
Cy c l ic-AMP PDE s tudies : In 19 5 8 ) . Suther land e t al  ( 1 63 , 164)  r e p o r t ­
e d that me t hy la t ed xanthines , such as c af feine and theophyl l ine , inhibit 
cy cl i c  nuc leo t ide phosphodie s teras e (PDE) . Subsequicn tly , s truc tural 
mod if ica t ions o f  the s e  alky1ated xanthines has led to more p o t e n t  a nd 
s e l e c t ive inh ib it o rs ( 16 5 -1 6 9 ) . Fo r examp le ,  l-me thyl-3-isobutylxan­
th ine ( IBMX) was found to  b e  at least f if teen t imes �o re p o t ent than 
theophyll ine as an inh ib itor o f  PDE . A s er i es of 8-sub s t itu t ed the o-­
phyll ine derivat ives were also t e s ted for inh ib it ion of PDE in an in 
v i t ro assay system and it 'vas found that a s  the leng.,th of  the s i d e  chain 
a t  p o s i t ion 8 increas e d , the a c t iv ity increased . By c ontrast , the 
7 - s ub s t ituted theophy l l ine d e r ivat ives were le ss po tent inhib itors t han 
wa s the ophy lline . 
S ince the Clas s II mes o ionic xanthine analogs bear close s t r uc tural 
and is o s t e r i c  similar ity w i t h  the methy l a t e d  xanthifl.<e s , s everal such 
comp o unds \vere prep are d ·  a n d  evaluated by Glennon e t .al ( 8 , 1 0 , 1 1 ,  1 5 2 ) a s 
inhib itors o f cy c 1 i c-AHP P DE . Theophylline ( 5 4 ) , w'as the s tandard ref­
e rence agent , and the comp ounds were as s ayed u s ing t:be me thod o f  Klee , 
( 170 ) against  bovine hear t PDE ;  some of the ir result. s are shmvn in 
Table 1 .  The general conclus ion was that the me s o i onic xant hin e  ana­
l ogs d isplayed a moderate degree of ac t ivity ,  and , fur thermore , that 
the type of inhib it ion , a s  determined us ing Linewea,,"'er Burk and 
Hanes-Woo l f  p lo t s , appeared to be s im ilar to that pr oduced by theophy l­
line . In add ition , several mes oionic derivat ives l :ike theophy l l ine 
itself , were found t o  pr oduce hypotens ive ef f e ct s · i.n vivo ( ana es the t ized 
rats ) ( 11) . 
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"F igur e 17 : S t r u c t ur e s  o f  target  rn e so io n i c nucl eo s id e s  as po t en t i a l  ant i­
neo pl a s t i c  ag ent s .  
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Tab l e  1 :  Inhib i t i o n  o f  cyc l i c-AHP p ho spho d ie s t e r a s e  b y  me s o  i o n i c.  
xanth ine anal o g s  ( 1 5 2 ) . 
THEOPHYLLINE 1 
C omp o und R1 
R3 
Ia Et E t  
b E t  B z l  
c B z 1  Et 
d Et p 0 -B z l  
I I a  E t  E t  
b Me B z 1  
c B z l  E t  
d Et pCIB z 1  
Theo phy l l ine 
R 4 3 1 -... _ .  N - N  6 ' +A' '\\ 
\ .. -... ' / 2  
0 7 N 5 1  I 8 
R3 
:t.I 
RELAT I V E  
POTENCY 
0 . 3  
0 . 9  
2 . 5  
31 . 7 
0 . 4  
2 . 2  
7 . 9  
42 . 9  
1 . 0 
5 5  
Adenos ine b ind ing s tud ie s ; Hore re cent ly , it has been demonstrated 
that a lkylxanthine s are inhib itors o f  adenos ine b ind ing . Adenos ine is  
a naturally o ccurr ing nucleos ide that  p lays an imp or tant role in many 
func t ions related t o  the central nervous sys t em . Behaviorally ,  adeno­
s ine and its analogs produc e sedat ion and ant iconvuls ant  e f f e c t s  ( 171) . 
B iochemically ,  adenos ine modulates  ad eny lat e cyclase CAC)  ac t iv i ty by 
b inding at e ither intracellular and / or extracellular recep t or s it es . 
Adeno s ine s t imulat es AC by b ind ing at  the extrace llular A2 s t imulatory 
or low af f inity recep tor and inh ib its AC via the Al inhib it ory or high 
aff inity receptor (Fig 18) . I t  a l s o  interac t s  \'lith AC by b ind ing t o  an 
inhib it ory intracellular regula tory I I p l l  s ite ( 17 2 ) . 
The alky lated xanthines such as  caf f e ine and theophylline a re kno\� 
t o  a c t  as adenos ine antagonis t s  at the extr ace llular Al and A2 recept o r  
sites , but have no e f f e c t  o n  the intracellular P s i te . The behavioral 
and b iochemical e f f e c. t s  of  alky lated  xanthines sugge s t  that the s t imula­
t ory e f f e c t s  of caffe ine and theophyll ine on  the cent r a l  nervous sy s tem 
may b e  due , t o  a large extent , t o  the ir antagonistic e f fe c t s  on the ade� 
no s ine recep tor s ( 1 7 3 ) . S t ructure-ac t ivity relat ionship s for the alky­
la t e d  xanthine s have been s tudied and recent ly s ome p o tent xanthine 
analogs have been developed ( 1 74 ) . For examp le , 8-pheny lthe ophylline 
(J2) and l , 3-d ip ropylxanthine ( 5 6) ''lere found to be the mos t pot ent in 
d is p la c ing rad iolabel le d  N6-cyclohexyladenos ine from adenos ine Al s i tes , 
while caf f e ine vlaS the leas t potent ( 1 7 4 , 175) . 
Thus , it was of intere s t  t o  examine the effects  o f  s everal mes o ion ic 
xanthine ana logs in this sys tem .  Many o f  the required compounds were o n  
hand as a result of previous s tudies in the s e  laboratorie s , and s ome 
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F igur e 1 8 : Po t ent ial int er a c t ions of ad eno s ine with ad enyl a t e  cycl a s e  ( 1 71 ) . 
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5 5  
5 6  
6 8  
7 6  
Rl R3 R8 
CH3 CH 3 
H 
CH 3 CH3 Ph 
Pr Pr H 
X RZ R6 R8 
Cll H Pr Pr 
N Ph Et  E t 
Synthe s is : Mes o ionic heter ocycles have previously been synthe s i zed 
by react ing sub s t ituted or unsubs t ituted b is ( 2 , 4 , 6- t r ichloro phenyl) 
malonate e s ters with 2-sub s t ituted-amino thiazole s  or thiad iazole s at 
1600C to yield the c orresp onding mes o  ionic xanthine ana log in which the 
subs t ituent at C6  can be var ied depend ing on the ester emp loyed ( 5-10 , 
33 , 15 1 , 153) . The b is- ( 2 , 4 , 6-trichlor ophenyl) -malonate e s ters  wer e  pre-' 
pared ac cord ing to the l ite rature procedure s ,  by a llow ing a sub s t ituted 
(eg 2§..22) or unsub s t ituted ( eg 2!) malonic ac id derivative t o  r eac t 
with 2 , 4 , 6- tr i chlorophenol ( 60 )  in the presence o f  POC 13 ( S cheme 1) . 
The mesoionic analog 6 8  '-las prepared by a fus ion reac t ion be t,.;reen 
�, 
2- (n-propylamino ) thiazole (!i1) and 6 3 ; 2 - (n-propyl amino) thiazole (67 ) ,  
the required start ing mat erial for this reac t io n  ,,,a s prepared f rom com-
merc ially available 2-amino thia zole (�) by acylat ion ,.;rHh prop i onyl 
chlor ide ( 6 5 )  ( 1 7 6 )  followed b y  reduct io n  o f  the resu l t ing amide 66  w'ith 
" Reda:l tl ( S cheme 2) .  
58 
R�(C O O H) H 2 
57 R = H  
58 R = Et 
5.,1) R = Pr 
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S cheme 1 :  Synthe s is o f  bis ( 2 , 4 , 6-t r ichloropheny l )  malona t e  e s t ers . 
The mes o ionic analo g  12... was prep ared in s imila:r f a shion from 
2-ethylamino -5-phenyl- l , 3 , 4-thia d ia z ol e  (ll) ; the l a t ter s tart in g  ma-
terial was prepared by two d if f erent synthe t ic routes . In the f irs t 
2 
metho d , ( 6 , 1 7 7 )  ( S cheme 3 )  4-e thyl-3- thio semicarbaz�id e (§.2) ,.;a s rea c ted 
with t r imethylorthob enzo ate (J..Q) in an acid med ium t o  af ford a produc t  
64 65 
o 
---...... � HN}[) 
I 
n Pr � 
.scheme 2 :  Syn the t ic path�.;ay for the preparat ion of Anhydro- 6 ,  8-d i-n­
propyl-S-hydroxy- 7-oxo-thia zolo [ 3 , 2- a ] pyr imid inium Hydrox id e 
( 68 ) . 
5 9  
S 
HLN -NI+C-N H-Et  + Ph-C(OMe) 3 
69 70 7 1  
S cheme J :  Pr eparat io n  o f  2,-e thyl amino -5-phenyl -l , 3 . 4-thiad iazo l e  (Zl) .  
tha t me l t ed at l 7 3�1 7 5 0C ,  and whos e  spectral d a t a  ind icated the des ired 
2-ethylamino-l , 3 , 4- thiad iazo le ( 7 1 ) . However ,  Chandra et al ( 1 7 8 )  h ad 
previous ly prep ared 71 by t r e atment of benzal thiosemic arb a z one with 
o 
ferric chloride and rep orted a melt ing p o in t  o f  2 38- 24 0 C .  B e c ause the 
thiosemicarba z ide may have cyclized t o  a f ford 3 -pheny l -S,.. merc ap t o - l , 2 , /+ -
t r ia z o l e , it wa s ne ces sary to  fur ther ident ify the pr oduc t . S a t is f ac-
tory e lemental analys is wa s ob ta ined f or comp ound l!.; fur thermo r e  a 
search o f  the l iter ature revealed tha t the mercap t otr iaz ole had been 
previous ly rep or ted by Shah e t  al ( 17 9 )  t o  me lt a t  l4l-l42oC .  In order 
to r es o lve th is problem ,  c omp ound · 71 \oJas p r ep ar e d  by a s e cond r o u t e . 
Thiosemicarbaz ide ( 7 2 )  '\va s b enzoylated and cy clized to g ive 2-amino-
S-phenyl-l , 3 , 4-thiad iazole ( 74) via ac id cata ly sis . Comp o und l!i... me lted 
at 2 2 4°C ,  which is ident ical t o  the comp ound prepared by Hoggart h  ( 180) , 
Young e t  al ( 182) , Kurzer ( 1 8 3 )  and Kub o t a  e t  al ( 181) . However ,  
o 
Chandra e t  a l  ( 1 7 8 )  reported that 2i me lted 2 13-214 C .  Comp ound l!!.. was 
subsequent ly acylated to  give N7a cetamido� 5-pheny l- l , 3 , 4 - th i a d i a z ole 
o . 
. <!1) ,  me lt ing p o int 2 7 8- 2 8 2  C ,  which corresponded vli th l i ter a ture val-
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ues ( 18 1- 183) . Reduct ion of l2. vith LiAlH4 afforded the des ired com-
pound 71 \vhich \vas ident ical to that p repar ed by the cyclizat ion of the 
thiosemicarba z ide . Thu s , it might be conclude d that� the s tr uc tura l 
a s s i gnment made by Chandr a e t  a1 ( 17 8) \vas incorre ct . Fus ion of  
o 
2-ethylamino-S -phenyl- 1 , 3 , 4 - thia d ia zole (]J) \vith &2 a t  1 6 0  C af forded 
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S eheme 4 :  Synthe s is o f  Anhydro-2 -phenyl- 6 , 8-diethyl- S-hydroxy-7- oxo ­
thiadiaz ol o [ 3 , 2-a ] pyrimidinium Hydroxide' ( 7 6) 
The meso ionic c ompounds 21, .1§.... and o th er derivatives 'vere evaluated a s  
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adeno s ine antagon is ts  at the A1 or h igh af f in i ty re c ep t or s ite . Res ults  
o f  the s tudy , which 'vill b e  d i s cussed in detail in S ection I V  ( i . e . (Dis-
c�ss ion of B io 1ogical Results ) ,  sugges t that s evera� of thes e meso ionic 
compounds d id d isp l ay p ropert ies comp arable to theoI�hy11ine and sugges t 
tha t  a b io is osteric relat ionship does exi s t . 
B .  Thiadiazolopyr imid ine Nucleos ides 
Rat ionale : 2-knino- l , 3 , 4- thiadiazole ( 2-ATD ; 22) and its  deriva­
t ives have been shmvn to produce several different chemo therapeut ic 
effec t s . For examp l e , Burchena l and cO\vorkers (184) rep orted that 
2-ethylamino-l , 3 , 4-thiad iazo le ( 2E-ATD) was active agains t leukemia 
8174  of the C 5 8Fl mous e ,  ',hile Troy et a l  ( 185)  found tha t 2-ATD in­
hib ited  me lanoma cells , S arcoma 180  and leukemia P1534  in mice . In 
addit ion , Kr ako f f  ( 186)  demonstrated that 2-ATD p roduced an inc rease in 
de novo synthes is o f  uric a c id in man . S ince these ant ineoplas t ic and 
uricogen i c  effect s  could be rever sed by n ico t inic a c id and n ic o t inamide , 
2-ATD and 2E-ATD \'-Tere init ial ly considered a s  n ia c in antagonis t s  ( 185) . 
Ole s on and his asso ciates ( 18 7 )  demons trated that 2-ATD exhib ited c ar­
c inos tat ic a c t ivity agains t S-9l  me lanoma and 6C3HED lymphos arcoma . A 
ser ie s  o f  compounds were evaluated (Table 2)  and the results r evealed 
that the p arent compound , 2-ATD , app eared t o  b e  the mo s t  ac t ive ; s ub­
s t itut ion a t  either the 5-p os ition or on the amino group of 2-ATD r e­
duced or to tal ly abo l ished activity . 
Cio t t i  and coworkers ( 18 8 )  comp ared the rela tive e f f e c t ivene s s  o f  
2-ATD and aminop terin in incre a s ing the life span o f  mice with advan ced 
leukemia (L12 l0) ; Figure 19 shows that 2-ATD was capable of increas ing 
l ife span ( even when the treatment was init iated late in the c ourse o f  
the d is ease s tate) . At the mo s t  effec t ive dose  levels , the tumo r s  
showed marked regres s ion , but this '\Tas accomp an ied by we ight lo ss  in 
the animals . Higher d os es were more toxic t o  the ho s t , resul t ing in a 
decrease in survival time . 2-ATD was equief fective with aminop terin ,  
but was les s po tent in pro long ing the life span o f  mice with advanced 
leukemia .  
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T ab l e  2 :  C ar c ino s t a t i c  a c t iv i t y  o f  s ev e r a l  2-amino -l , 3 , 4 - t:hiad i a z o l e s  
( 1 8 7 )  . 
C 







a r c l no s t a t ]. c  A C t lV l t y  (R 
S 9 1 
I 
R = R  = H 
e p r e s en t a t lv e  1 ) examp _  e s  
6 C 3HED 
Helanoma Lympho s a r c o ma 
D a i l y  do s e % Tumo r D a i ly d o s e  % Tumo r 
mg/ kg inhib i t i o n  rug / kg inh ib i t io l  
2 5 . 0  9 4  1 0 0  9 9  
3 . 7 5 5 7  5 0  9 Lf 
2 5 0 . 0  9 !f - -
1 0 0 . 0  8 8 250 9 4  
1 5 0 . 0  0 - -
5 0 0 . 0  2 7  5 0 0  0 
6 3  

Nelson et al (189) studied the in vivo effects of 2-ATD on the pur­
ine and pyrimidine ribonucleotide pools of L12l0 ascite c ells. An hour 
after administration of 2-ATD, the levels of GTP, GDP, ATD and ADP ,,7ere 
considerably decreased; however the level of IMP Has increased (Table 3). 
When nicotinamide 'vas administered simultaneous ly \<,lith 2-ATD, it pre­
vented, to a large extent, the ettects of 2-ATD on INP, ADP and ATD, 
and to a lesser extent, the effects of GDP and GTP. Using radiolabelled 
precursors, Nelson et al (189) reported that 2-ATD prevented the synthe­
sis of GNP from IMP, suggesting that 2-ATP produces i.ts blockade by in­
hibiting n� dehydrogenase, the enzyme that converts IMP to GMP (Fig 20). 
Mycophenolic acid, a kno,m inhibitor of IMP dehydrogenase, produced the 
same effects of the ribnucleotide pools as 2-ATD (190). In theory, the 
inhibition of the IMP to GHP conversion could result from a blockade of 
D� dehydrogenase or GMP synthetase, or, from some other blockade that 
results in an inhibition of GMP synthes i s as a secondary effect. Hmv­
ever, nIP dehydrogenase appears to be the most likely site because of 
the nicotinamide-2-ATD rel ations hip seen earlier (Table 3), and also 
because of the fact that NAD is a cofactor of the enzyme I}� dehydro­
genase. 2-ATD did not , however, inhibit nIP dehydrogenase that was 
isolated from the leukemia LI210 cells, suggesting that a metabolite of 
2-AT D may be responsible for the antineoplastic activity. 
Ciotti, et al (188) have prepared the NAD analog of 2-ATD (i. e. J.!i), 
by an exchange reaction between 2 ... ATD and NAD in the presence of the 
enzyme NADase, (Fig 21). This analog, �, Has found to inhibit IMP 
dehydrogenase in Ll210 cells. Adduct 78 ,vas treated with nucleotide 
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pyrophosphatase to afford 79, a presumed metabolite of 2-ATD. Crude 2-ATD 
mononucleotide (79) \-Tas determined to be an even more potent inhibitor 
Table 3: Effects of aminothiadiazole on ribonucleotide pools of L1210 in vivo (189). 




3 mg/kg 10 mg/kg 100 mg/kg Nicotinamide, mg/kg each 
Control(10)a (1) (1) (7) 100 mg/kg (3) (3) 
ADP 151 96 71 64 124 112 
ATP 573 536 360 328 472 516 
GDP 40 21 8 11 29 19 
GTP 132 96 26 25 105 53 
CTP 24 17 19 26 19 22 
UTP 1 58 U5 227 2 38 125 206 
IMP 10 32 145 127 10 48 
NAD 90 64 79 90 87 83 
aNumbers in parentheses numbers of separate experiments. 
Mycopheno1ic 
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Figure 20: Major sites of inhibition of purine nucleoside analogs. 
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Figure 21: Exchange reaction between NAD and 2-ATD to form 
2-ATD-mononuc1eotide. 
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of IHP dehydrogenase than J.Ji.. Nelson et al (191) have stud ied the NAn 
analog of 2-ATD (i.e. �),more thoroughly than 2-ATD mononucleotide, 
CIJ), yet, a question not yet ans,-lered, is the point of attachment of 
the sugar moiety to 2-ATD. According to Nelson et al (191), since 2-
ATD exchanges with the nicotinamide moiety of NAD in the presence of 
NADase, the sugar moiety may be attached at either of the ring N atoms. 
However, the possibility that the sugar moiety may be attached at the 
primary amino group of 2-ATD cannot be excluded. In order to investi­
gate the point of attachment of the ribonucleotide to 2-ATD and to bet·­
ter understand the mechanism of action of 2-ATD, the synthesis of a 
nucleoside of 2-ATD, in which the sugar moiety is attached at the pri­
mary amino group, (i.e. 82) was attempted. 
Synthes is of thiadiazole nucleosides: The reaction products ob­
tained \-lhen sugars are allowed to react. with amines have been known for 
many years. Honeyman et al (192) have reported that aromatic amines 
such as aniline and p-toluidine react ,-lith aldohexos es to form N-glyco­
sides via a condensation reaction in alcohol. The presence of a cataly­
tic amount of acid c an help to promote the condensation reaction, 
especially in the case of less basic amines. Panagopoulos et al (193) 
have shmm that N-glycosides of thiazole can be prepared by heating at 
reflux a methanolic solution of 2-aminothiazole and anhydrous glucose; 
hm-leyer ,  recent attempts to repeat this reaction in our laboratory have 
been unsuccessful (194), Prisbe et a1 (161) prepared 2-(2' ,3',S'-tri-0-
benzoyl-B -D-ribofuranosylamino) -imidazole as an unexpec ted product vlhen 
a condensation of 2-aminoimidazole with tetrabenzoyl ribose was carried 
out in the presence of SnC14 and HgCN. Glennon et al (107) have recent­
ly prep ared 2(2',3',5'";"tri-0-acetylribofuranosylamino)thiazole (84); a 
69 
similar method was employed for the synthesis of 82. (Scheme 5). Heat-
ing 2-amino-l, 3, 4-thiadiazole (ll) and ribose (81) in methanol (contain-
ing 1% Hel) for t\vO hours on a steam bath, while allowing the solvent to 
evaporate slmvly, afforded crude 82. Evaporation of the solvent aided 
in the removal of water of condensation from the reaction mixture, 
shifting the reaction equilibrium to the right. The resulting N-ribo-
side, 82, a hygroscopic compound, was a solid under vacuum, but became 
a gummy residue on exposure to air. Due to the difficulty encountered 
in isolating g, the crude reaction mixture "laS acylated without further 
purification. 
Protection of hydroxyl groups in nucleoside chemistry has been suc-
cessfully achieved \vith acetic anhydride in pyridine or in trietbyla-
mine. The latter procedure \vas employed according to the method of 
Schubert et al (195); reaction time \vas varied in order to optimi,ze the 
yield of the desired product. The acylation step was monitored ely thin 
layer chromatography (EtOAc) , and the crude product was subjectecM to 
column chromatography; two major fractions were collected. Acetylatio n  
of ribosylamino thiazole 85 has also been reported to afford t,vo major 
f to ° (2',3',5'-tri-0-acetylribofuranesylamino)thiazole (84) raC'1.ons, 1..e. 
and its exocyclic N-acylated derivative 86 (195) (Scheme 6). 'Jl'hus, 
it was suspected that 82 had undergone. a similar reaction. 
The fraction �vith the higher Rf value "laS identified as containing 
2 (2' ,3' ,5 t-tri-O-acetyl...,d 7D-ribofuranosylamino)�1, 3,4-thiadiazole (83), 
(Scheme 5); structural assignment was made on the basis of infra:a:ed and 
lH,..,NMR. da.ta, correct elemental analysis and mass spectroscopy, (m/e = 
359). 'Mass spectral analysis of the second fraction suggested a com-
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Scheme 5: Synthetic pathway for the preparation of 2-(D-ribofuranosylamino)-1,3,4-thiadiazole (82). 
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Scheme 6: Formation of 2' ,3' ,5'-(tri-O-acetyl-D-ribofuranosylamino) 
thiazole (84) and the N-acylated derivative, 86. 
further supported by correct elemental analysis. The ultraviolet spec-
tra of both fractions were identical, A max (EtOH): 251 nm (e 7200). 
Comparison of the ultraviolet spectra of these products with those of 
other 2-(amino-substituted)-1,3,4-thiadiazoles (196) support the notion 
that ribosylation had occurred at the exocyclic N and not at either of 
the ring nitrogens. The infrared spectrum of both fractio ns indicated 
an absence of amide absorption bands and the two fractions were ulti-· 
mately assigned the structures 83a and 838 respectively, based on the 
characteristic appearance of the anomeric proton signals in their lH_ 
}MR spectrl�. According to the literature (55), the anomeric proton 
signal for the a anomers of various ribosides is further dovmfield as 
compared to that of their 8 anomers; furthermore, the signal for the 
former proton usually appears as a doublet (J = 10 Hz), 'V·hereas the 
anomeric proton signal for the S anomer appears as an apparent singlet 
(J = 1-2 Hz). In the case of ·83, the anomeric proton signal for the a 
anomer appears ato 5.38 as a doublet (J = 9 Hz) (Fig 22) whilst the 
anomeric signal for theS anomer, i.e. 838, appears further upfield at 
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o 5·24 (J = 2 Hz) (Fig 23). This pattern is therefore in agreement with 
the literature report (55) for structural assignments o f  rib os id es . 
During the preparation of the acylated thiazole nucleoside 84 the tHO 
anomers could not be separated by col umn chromatography (195). 
Since the individual anomers) 83a and 8313 were found to undergo 
mutarotation in solu tion to yield an anomeric mixture, deprotection stu-
dies ,,,ere performed on the anomeric mixture) 83a-f{3. Hydrolysis of the 
blocking groups were readily accomplished by stirring a meth anol i c di­
ethylamine solution of 83 at room temperature for four hours (Scheme 5). 
The pr oduct) 82) while hygroscopic) ,,,as i solat ed as a white crys talline 
material . Infrared and mass spectral data were consistent "lith the 
assigned structure; the results of e lemental analysis suggested that 82 
had crystallized with 0.25 mole of water and 0 . 5 mole of MeOH. Unfor­
tunately, g was not very stable in solution and underwent rapid hydro­
lysis to afford 12 and g, as evidenced by the results of thin layer 
chromatography. 
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Hesoionic nucleosides as potential prodrugs: In an attempt to overcome 
the above problem, the next approach vlaS to prepare a mesoionic nucleo­
side that might serve as a pro-drug of 82. The rationale for this is 
tha t mesoionic thiazolopyrimidines and thiadiazolopyrimidines are kno\m 
to be susceptible to nucleophilic attack, i.e. hydroJ.ytic ring cleavage, 
under the appropriate conditions. For example, mesoionic thiazolopyri­
midines un dergo attack by amines at both psuedocarbonyl p os it io n s ; this 
process occurs in a stepwise manner to eventually afford the p arent al­
kylaminothiazole (Fig 24). Glennon et al (11) have found that alkyl 
substituents at the position bet\"een the carbonyl groups significantly 




Figure 24: Nucleophilic ring opening of a mesoionic xanthine analog. 
of rin g opening in detail, and has obtained confirming data, and Coburn 
et al (6) have reported that the mesoionic l,3,4-thiadiazolopyrimidines 
undergo ring opening about 103 times faster than the corresponding mes-
oionic thiazolopyrimidines. Thus, mesoionic thiadiazolopyrimidine 
nuc1eosides such as 91 and 92 as well as the 1-aza analog .21 may lvell 
serve as potential pro-drugs in vivo, by undergoing ring-opening to 
afford 83. 
Even though these meso ionic nuc1eosides were designed as potential 
pro-drugs, the possibility exists that these mesoionic nucleosides may 
not undergo ring-opening in vivo to generate 83. Nevertheless there is 
evidence that the intact mesoionic nucleoside may be active ��. 
Allopurinol (�) is rapidly metabolized to oxipurinol (88) (Fig. 25); in 
addition to inhibiting xanthine oxidase, oxipurino1 also causes an in-
crease in the excretion of orotidine and orotic acid in vivo. Kelley 
(197) reported that since allopurinol and oxipu rinol decreased the in-
corporation of labelled orotic acid into nucleic acids in cultured hu-
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Figure 25: Formation of I-allopurinol ribonucleotide (�) and 7-oxipurinol 
ribonucleotide (90) from allopurinol (§J). 
man fi brobl asts , a probable site of inhibition by these c ompounds in­
volved some enzymatic steps in the bioconversion of orotic acid to U}W. 
(Fig 20). Beardmore et al (198) have reported that a metabolite of 88 
appears to be responsible for the de novo inhibition of pyrimidine bio­
synthes is. In man, the conversion of orotic acid to liMP is catalyzed 
by orotate phosphoribosyl transferase (OPRT) and orotidylic decarboxy­
lase (ODC) r espe ctivel y . Previous studies by Fox (199) and Kelley (200) 
suggested that allopurinol ribonucleoside (�) might be responsible for 
the inhibition of pyrimidine biosynthesis de novo. However, re cent 
evidence suggests that this may not be the case. In c hildren with Lesch 
Nyhan syndrome (201) (i. e. a familial disorder of uric acid metabolism 
and a central nervous system disorder) , in v7hich there is functional 
ab senc e of hypoxanthine-guanine phosphoribosyl transf e r ase (HGPRT), it 
was observed that there vTaS an incre as ed excretion of oro tid ine when 
these p atients ",ere treate d with allopurinol. It was also found that 
ox ipurinol 'vas at le ast 6 times more potent than al lopurinol in inhibit­
ing pyr imidine biosynthesis de novo. It 'vas further suggested that in­
hibition of ODC ",as due to the synthesis of a ribonucleotide of oxipuri­
nol ( i.e. 90) (Fig 25). Thus it appear s that purinone iso-nucleosides 
might be recognized in vivo as potential pyrimidi ne antimetabolites. 
The designed me s oionic thiadiazolopyrimidine nucleosides display a 
distinct structural similarity to 2Q, p art icu larly in that the ribosyl 
moiety is attached to the purine 3-position and that they possess the 
2,6"dioxo sub st itution pattern, Thus , the mesoionic nucleosides 91, � 
and 25 might act in a similar manner and serve as inhib itors of pyrimi­
dine biosynthesis without undergoing ring-opening to generate 2-ATD 
nucleoside in vivo. 
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In addition to the salient fe atures of these mesoionic nucleosides, 
they may also serve as potential irreversible inhibitors by acting as 
latent acylating agents. This is a direct consequence of the ir step-�vise 
ring-opening capability in the presence of a nucleophile (Fig 26). 
Synthesis of mesoionic thiadiaiolopyrimidine nucleosides: The re-
qui red mesoionic nu c leos ide 91 was prep ared by heating 83afS with malo-
o 
nate ester 62 neat, at 160 C (Scheme 7). Attempts were made to cy-
cl:lze separately either 83a or 838 to a fford the corresponding mesoionic 
nucleosides 9la and 9113. However, under the cyclization conditions em-
ployed , the individual (83a and 838) nucleosides undenvent therm al race-
mization to afford an anomeric mixture of 83, and, consequently, an 
anomeric mixture of 91. In a separate expe ri men t , heating 83a or 83S 
neat, at l600C in the ab s ence of 62 also resulted in racemization of 
starting materials as evidenced by thin layer chromatography. Thus, 
subsequent cyclization reactions were performed on the anomeric mixture, 
83afS, and the anomeric mixture of products, 9lafP, 'vas subjected to 
chromatography, in order to isolate 9la and 9113. The column Has first 
treated with EtOAc to remove unreacted malonate ester 62 and traces of 
unreacted 83. The mesoionic nucleosides were then eluted off the column 
using a 1:1 EtOAc-MeOH mixture. The 10 mL fr actions containing the sep-
arated a and S anome rs ,,,ere collected and upon evaporation of the solvent 
yielded the two anomers in crystalline form. The anomer Hith the higher 
Rf value ,,,as found to be nO,; this assignment is supported by �l-NMR 
chemical shifts and splitting pattern of the anomeric proton signal, and 
is consistent with cor rect elemental analysis, The anomer with the low-
er Rf value ,vas found to be the S anomer , · 9l8, on the basis of its 
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T he unsubstituted meso ionic n ucle o s id es 92a and 9� could not be 
satisfactorily prepa red with unsubstituted malonate ester 61. The fus­
o 
ion reaction at 160 C gave an orange oil Hhich upon trituration Hith 
anhydrous ether gave very small amounts of desired co mp ound , along Hith 
several un identified side products. Attempts to purify the product 
using column chromatography were unsuccessful. In order to synthesize 
the desired nucleos ides 92a and 926, another method of cyclization Has 
investig a t ed . 
Use of Carbon Subexide: Several investigators (202-205) have employ-
ed the use of carbon suboxide (C302), a very reactive bisketene in the 
preparation of mesoionic heterocy cles, unsubstituted at th e C6-position. 
This method of cyclizat ion offers the advantage of usually being a 
high-yielding reaction that can be performed at low (i.e. room tempera-
ture or below) temperatures. 
Of the many reactions known to afford C30Z (�). there are at least 
four methods which can be u sed to generat e 99 in a relatively convenient 
manner. These include: 




o thermolysis of O , O-diacetyl tartaric anhydrid e  at 600-700 C (208). 
o 
pyrrolysis of diethyl oxaloaceta t e at 850 C (209 ), and 
dehydrohalogenation of dibromomalonyl dichloride ''lith zinc at room 
temperature (210-213). 
Because of the app arent ease of synthesis and mild r e a cti on condi-
tions , C302 (�) was ultimat e ly prepared by the last method (Scheme 9). 
The requisite dibromo malonic a cid (JJ) \'las prepared from commercially 
available malonic acid (96) by the method of Teichman (213). The cor-
responding dibromomalonyl dichl o ride (98) was prepared by the method of 
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Staudinger et al (210), and C302 (22.) ,,,as generated by the addition of 
dichloride 98 to a stirred mixture of zinc turnings and anhydrous 
ether (210) (Fig 28). 
Model reactions were first performed with 22. to confirm its genera-
tion and to work out the necessary conditions. Carbon suboxide 99 was 
generated as discussed above and was bubbled into a solution of 2-ethyl-
amino-l,3,4-t hiadiazole (100) in ether at room temperature (Scheme 8). 
A thick "lhite precipitate formed almost instantaneously and ,,,as identi-
1 
fied as the mesoionic c omp ound 101 by infrared and H-m�R data and by 
melting-point, as compared ,·lith literature values (6). 'This consti-
tutes the first synthesis of 101 by the carbon suboxide method, and the 
yield (92%) was found to be better than that (73%) obta:iined by the pre-
paration of 101 via the fusion reaction ,"ith malonat.e ester 61 (6). 
Carbon suboxide (22.) ,,,as also used to prepare the known mesoionic 
thiazolopyrimidine nucleoside 102 from .84 (Scheme 8). .l\gain, the pro-
duct ,vas identified by spectral and melting point comparison with that 
previously reported (195) and by thin layer chromatographic analysis 
using an authentic sample of 102. 
Hith respect to the mesoionic 1,3,4-thiadiazolopyrimiciine nucleo-
sides, the initial carbon suboxide condensations ,,,ere performed on the 
individual Ci. and 8 anomers of 83 at room temperature, using EtOAc as 
solvent (Scheme 9). In b oth cases ,  a white precipitate formed ,·lithin 
20 minutes; thin layer chromatography of solutions of t£1e precipitates 
indicated that even though individual Ci. and 8 anomers OlC' 83 had been 
employed in the cyclization procedure, anomeric mixtures of product had 
been obtained. It is possible that during the cyclization reaction, 
some dibromomalonyl dichlo ride (98) bubbles over along\.;rith the C302 
84 
o 
A � Nitrogen inlet 
B � Circulating water ( inlet and outlet not shown) 
C � Carbon Suboxide 
Figure 28: Apparatus employed for the generation of carbon suboxide 
in situ. 
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Scheme 8: Preparation of Anhydro-8-ethyl-5-hydroxy-7-oxo-l,3,4-thiadiazolo[3,2-a] 
pyrimidinium Hydroxide (101) and Anhydro-8-(2' ,3' ,5'-tri-0-acety1-D­
ribofuranosyl)-5-hydroxy-7-oxo-thiCl.;1:o1o[3,2-a]pyrhidinium Hydroxide (102) 
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Scheme 9: Synthesis of Anhydro-8-(2' ,3' ,5 '-tri-O-acetyl-D-ribofuranosyl)5-hydroxy-7-
oxo-l,3,4-thiadiazolo[3,2-a]pyrimidinium Hydroxide (21). 
co 
'-J 
(99), and/or that C302 (22.) itself reacts with atmos pheric moisture to 
afford malonic acid that catalyzes this racemization. In a separate 
experiment, the individual 0; and 13 anomers of 83 were dissolved in a 
minimal amount of EtOAc and kept at room temperature for 30 minutes. 
There was no sig n of mutarotation, confirming that mutarotation does not 
occur spontaneously in solvent (EtOAc) alon e . Consequently, cyclization 
was performed on an anomeric mixture of 830;� and the corresponding mes-
oionic nucleosides 920; and 9213 were separated by column chromatography 
(Scheme 9). The co lumn was first treated with EtOAc to remove unreacted 
�0;-tB and then with a 1: 1 EtOAc-NeOH mixture;  it was observed that the 
mesoionic nucleoside 22 unde rg oes ring-opening on exposure to HeOR on 
the column, to afford some starting materia l 830;�, which ,'laS evidenced 
by thin layer chromatography. This accounted for the 10y7 yields of 920; 
and 928 during column separation. Subsequently, the 8 anomer of 92 was 
purified by crystallization from EtOAc and structural assignment 'vas 
made on the basis of its infrared and �-NHR spectrum and correct ele-
mental analysis. The 0; anomer of � could not be purified easily and, 
after several unsuccessful attempts with column chromato graphy, was 
purified by preparative thin-layer chromatography; structural assign-
1 ment of 920; was based on the H--NMR spectral data (Fig 29). 
As mentioned previously. the preparation of the �-aza analog of 
meso ionic nucleoside � (i.e. 95) was also prop osed . Before attempt i ng 
the synthes is of the nucleoside � , it became nec essary to perform a 
model reaction with phenoxycarbonyl isocyanate (105) as the cyclizing 
reagent and 2-ethylamino 1�3,4-th:ladiazole (100) to afford the corres-
ponding mesoionic thiadiazolo triazine (}06). The compound 105 was pre-
pared according to the procedure of S pez i ale et al (214) from phenyl 
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carbamate (103) and oxalyl chloride (104). The mesoionic compound 106 
was synthe s i zed by the method of Coburn et al (159) (Scheme 10). The 
product 106 \"as found to be very unstable, and rapidly decomposed to the 
urea 107 on exposure to moist ure. The structures of 106 and 107 \"ere 
based on their infrared and lH_�m spect rum and melting point compari-
sons, with those previously reported (159). The mesoionic compound 106 
could not be recrystallized to afford pure 106. The crude product exhi-
bited low s o lub il ity in organic solvents such as EtOH, DMF, and DHSO. 
Hhile glacial acetic ac id was reporte d to be the solvent of c.hoice, (159) 
attempts to recrystallize 106 \-lere unsuccessful and yielded the ring 
opened product 107. Greco et al (40) syn thesized mesoionic pyrimidino-
triazines (Fig 4c) and also rep or ted t hat the insolubility and instabil-
it y of mesoionic compounds such as in Figure 4c made purification ex-
tremely difficult. Thus the preparat ion of the mesoionic nucleoside 95 
Has abandoned. 
o 






Scheme 10: Preparation of 1-Ethy1-1 (1, 3,4-thiadiazol-2-y1)urea (107). 
Deprotection studies: Deprotection of p rotected nucleosides have 
been accompl ished by both acid or base c atalyzed hydrolysis. Since it 
has previousl y been reported (11,158) that mesoionic xanthine analogs 
substituted at the C6-position are more stable to nucleophilic attack 
than the correspond ing unsubs tituted a nalog, and due to the fin d ing that 
92a and 928 undergo rapid ring-opening in MeOR, the initial deprotection 
studies were conducted ,·rith 91. Several at tempts were made to deprotect 
the nucleos ides , using varying condit ions of time, temperature and 
amines and the solution was thin layer chromatogramed periodically, 
( Table 4). Results of a ll these at tempts indicated that ring-opening 
appears to occur faster than deacylation . It has previously been re­
ported (151) that ring opening of meso ionic xanthine analogs can occur 
by a nucleophilic attack at either the C5, C7 or 8a position to give 
ring-opened products . Thin lay er chromatogram of the solutions indi­
cated several uniden tifiab le products , some of which could be the ring­
opened products. In one instance, the crude product was isol a te d and 
the �-NMR spectrum indicated the loss of the aromatic proton, suggest­
ing that ring opening may have occurred at the 8a position. Hmvever, 
the possibility exists that ring opening of 9la+s can also occur by 
a t tack of the amine at either of the pSlledocarbonyl positions. Thus 
all attempts to d eprotect either .21. or 92 were unsuccessful and no de­
sired p roducts ,,,ere isolated. 
Evaluation: There have b een several reports that unprotected nucle­
os ides suf fer from certain limitations such as low lipophilocity and 
higher susceptibility to enzymatic degradation in vivo. Since the pro­
tect ed mesoionic nucleosides 91a, 918, 92a and 928 were stable crystal,... 
line solids , they were submitted for evaluation of antitumor activity in 
91 
Table 4: Deprotection conditions employed for the deacy1ation of 
meso ionic thiadiazolopyrimidine nucleoside 92. 
ANOMER SOLVENT BASE TEMP. TTME 
1. a,-tS MeOH HNEt2 RT 17h 
2. a-tB MeOH HNEt2 RT 12h 
3. a-tS MeOH HNEt2 0 C lh 
4. a-tB MeOH HNEt2 0 C 5min 
5. a-tj1 MeOH l-U\"'Me2 0 C 36h 
6. a-!f3 MeOH HNMe2 RT 2h 
7. a-tS MeOH HNMe2 0 C 2h 
80 a MeOH HNMe2 0 C Ih 
9. a MeOH NH3 0 C 2411 
10. a MeOH NH40H 0 C 2lfh 
11. a NeOR NH 3 0 C 2h 
12. a-tB Meon - 0 C 12h 
13. a-fj3 - HNEt2 RT 2h 
14. a-tS - HNEt2 0 C 2h 
15. a MeOH pyridine 0 C 4811 
16. a MeOH pyridine 0 c: 12h 
17. a MeOH HN- ( iPr ) 2 0 C 36h 
18. a-lS MeOH HN- ( iPr ) 2 0 C 24h 
19. a-tS NeOH HN- ( iPr ) 2 J 0 C 18h . ...� ---�.-- J.:O--� 
� Ring opening (RO), as evidenced by thin layer chrmnatography 
RESli'LTS 



















b Loss of aromatic thiadiazole proton on work up of Ilroduct, sugges t ing 
r ing opening may be occurring by attack at the 8a position. 
c Stable in MeOlI upto 12h, as deter.mined by thin layer chromatography. 
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several assay systems. Results will be discussed in Section IV 
(i.e� Discussion of Biological Results) . 
C. Thiazolinopyrimidine Nucleosides 
Rationale: Thymine was the first pyrim idine derivative is ola ted 
from hy drolys a tes of nucle ic acids; Kossel d is covered the substance in 
1893 and named it after the source from w hi ch it was originally iso­
lated, i.e. thymus nucleic acid (21S). 
Thymidylate s ynthetase catalyzes the reduc tive methylation of 2'­
deoxyuridine monophosphate (dTn�) to a thymine nucleoside phosphate, 
i.e. thymid ine monophosphate (TMP), with the concomitant conversion of 
NS,NlO-methylcne tetrahydrofolic (THF) acid to 7,8-dihydrc folic (DHF) 
acid (Fig 30). THF acid plays the dual role of serving both as a one 
carbon unit donor as well as a direct hydrogen donor. The convers ion 
of dUHP to TIIP involves a "processing" of the deoxynuclcotide before 
it can be utilized for DNA synthesis, since dUMP cannot be directly in­
corporated into the DNA. Thus, we see the important role that THP 
plays in DNA biosynthesis. 
The phenomenon of " l�hymineless death" further emphasizes the impor­
tance of TNP. This is a p henomena in '''hich irreversible events occur 
within the cells that continue to synthesize RNA and protein but not 
DNA. Cohen (216) has proposed that irreparable DNA degradation during 
thymine depravation could be the mechanism of "thymineless death." 
The enzyma tic site involving thymidylate synthetase and the cofac­
tor, THF acid, has been the target of research in cancer chemotherapy 
for over 15 years, in an attempt to inhibit DNA synthesis in rapidly 
grm"ing cancer cells . Efforts in this direction involve the synthesis 

















trexate) (218). An antagonist that blocks the synthesis of thymidylate 
synthetase has the potential of destroying the viability of tumor cells 
and could serve as a useful c hemotherapeutic agent. Intracellular reg­
ulation of thymidylate synthetase activity by means other than the use 
of direct antagonists, involves the design of molecul e s  that resemble 
the components involved during enzyme catalysis, and is certainly worthy 
of consideration. 
The conversion of dUMP to 1}W has been s tud ied by several investiga­
tors (219-222), in an attempt to elucidate the mechanism. The catalysis 
by thymidy late synthetase is suggested to proceed in three steps (223) 
(Fig 31). 
(1) An active-site nucleophile of the enzyme adds to the C6 po si­
tion of dUMP to form an enzyme-substrate adduct, in which there is 
high electron densi ty at the CS-position, resulting in an eno late 
anion. Pogolotti et a1 (224) have reported that the nucleophile on 
the enzyme appears to be a sul fhydryl group of a cysteine residue. 
(2) The resultant CS-enolate anion attacks the NS>-N10-methylene­
tetrahydrofolic acid to form a ternary complex in which the enzyme, 
subs trate and cofactor are covalently bound. 
(3) A reduction step oc curs via a 1,3 hydride shift, where the 
hydride is transferred from the cofactor to the substrate to y;i.eld 
the thymidylate-enzyme adduct in Hhich the CS-C6 bond is saturated. 
The driving force for this step appears to come from the expulsion 
of DHF acid. Finally enzymatic base ca talys is on tIle adduct leads 
to thymidylate monophosphate and the enzyme is simultaneously elim­
inated. 
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Figure 31: Proposed mechanism for the conversion of dUlfP to TMP (219). 
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of the ternary complex (Fig 32) as an inhibitor of the enzyme thymidy-
late synthetase. 
Examination of the mesoionic thiazolinopyrimidine nucleoside III 
(Fig 33) reveals tha t this nucleoside incorporates within its structure 
the reactive sites of the enzyme, substrate and cofactor when they are 
all covalently bound, to give a complex resembling a multisuhstrate ana-
log. Thus the mesoionic nucleoside appears to structurally mimic the 
complex that is formed during catalysis by the enzyme, and may serve as 
a potential inhibitor of thymidy1ate synthetase. The mesoioni:c nuc1eo-
side 113 may also exert its inhibitory effects as an irrevers�ble acy-
1ating agent in vivo (as shown in Section IIIB� for the mesoionic thia­
diazo1opyrimidine nuc1eos ide, Fig 26) by virtue of ring-openi-ng by 
attack of an active-site directed nuc1eophile on the enzyme. Further-
more, the fact that certain purinone isonucleosides can act as pyrimi-
dine antagonists (as discussed in SectionIIIB ) , suppor ts the possibility 
that derivatives of 113 might be of potential chemotherapeutic interest. 
Synthesis: The deoxyriboside of 2-aminothiazo1ine, i.e. 111.0, ,.,as 
prepar ed by reacting 2-aminothiazoline (108) with D-2-deoxyr�hose (109) --- ---
in methanol containing 1% He1 (Scheme 11). The solution was heated on a 
steam bath and concentrated to half its volume to affor-d a pale brmm 
viscous residue. The reaction mixture contained 110, as well as the 
starting materials, 108 and 109. Since the mixture could not be readily 
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separated, the crude residue was dried under vacuum to give a pale cream-
colored solid, that was hygroscopic on exposure to atmosphere. 
Acetylation of this solid was ac compl is hed with acetic anb-ydride to 
afford a mixture of acy1ated products (Scheme 11). Most of these pro-
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Figure 32: Structure of 8-deaza-dihydro analog of
 the ternary complex as an inhibitor 







Figure 33: Structural similarity between the ternary complex f above) 
and mesoionic thiazolinopyrimidine nucleoside, 113. 
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Figure 34: Products obt�ined during the acylation of crude 110 as 
evtdenced by thin layer chromatographic analysis (using 
EtOAc as solvent), 
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pIe, 2-aminothiazoline (108) was identified by thin layer chromatog-
raphy. N-Acetyl-2-aminothiazoline (115) was isolated and compared with 
an authentic sample previously prepared in these laboratories (151). 
In addition to two products to be described below , several additional 
minor products were neither isolated nor identified (but may be mono-
acylated derivatives of 110). Several attempts �.;ere made to increase 
the yield of the des i red acylatec1 nucleoside III by prolonging the reac-
tion time and by varying the temperature of the reaction mixture during 
the acylation; however, these attempts resulted in increased amounts of 
what has tentatively been assigned as the N-acetyl derivative of 111 
i.e. 117. The tentative structural assignment of ll� is based on the 
subsequent finding that although III and 117 possess similar chromato-
graphic characteristics, ll� did not yield a mesoionic product upon re-
action ,.,ith malona te esters. 
Separation of the individual components of the acylation reaction 
was ach ieved by column chromatography and product 111 was obtained as a 
o 
liqu id. Attempts ,.,e:t;"e made to crystallize III by cooling to 0 C and 
triturating with anhydrous ether; however, thin layer chromatographic 
analys is of III after storing at OOC overn ight indicated that the pro-
duct was unstable and unden.,ent hydrolysis at the glycos idic bond. In 
order to prevent decomposition, it became necessary LO prepare the de-
sired acylated nucleoside ill and to inunediately perform the cyclization 
reaction without further purification . 
The mesoionic nucleos ide 112 was obtained in optimal yield by fusion 
of crude III with bis(2,4,6-trichlorophenyl) malonate ester (62) at 
160°C for three minutes ( Scheme 11). The resultant yellow oil was tri-
turated \v;i.th anhydrous ether to afford cream-colored crystals that ,.,ere 
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recrystallized f rom methylene dichloride. Thin layer chromatographic 
analysis of this product in several d ifferent solvent systems, and also 
using tvo-dimensional thin ],ayer chromatography, indicated homogeneity . 
This suggests either that o nly one anomer was obtained exclusively over 
the other, or that both anomers, if present, have idelltical Rf values. 
The IH-NNR spectrum of 112 showed the anomeric signal as a doublet of 
doublets at <56.6 (JIJ" == 10 Hz) (Fig 35). This pattern is characteris­
tic for the a--configuration of 2-deoxyribosides, (225) whereas in the 
case of the B -anomer, the s ignal would have appeared as a psuedo-triplet 
(Jl J" 14 Hz) (226). The infrare d spectrum of 112a i.ndicates the car-
bonyl absorption bonds at 1625cm-l and 1635cm
-l 
as well as the acetate 
absorption bands at 1760cm-l. Although several explm:tations are possi­
ble, it may be that during the fus ion reaction, any 1�2P present under-· 
goes thermal racemization to finally afford 112a exclusively. A second 
product was isolated in one of the initial cyclization reactions; hm-l­
ever this compound ,-las la ter identified to be the non�mesoionic thiazo­
line d erivative 114 by compar ison \\lith an. authentic sample previously 
prepared in thes e laboratories (153). The formatio n of .114 can be 
explained by the presence of 2-aminothiazoline, a COilU'llOn hydrolytic con­
taminant in several of the earlier reactions vlhen 111 was stored at OOC 
overnight. 
Deprote ction of l12a to the desired deoxyribonucl.eoside .113 was 
achieved by two methods ( Scheme 11). In one case, 112a was dissolved 
in MeOH containing a catalytic amount of HNEt2 and the so lution was 
stored at oOe for 4 days. In the se cond case, the solution was stirred 
at room temperature for 24.,..30 hours,' and the deprote c tion was monitored 





the antibiotic tub ercidin (7-deaza-adenosine) by treatment ,.,ith nitrous 
acid, (229) was found to inhibit Sarcoma cells in vitro and leukemia 
P388 cells in vivo (230). Also, 7-DI was one-fourth as toxic as tuber­
cidin to mice and rats. In extracts of Sarcoma 1 80 cells, 7-DI inter­
fered with the phosphorylation of inosine and adenosine and it appears 
to exert its antineoplastic activity at the ribonucleotide level. Thus 
7-DI, due to its close structural similarity to inosine, may be acting 
as an antimetabolite of IMP (Fig 37). 
Hesoionic imidazothiazine nucleoside 146, (X=CH) represents the 
first example of a Class II mesoionic xanthine nucleoside, in which the 
sugar moiety resides at the purine 9-position. Until now> there have 
been no reports of modified nucleosides in which the N3 nitrogen atom 
has been replaced by a sulfur atom; thus these compounds are also the 
first examples of these types of nucleosides. This mesoionic nucleoside 
could be of potential biological interest since it is strlLlcturally and 
isosteri.cally similar to non-mesoionic purine nucleosides> such as ino­
sine, 7-DI, xanthosine and related agents (Fig 37) and as such, might 
inhibit the conversions of IHP to XHP or the conversion of XHP to GHP 
( Fig 20). Thus, these compounds were proposed for synthesis and for 
subsequent evaluation as a potent ially useful chemotherapeutic agent. 
Model studies with the mesoionic heterobase: Since tile mesoionic 
imidazothiazine nucleoside 146 represents the first example of a novel 
Class II meso ionic xanthine nucleoside, in which the sugar moiety is 
attached at the purine 9-position, and because virtually nDthing was 
kno\m about the parent heterocycle, it became necessary to first study 
the mesoionic imidazothiazine ring system before attempting to synthe­


















� ..�N) "'. 
I 
R 
R :: Ribose 




first example of a mesoionic imidazothiazine (ie 122), but i1ts chemistry 
was not investigated. Thus, the first goal of this work ,.;as to prepare 
several examples of mesoionic imidazothiazines and at least one example 
of a related non-mesoionic imidazothiazine (e.g. 123) as well as a mes­
oionic triazolothiazine (e.g. 125) in order to determine their stability 
and to obtain comparative spectral data (Fig 38). 
The ethy1�substituted mesoionic compound 121 \Vas prepared b;y a fus­
ion reaction between 1�methyl-2-mercaptoimidazole (methimazole; :120) and 
bis-(2,4,6-trichlorophenyl) ethyl malonate (62) (Scheme 12); aH.:empts 
to prepare the unsubstituted derivative 122 by this same method vere 
unsuccessful. Hhen methimazole (120) was heated with bis-(2,4�6-tri­
chlorophenyl) malonate (61) at l2SoC for 20 minutes, an orange product 
was obtained that could not be purified or characterized. React.:ion 
temperature and duration of heating were varied but resulted either in 
formation of this same decomposition product, or, at lower temperatures, 
in no reaction. Kappe (41) had previously reported the preparat:ion of 
several mesoionic thiazines, such as 128 and ih (Fig 4), by the. :reaction 
of substituted malony ldich1orides with the appropriately substH.:uted 
thioamides. Benzyl malonyl dichloride (126) was prepared (231, 232) and 
reacted with 2�mercaptopyrimidine(127) to afford a product (i.e. 128) 
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that was identical in all respects to that prepared by Kappe (4L). 
Benzylmalonyl dichloride was next reacted \Vith methimazole (1-20) to afford 
the desired 129 (Scheme 12). Due to the success of this reaction, un­
substituted malonyl dichlor:i..de was allowed to react w:i..th metbimazole. 
(120) in an attempt to prepare the des:i..red 122, however, no mes'o:i..on:i..c. 
product was :i..solated, Compound '122 was subsequently prepared by reac­
tion of methimazole (120) with carbon suboxide (Scheme 12). The mesoio-
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Figure 38: Mesoionic imidazothiazines, triazolothiazines, tetrazolothiazine, 
pyrimidinothiazine, and non-meso ionic imidazothiazines. 
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nic triazolothiazine 125 was prepared by the fusion of 3-methyl-4-ethyl 
-1,2, 4-triazo1e-5-thione (233) (124) with g Hhile the non-mesoionic 
123 was prepared by reaction of imidazo1ine-2-thione (130) with carbon 
suboxide. The s truc tures of 125 and 123 were assigned on the basis of 
their infrared and NMR spectra, and elemental analysis. 
While this work was in progress, Coburn et al (234) and Potts et al 
(235) reported the preparation of several related mesoionic conpounds. 
(e,g. 121, 129, 131-134), including the non-mesoionic derivative 135. 
The physico-chemical and spectral properties reported for 121 and 129 
were comparable with those for the 12� and 129 prepared herein; conse-
quently, microanalytical data Here no t obtained for these two compounds. 
It has been observed tha t the infrared spectra display carbonyl 
stretches at loHer frequencies when there is a phenyl substituent at the 
C6-position as in the case of the mesoionic compound 131 (1599 and 
1581cm�1) as compared with the m esoionic compounds 121 (1655, 1570cm-1), 
-1 
· 
... 1 1� (1690, 1635cm ) and the non,mesoionic compound 12� (1680, 1620cm ). 
A similar trend has been observed \vith the mesoionic thiazolopyrimi-
d:i,nes (158,235). 
Structural assignment of the non-mesoionic compound 123 can be made 
1 on the basis o f  infrared and H,NMR da ta. The infrared spectrum of 123 
displays two carbonyl stretching bands at 1680 (C5 C�O) and 1620 (C7 C= 
0) cm�l. Clayton et al (236) have reported that the 5-oxo compounds 
such as � possess a single carbonyl stretching band in the 1670cm-1 
region, while the thiolactone 137 absorbs in the 1625cm-1 region. In 
1 the H,NMR spectrum of 123, aromatic signals for the imidazole protons 
were obtained at IS 8.2 (C3H) and 7.9 (C21I), a singlet at <5 5.0 corres-
ponding to the C6_proton, and a broad D20.,-exchangeable singlet at 0 
112 
137 
11.75, suggesting an -OH group. The assignments for the imidazole pro-
tons at C2 and C3 were made on the basis of the structural assignments 
of compounds 131 and 136 by Coburn et al (234) and Clayton et al (236) 
respectively. However, Potts et al (235) have assigned the signal at 0 
8. 1 for the C2 proton and 0 7.8 for the C3 proton for the compound 131. 
Since compound 123 displays two carbonyl stretches in the infrared 
spectrum, but exhibits a D20-exchangeable singlet at 0 11. 75 for an -OR 
1 group in solution in the H-NMR spectrum, the compound may be best rep-




















The infrared spectrum of the mesoionic compound 122 displayed carbonyl 
-1 1 stretches at 1690 (Cs C�O) and 1635 (C7 C=O)cm and the 1H-��1R spec-
trum exhibited imidazole signals at 0 8.0 (C3) and 7.8 (C2) respective-
ly, a singlet at 0 5 .1 corresponding to the C6-proton and <5 3.7 for the 
N-CH3 protons. The aromatic imidazole signals were further do��field 
than those for methimazole (120) itself (i.e. 0 7.1 (C3H) and 6.9 (C2H» , 
suggesting extended conjugation resulting from cyclization. 
Synthesis of the mesoioriic imidazothiazine nucleoside: In order to 
synthesize the mesoionic nucleoside 146, it �"as first necessary to pre-
pare the precursor nucleoside 139 (Scheme 13). The required nucleoside 
139 was prepared using the procedure by Imbach et al (237); imidazo1ine-
2-thione (130) �'laS fused with tetraacety1 ribose ( 138), in the presence 
of 12 as catalyst, to afford the mononucleoside 139 and dinucleoside 
140. This reaction vlaS performed, and the t�"o products v7ere separated 
by column chromatography. The u ltraviolet spectrum of'139 did not agree 
with t he spectrum reported by Imbach et al (237); instead, it exhibited 
a hypsochromi c shift, indicative of decreased conjugation. The �-!\11R 
spectrum of 139 did not show the presence of aromatic signals in the 
dmvnfie1d regions; instead, it exhibited a set of triplets further up-
field. Mass spectroscopy of the presumed 139 revealed a parent peak at 
m/e 360; whilst the desired nucleuside should have had a parent peak at 
mle 35 8 ,  suggesting that � was a dihydro derivative. Correct elemental 
analysis of presumed 139 was obta ined only ""hen the C ,H ,N ratios were 
calculated according to a molecular weight of 360. Investigation of the 
commercially available starting materials indicated that imidazoline-2-
thione '(130) was in actuality imidazolidine-2-thione, (141) and that the 
nucleoside prepared ""as r ea11y ' 142 and not the desired product 139 
114 




H AcO Ac 
130 138 139 AcO 
140 





(Scheme 14) . In order to synthes ize 139, it became necessary to pre-
pare imidazol ine-2-thione 130. Using the pr o cedur e of Marbvald, (238) 
aminoacetaldehy de diethylacetal (143) and po tassium isothiocyanate (144) 
\vere allowed to react at p H  5.0 to afford the desired heterocycle 130 
(Scheme 15). The procedure of  Imbach et al (237) was then repeated 
using 130 and ..:!-38, in the pres ence of IZ catalys t ,. to af ford 139 which 
\vas separated and purif ied by column chromatography. Nucleos ide 139 
existed as an oil at roo m  temp er ature, but 'vas a pink solid under vac­
uum. The ultraviolet, infrared and \I-Ntffi spectr& of nucleoside 139 
,vas identical with that rep o rte d by Imbach et al (237). 
Once the required nu cleoside 139 had been s ucces s fully obtained, 
attempts ",·ere made to prepare the desired mesoionic nucleoside 145 
(Schem e 15). The desired protected mesoionic nucLeoside, 145a could 
not be prepared successfully, by heating 139 , neat with g, at 1250 for 
20 minutes . Horkup of the reaction mixture only afforded starting 
materials . 
o 0 
Varying the temperature from 115 to 1.SO C and varying the 
time of heating from 15 minutes to 60 minutes did 1110t afford the de-
sired product l45a. Lower temp eratures gave back starting materials and 
higher temperatures yielded decomposition products that \V·ere not iden-
tified, When bis (Z,4,6-trichlor ophenyl) malonate, (�l) was heated neat, 
with 139, again, the desired nucleoside _145b , uns t�b s t itute d at the C6-
position c ould n o t  be obtained, even \-lhen several attempts 've re made 
with varied temperatures and time periods. Several att emp ts were made 
to prepare the benzyl substituted nucleoside l45c; however, when 126 
was allowed to react with ill, the desired nucleoside145c was not ob-
tained ::mccessfully. The next app roach was to prepare the unsubs tituted 
nucleoside l45b via the carbon suboxidemethod, since the corresponding 
116 
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Scheme 14: Preparation of 1-(2' ,3' ,5'-tri-O-acetyl-D-ribofuranosyl)imidazolidine-2-thione, (142). 







Scheme 15: Synthesis of mesoionic imidazothiazine, 145. 
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mesoionic heterocycle 122 had been prepared 'successfully by this method. 
When C302 (22.) was bubbled through a solution of 139 at room tempera-
ture, a ye1lo\v solid was obtained after 20 minutes; the solid could not 
be purified and \vas found to decompose on standing. In the next attempt 
to prepare l45b, C302 was bubbled into a solution of 139 at O
OC to af-
ford white crystals after 40 minutes. Hmvever, it was observed that the 
Hhite precipitate formed at OOC was not stable at room temperature and 
rapidly undenvent decomposition on exposure to moisture, although it was 
apparently stable for an indefinite period of time at OOC under vacumm, 
when moisture was excluded, All attempts to purify this compound by re-
crystallization or column chromatography were unsuccessful. Infrared 
and �l-NMR spectra of a freshly prepared sample indicated the presence 
of the desired mesoionic nucleoside, l45b. The infrared spectrum showed 
the presence of psuedocarbony1 and acetate stretches at 1635 and 1750 
-1 1 cm respectively. "tl-NMR. spectrum indicated the presence of the aroma-
tic proton signals at 15 7.7 and 7.5 respectively (,vhereas the aromatic 
protons signals for 139 appear at 15 6.95 and 6.8) and also a singlet at 
15 5.35 which ,vas due to the C6-proton, again suggesting that l45b was 
being formed during the carbon suboxide reaction. Mass spectroscopy 
and fast atom bombardment (FAB) spectrum indicated that l45b r apidly 
unJergoes ring-opening or a rearrangement to some unidentified product 
and does not exhibit the expected parent peak at mle 426. However, 
mass spectroscopy and FAB spectrum show mle 358 signal, which is due to 
the nucleoside 139. This suggests that the mesoionic nucleoside l45b 
rapidly loses carbon suboxicle (m/e 68) t o  afford 139 (m/e 358) , The 
FAB spectrum also revealed trace amounts of the nucleoside disulfide 
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Thin layer chromatography of a freshly prepared solutioru of l4Sb 
revealed a low Rf spot that is presumably the mesoionic compo\und; in 
addition, there \.,as a spot corresponding to the nucleoside l3�� , and a 
spot for a third unidentified material with a higher Rf value., This 
last material may be a t ransient intermediate in that thin layer chro-
matography of solutions of mesoionic nucleosides l4Sb that have been 
allowed to stand at room temperature revealed only the presen�e of the 
nucleoside 139. 
Stability of mesoionic imidazothiazines: Since the desir-ed meso-
ionic nucleoside l45b was so unstable at room temperature, it 'was de-
sirab1e to reinvestigate the corresponding unsubstituted mesa&onic 
heterocycle 122. It was observed that the y]hite crystals of freshly 
prepared '122 had changed into yellow crystals upon standing fOlT a per-
iod of,3 \veeks at room temperature. Thin layer chromatogra.phy indi-
cated the presence of 122, starting ma terial (Le. methimazole:'; 120) 
and another component that was not identified at the time. T�o weeks 
later, thin layer chromatog raphic analysis of the same yellow 'solid 122 
sho\.,ed only the presence of methimazole (120). \fuen a freshl]' prepared 
sample of 122 was dissolved in wet HeOR, thin layer chromatog:caphic 
analysis of the solution indicated
, 
that 122 rapidly undenvent ring-open­
ing to give 120 within 12 hours. A \-NMR spectrum of freshly/-prepared 
122 in mrSO-d6 showed that \vithin 15 minutes, the compound um;i:1erwent 
rearrangement or ring-opening either at Cs or C7 position, since the 
spectrum sho'Ned the presence of aromatic signals (dd) at 0 8�O and 7.8 
indicative of 122 and also aromatic signals (dd) a t  15 7.5 and: 7.25 in-
dicatiye of a ring-opened or a,raarranged product. Furthermo:re, the 
non-mesoionic compound ' 123 was also observed to be unstable in HeOR and 
120 
gave starting material 130. \r ..... NHR spectrum of 123 in DHSO-d6 indicated 
ring-opening or rearrangement similar t.o that observed with the meso­
ionic compound 122. 
Neither Coburn et al (234) nor Potts et al (235) reported any kind 
of instability at r oom temperature or in solution for the mesoionic 
heterocycles that they reported. HmoJever, neither Coburn et al (234) 
nor Potts et a l  (235) had prepared mesoionic imidazothiazines unsubsti­
tuted at the C6-"position, Glennon et a 1 (11) and Hbagwu (158) have pre­
Viously reported that mesoionic thiazolopyrimidines with a substituent 
at the C6-position are more stable to ring-opening tetan the correspond­
ing unsubstituted mesoionic heterocycle. The mesoionic imidazothiazines 
appeared to exhibit the same kind of behavior. Reinvestigation of the 
ethyl substituted and benzyl substituted compounds 121 and 129 respec­
tively, showed that both these heterocycles were stable at room tempera­
ture and in solution. Stability of these compounds could be resulting 
from electronic and steric factors of the substituents at C6-position, 
\vhich would b e  lacking in l45b and 122. 
At this point, it was necessary to determine the mode of ring­
opening and to identify the ring-opened product itself, if stable. 
Since the thioesterbond is less stable to hydrolysis than an amide 
bond (239), it would be expected that ring opening would preferenti.ally 
occur by a nucleophilic attack at the C7-position of 122 to afford 148 
(Scheme 16). S-Keto acids are known to undergo spontaneous decarboxyla­
tion by either a SE1 or SE2 mechanism (240), aided by electron withdraw­
ing groups, Hence 148 could spontaneously decarboxylate to afford 149. 
To confirm this manner of ring-:-opening, methimazole(120) was acylated 







Scheme 16: Proposed scheme for ring-opening of 122. 
149 
purified by column chromatography. It was observed that thin layer 
chromatogram of a fres hly prepared solution of 149 in MeOH sho\ved a ma-
jor spot (higher Rf) cor resp onding to 149 and a minor spot (lower Rf) 
corresponding to methimazole (120). If a solution of 149 in NeOR was 
allowed to stand at room temperature, within 12 hours, thin layer chro-
matogram revealed that the spot corresponding to 149 disappears to af-
ford 120 exclusively, suggesting that the amide bond also cleaves read-
ily in solution.. Hhen a solution of 149 in NeOR �vas thin layer chroma-
tographed alongside with a solution of 122 in NeOR, it was observed 
122 
1 2 3  
that 149 cochromatographed (in at least four different solvent systems) 
with the unidentified component formed from 122 (as mentioned earlier in 
this section); suggesting that l4� may be formed during ring opening of 
122 as a transient intermediate before further hydrolysis to methimazole 
(120) • 
The mesoionic nucleoside 145b also underwent rapid ring opening in 
solution to afford two major components, one of which ,,,as identified to 
be the nucleoside 139. The second component, by analogy to the ring 
opening studies on 122 and preparation of the N-acetyl derivative 149, 
may be the N-acetyl derivative of 145 (ie 150) which undergoes further 
breakdmvu :to give 139. 
o 
H� 
O Ae OAe 
Potts et al (235) have reported that the phenyl substituted meso-
ionic compound 131 undenvent a thermal rearrangement to a pyrro1o[1,2-
c] imidazolethione (151) ,,,hen 131 was heated to 2200 C for 1 minute, 
Potts et al (235) further reported that the benz-fused analog 134 under-
went hydrolysis in aqueous DHSO to form a benzimidazo1ethione 153 via 
a decarboxylation of the intermediate acid 152 (Fig 39). The product 
153 was obtained by an initial attack on the C2-carbonyl group. This 
mode of ring opening was also reported by Hagemann(42) for the hydroly-
4· -J 154 
sis of the fused mesoionic thiadiazine (Fig Llj) to 154. Freshly pre-
pared mesoionic compound 122 \vas dissolved in aqueous D1'lSO and stirred 
at room temperature for 12 hours fo11mving the procedure of Potts et al 
(235). However, no solid was obtained at the end of the reaction period 
as reported. Instead, thin layer chromatography indicated the formation 
of two major products. The spot with the lower Rf \-las found to be meth-
imazole (120) and the second spot (higher Rf) was found to be 149 since 
both � and 149 co-chromatographed '-lith authentic samples of 120 and 
149 respectively, in different solvent systems. Furthermore, when 
attempts were made to isolate 1'149" from the solution of 122 in DMSO � 
either by column chromatography or by preparative thin layer chromatog� 
raphy, it was observed that an isolated fraction of 149 rapidly decom-








Ph;@:_ , N� �:,' l I o S/"� .0-Me 
11! 
O' 
Ph�r� O�� I 
Me 
131 










1'7-0 Ph s��  Me 
� 
Figure 39: Formation of pyrrol0 [1,2-c]imidazolethione (151) (231) and benzimidazolethione, 
153 (231). 
I-' I',J \.J1 
ed mesoionic comp ound 122  probably undergoes ring-opening similar to 
l3�, as reported by Potts et al (2 3 5); ho."ever � the ring-opened product 
llf8 was not as stable as 153. and therefore could not be isolated. 
This is consistant vlith what is known about N-acylimidazoles in that 
the half-life upon hydrolysis of N-acetylimidazole at 250C is 41 
minutes (242). 
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IV. DISCUSSION OF BIOLOGICAL RESULTS 
A. Adenosine Binding: 
Adenosine and its analogs affect the enzyme adenylate cyclase via 
tHO types of extracellular receptors i.e. Al or high affinity inhibitory 
receptors, and A2 or 10H affinity stimulatory recept�rs. In addition, 
adenosine also inhibits adenylate cyclase by binding t:o a 10H affinity 
intracellular "p" site (171) (Fig 18). Alkylxanthine:s have been report­
ed to act as antagonists at the Al inhibitory receptor site. Since mes­
oionic xanthine analogs bear close structural and isosteric similarity 
\"ith alkylated xanthines, it Has of interest to exam:ine the effects of 
several mesoionic xanthine analogs on the binding of adenosine at the Al 
or inhibitory site. Derivatives of seven different ring systems ,,,ere 
evaluated as inhibitors of adenosine binding at the Al site. All the 
compounds were assayed for their ability to antagonize the binding of 
lnM [3HJN6 -cyclohexyladenosine to rat cerebral cortic>al membrane (243). 
(Table 5). Although the aim of this investigation was to determine \vhet­
her or not the mesoionic thiazolo or thiadiazolopyrimidine nucleus might 
be a bioisosteric mimic of the non-mesoionic xanthines. and although too 
fe\v compounds were evaluated to allow for a detailed .analysis of struc­
ture�activity relationships, certain statements may be made concerning 
activity. 
Interpretation of Results: Comparing the mesoionic thiazolopyrimi­
dines �, 157-162, there is little difference in activity as R2 is varied 
from Et to CPM to Bzl group, The.most active compound in this series was 
the dipropyl derivative 68 (IC50:: 58�M) . 
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Table 5: Antagonism of binding of InN [3H] Cyclohexyladenosine to 


































Et H H 120 
CPM H H 100 
CPM H 0 120 
Bz1 H H 160 
3,5�diOMeBz1 H H 95 
Pr H H 58 
Et H H 160 
Et H 20 
Et H 115 
Penty1 H 100 
Et H 60 
Et f/J 60 
Et H 62 
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�umber in parenthesis corresponds to the reference for synthesis 
of the compounds. 
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The me so ionic thiadiaz0 10pyr imidines J..!!..., 1 6 3- 1 6�, \'ler e  f ound t o  be , 
in g en era l , 2 t o  3 t imes mor e  ac tive than t he thiazolopyr imidine c om-
p ound s ; for exampl e ,  c omp are 1 6 6  with 1 5 7 , or 1 6 7  with 1 6 2 . The mos t 
a c t iv e  comp ound in t h i s  s eries  wa s the R1 -un s u b s t i tut e d  d er iva t ive 1 6 3 . 
Alky l group s at R1 did not enhan c e  activity ( e . g . 1 6 /:, 1 6 6 ,  1 6 7 )  and , in 
f ac t , p o t ency dec rea s ed in the o rd er H > Me > Et <:! Bzl . However , \vhen R1 
vla S  a p - C l B z l  sub s t i tu en t , ( 1 .  e .  1 68 )  ac t ivity wa s s l ightly enhanced , sug-
g e s t ing the p o s s ibil ity o f  a l ip o ph i l ic reg ion at s ome distance  from t h e  
ring s i t e  t h a t  may accomodate the  p- Cl B z l  group , but not a H e  o r  Et g r o up . 
Haking the thiad iazo lopyr imidine c omp ound mor e  s imi l a r  t o  55 ( i . e . J..!!...) 
d id not enhan c e  ac t ivity a s  an t i c ip a t e d . Sup erimp o s ing the s t ructure o f  




7 6  
7 6  Bond Length 
S C C 2 1 .  7 1 A
o 
S l - CS a 1 . 7 0  
CZ-N3 1 .  2 8 
NrN4 1 . 3 8 
N4 - C8 a l . 3 3 






Bond Angl e s  
C2- S 1-C8a 8 8 . 1
0 
S C C2 -N3 1 1 6 . 5  
C2-N3-N4 1 0 9 . 2 
NTN4- C 8 a1 l 5 . 1 
S l C Sa-N4 1 1 1 . 0  
55 Bond Lengths 
C�-C5 1 .  3 7Ao 
Cs H7 1 . 3 4 
C7 -C8 1 .  3 1 
C 8 -N 9 1 .  3 1  
N 9- C4 1 .  3 3 
- - - - 55 
Figure 4 0 :  Bond l engths and bond ang l e s  o f the five-membered r ings o f  
8-phenyl t h eophy l l ine (55 )  and t h e  meso ion i c  t h iad i a z o 1opy­
r imidin e ,  7 6 ,  bas ed on x- ray crys t a l lographic s t r u c t u r e s  o f  
theophyll ine and the mes o ion ic thiad iazolopyrimidin e  r e sp e c ­
t ively . ( 1 4 8 , 7 ) 
( F ig 4 0 )  r eveals that the narro\., b on d  ang le and l onger b ond len g th o f  76 
as comp ared to the co rresp on d in g  b ond angle and b on d  leng t h  o f  55 may 
n o t  allo\-7 the pheny l group o f  t he tHO comp oun d s  t o  o c cupy the s ame p o si­
tion on the re cep t o r  site . The phenyl group is drawn coplanar in F igure 
2 7 ; h owever , the p o s s ib i l ity t ha t  the phenyl ring may exi s t perp end i cu lar 
t o  the plane o f  the het e ro cy clic rings c anno t  b e  ove r l ooke d . S ubs t i tu­
t ion of S by a N-me thy l  group , (e .  g .  174)  abo lished al l ac t iv i ty . Th is 
ab o l i s hmen t of a c t iv ity may be due ei ther to s ub s tLtut ion o f  a N a tom f o r  
S a t om , o r  may b e  due t o  the N-me thy l  g r o up . Further ,.,ork yl i ll have t o  
b e  c a r r i e d  o u t  t o  det e rmine the s t ruct ural requirem e n t s  fo r inc r eas in g 
act iv i ty .  
The benz fused me s o ion ic th iaz o l op y r imi d ine. der iva tiv e s  169-172  
showed incr eas e d  ac t ivity an d a t t achmen t o f  a po la r e l e c t ron d ona t ing 
group at RS ( i . e .  1 7 1) a f fords a comp ound tha t  exhib it s grea t e r  activi ty 
than theophy l l ine . 
Rep lacing the five-memb ered he ter ocyclic r ing with a s ix memb e red 
ring o r  a fus ed r i n g  sys tem ( e . g .  1 7 3 )  w a s  again found to  b e  qu ite fav­
or able  as c omp ar e d with the thia z o lo and th iadia zolo c omp ound s ; s ugges t­
in g tha t there is p r ob ab ly a hydrophobic area ,.,i th bu lk toleranc e  whe r e ­
i n  the ben z fu s e d  c omp ounds such as 169-172 and 1 73 can b in d  m o r e  favor­
ably . 
R.eplacement o f  N-R.2 (mes o ionic pyrimidin e s )  in. the s ix memb ered 
ring by a S atom (me s o i on i c  thiaz ine s ; 121 and 125 ) , decreas e s  a c t ivity . 
This may be due t o  the s i ze o f  atom, as well as bond len g ths and angle s  
between the re s p e c t ive a t oms . I t appear s that a n  N-R2 group is well 
t o lerated in the meso ion ic pyr imidine analo gs so long as the R2 gro up 
does n o t  extend b ey ond the a 5-C ch ain . Thus , the po s s ib i l ity exis t s  
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that it  may be the purine 9-po s i tion nit ro gen sub s ti t uent that is un­
f avo rab le to a c t ivi ty in comp ounds 121 and 1 2 5 . 
As shown in Tab le 5 ,  sub s ti tution on the meso ionic nu c leus c a n  al­
ter in a dramat i c  manner the b inding of adenos ine at the Al s i t e , and 
although some parallel ism c an be drawn between the mes oionic derivat ive s 
and the alkyla ted xan thine de rivat ives , there are a l s o  s ome obvious  d i f ­
f erences and disc repencies . Al though cer tain c omp ounds �vere mo r e  p o ten t 
o r  near ly as p o ten t  as theophylline , there d id not s e em to b e  any s ign i­
f icant in creas e  in activity by alterations in the s ub s ti tution p at t erns . 
Based on the results , it  app ears neces s ary , and wo rthwhile , t o  inves t i­
gate o ther sub s t itut ion p a t terns and o th er ring sys tems in o r d e r  to fu r-· 
ther s tudy and /or  op timi z e  p o tency comp ared to theophyl line . Neve rthe­
les s , it appears that comp ounds such as  1 6 3  and 164 do indee d mimic the 
p o t ency of the ophyll ine , and sugges t a p os s ible b io i s os te ric int erac t i on .  
B .  Ant itumo r Evaluat ion o f  the Thia d iazolopyr imid ine Nucleo s i d e s  
The th iadia z o le nucleos ide 83 ( anomeric  mix ture) and the me s o  ionic . 
thiadia z ol opyrimidine nuc le osides 9 1a and 9m were a s s ayed for  t oxi c i ty 
to  L12 l0 cells and H . Ep-2 cells in culture . The nu cleos ides �v e r e  ass ay­
ed at c oncen trat ions o f  1 , 3 , 5 , 10 , 20 , 3 0 , 40 , 60 , 80 ,  and 100 �M/mL for the ir 
ab ility to inhib it colony forma t ion of L12 l0 and H . Ep - 2 c el1s . Resul ts 
indicate d  that all counts were the same as the cont rols 1 .  e .  numb er o f  
c olonies f ound in contro ls and in the p res ence o f  added comp oun d . 
The po t ential an tineop las t ic agents ��a-tf3 and 84a-tf3 prep are d  in 
this work were also evalua ted in the L1210 leukemia sys tem in vivo . 
E ight a.nima ls were used in each . tes t and in the cont ro l group s . Al l 
c omp ounds were adminis tered by the intrap e ritoneal route in an aqueo us 
suspens ion . The Nat ional Cancer Ins ti tut e ' s pro tocols fo r s creening of 
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chemi cal agents agains t animal t umors was fo llmved ( 2 /14) . Ac t ivity is 
measured a s  a p e r cent increas e in l i fe s p an over m e a n  survival time for 
the contr ols ; an increase of  25%  o r  greater was c ons idered to  b e  indica­
t ive of an " a c t ive" comp ound . 
Da t a  for the comp ounds p r ep ared and tes ted are shown in Tab le 6 . 
Negat ive results sug ges t ed that the compounds tes ted \vere  ina ctive and 
nont oxi c to  L12 l 0  leukemia in mice . 
The th iadiazole nucleos ide � ( anomeric mixture) and the me s o ionic 
thiazolopy rimidine nucleos ides 1 5 5C/. , 1 5 53 , and 1 5 68 ( dep ro t e c te d) ",e re 
p rep are d  and t e s ted in mice agains t lympho id L 1 2 l 0  leukemia , by the 
National Cancer Ins t itu te at B e thes da , Maryland ( 245) . S ix animals w e r e  
used  in each tes t and control g roup , and dos e s  o f  comp ounds from 11 . 2 5 
mg /kg up t o  1 8 0  mg /kg were adminis tered by the int raperitonea l rou te 
daily for 5 day s  in an aqueous suspens ion . No a c t ivi ty y]as ind ica ted  
s ince the res ul ts  of  the s tudy showed that the 1)  tumor we igh t Has the  
s ame b e fo re and after admini s tration of comp ounds 2) cell p opulat ion was 
greater after  adminis tration of comp ounds 3) no s urvivo rs for a ll the 
c ompounds tes ted . 
Int erpretation of Results : The neg a t ive resul ts ob tained fo r the 
thiadiaz o lopyrimid ine nucleos ide 83 q-+t3 sugges t s  that p robably the nucle­
os ide ( tes ted a s  t h e  acetates)  was not bein g  conver ted  to the free 
nucleos ide which would b e  neces sary before phosphoryl a tion c an oc cur to 
a f fo r d  the des ired nucleotide . On the o ther hand , the nucl eo s ide may b e  
rapidly deacylated i n  vivo ; however i t  may no t b e  effectively ph osphory­
lated t o  g ive the corresponding nucleotide . Anothe r  p os s ib il ity is that 
2- amino.thiadia z o l e  (2 ... A,TD) may no t be r ibo sylated and subs equen t ly phos­
phoryla ted in vivo to afford 2-ATD mononucleo tide ( see  s e c t ion IIIB ) . 
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Tab l e  6 : R e s u l t s  o f  An t i ne o p l a s t i c  a c t iv i t y  eva lua t i o n  o f  th i a z o l o  a n d  
a 
t h i a d i a z o l o  nu c l eo s i d e s  � a+S and .§l a+S-:-





A c O  OAc 
84 a+S 
� a+S 
D o s e  b 
mg / kg QDx8-
1 0 0  
200 
1 0 0  
200 
% i nc r e a s e i n  






-As s ay p er f o rm ed a t  MCV /VCU by D r s . van l t Ri e t  and Hamp l er 
b
Ad . .  . f d b 24 h f h 1 k . - mlnls t r a t l o n  0 comp o un s was egun a ter t e eu emla 
was i n t r o d u c e d  and wa s c o n t i nu e d  o n c e  d a ily f o r  8 d ay s . Ea c h 
d o s e  o f  each c omp ound wa s admini s t er ed i . p .  t o  groups o f  
eigh t mic e . 
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Ra the r ,  i t  is probab le that 2-ATD may b e  direc tly c onver ted to a nuc1e� 
o t ide  via a nucleot ide pyrophosphorylas e .  The lack o f  a c tiv i ty for the 
rnes oionic  th iad ia zolopyrimidine nucleos ides may als o be a t t ribu t e d  to  
the  ab ove men t ioned factors , even if  they undergo rapid r ing opening in 
vivo to af f or d  the thiadiazo l opyrimidine nucleos ide � . Thus , the p o s ­
sib ility that the s ugar mo iety may b e  attached at  the exocyc l i c  n i t ro gen 
and tha t the th iadiazo lopyrimid ine nucl eo s ide � may be the po tent ially 
ac tive s tructural metabolite  of 2-ATD cannot  be excluded . 
Becaus e the mes o ionic th iazo linopy rimidine nucleos ide l1 3a  was ob­
tained on ly as the a anomer ,  and becaus e the meso ionic iu'!.idazo th i a z ine 
nucleos ide l4 5b ,.;ras uns tab le in s o lut ion and a t  ro om t em!� e ra ture , the s e  
comp ounds ,·;ere no t s ubmit ted for  antineop las t ic evalu a tion . 
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S��Y AND CONCLUS ION 
Mo d i f i ed nuc l eo s id e s a r e impo r t an t b e c au s e  o f  th e ir s t r u c tur a l  s imi­
lar i t y  to t h e  pur ine and pyr imid ine nuc l eo s id e s , a nd b e c a u s e t h ey have 
aided in s tudying / inhibi t ing comp l ex p r o c e s s e s  such as RNA and D NA b io s yn­
the s i s , and enzyma t i c  r eac t i o n  mechanisms . M e s o i o n i c  nuc l eo s id e s r epr e s ent 
an entir ely ne,,7 c l a s s  of mo d i f i ed nuc l eo s id es . Becau s e  o f  t h e ir i s o s t er i c  
r e l a t ionship to na tur a l l y -o c curr ing o r  o th erwi s e  b i o l o g i c al ly a c t iv e  no n­
meso ionic nu c l eo s id es , an inv e s t ig a t i o n  of s u ch comp o und s as p o t ent i a l l y  
u s e f u l  chemo therap eu t i c  ag en t s  i s  c er t a inly war r ant ed . 
A l t hough the t erm "m e s o ionic nucl eo s id e "  was o nl y  r e c en t ly co i n e d  by 
G l enno n e t  a I , a r ev i ew o f  t h e  l i t er a t ur e  r eveal s tha t s ev eral  s u c h  d er iva­
t iv e s  have b e en known for over thir ty y ear s and , in f ac t , a f eH of t h em a r e  
even na tur a l l y  o c curr ing . However , th e s e  compo und s hav e no t b e e n  r ec o g ­
n i z ed a s  belong ing to a muc h  l ar g er c l a s s  o f  c ompound s ,  i . e .  m e s o  ionic 
nuc l eo s i d e s . They have now b e en c l a s s i f i ed and compr ehen s iv e l y  r ev i eHed , 
her e in , for th e f ir s t  t ime . Gl enno n and cowo r ker s l a id the gro undwo rk f o r  
t h e  synthe s i s  o f  what migh t now b e  c al l ed C l a s s  I I  m e s o  io nic xanthine nu ­
c l eo s id es ; s ev er a l  exampl e s  wer e p r epar ed and the chem i c al and s p ec t r a l  
pro p er t i e s  wer � s t ud i ed . O n c e  i t  was e s t ab l i s h ed that the s e  m e so io n ic 
nu c l eo s id e s  wer e synth e t ically f ea s ibl e , i t  was now p o s s ibl e to d e s ign s ev ­
eral typ e s  of me so ioni c nu c l eo s id e s  a s p o t ent ial chemo t h e r a p eu t i c  ag e n t s . 
But , b e fo r e  the r a t ional d es ign and synth e s i s  o f  the s e  nu c l e o s i d e s  c o u l d  b e 
und er t aken , i t  wa s nec e s sary to d e t ermine whe ther or no t t h e  m e s o io n i c  
heterobases po s s es s ed a b io i so s t er i c  in a d d i t ion to th e ir i so s t er i c  r el a­
t io ns h ip wi th no n-meso ionic h e t erobas e s . S om e  ev i d e n c e  t o  t h i s  ef f ec t  is 
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that meso ionic xanthine analo g s  d is p l ayed a mo d er a t e  d egree  o f  a c t iv i ty a s  
inhibito r s  of  cycl i c -ANP PD E .  In add i t ion , s everal meso io nic d er ivatives 
r e la t ed to theophyll ine wer e p r epared , and r esul t s  o f  the evaluatio n  ind i-
c a t ed tha t they po s s es s ed theophyll ine-l ike ac t ivity a s  ad eno s ine antago -
nis t s  a t  the Al or inhibitory s i t e .  Thu s , o n  the ba s i s  o f  thes e two s t u -
d i es , i t  app ear s tha t a bio i s o s t er ic r e l a t ionship d o e s  ex i s t  b e tween mes o -
io nic xanthine analo g s  and the  correspond ing no n-meso ionic xanthine analogs . 
Thr e e  d i f f er ent typ e s  o f  meso ionic nuc l eo s id es wer e des igned and pr e -
par ed fo r subs equent bio l o g ical evalua t ion . He so ionic thiad iazol.opyr imidine 
nuc l eo s id es , i .  e .  d er iva t ives of anhyd ro -S-hydroxy- 8 -D-r ibo f ur anosyl --7 -oxo -
1 , 3 , 4 - thiad iazolo [ 3 , 2-a ] pyr imid ine hyd roxid e ,  wer e d es igned to s er v e  as 
po t en t ia l  pro -drugs  o f  2-amino -l , 3 , 4 - thiad ia zo l e  mono nu c l eo t id e  which h a s  
b een r epor t ed to exhibi t  antineo p l a s t i c  a c t ivity . The nuc l eo s id e s  '.Jer e syn-
thes i z ed by f ir s t  pr epar ing the r i bo s id e  of 2-amino -I , 3 , 4 -th i ad i a zo l e , 
f o l l owed by pro t ec t io n  o f  th e hyd roxyl groups and subs equent cyc l i z a t ion to 
th e m e s o  ionic compound s . All a t t emp t s  to d epro t ec t  the hydroxyl gro up s  o f  
the m e s o  ionic nuc l eo s id es r esul t ed i n  r ing-o p ening o f  the meso ioni c  h e tero -
bas e .  
The meso ioni c  thiazol inopyr imid ine nuc l e o s i d e s  i . e . d er iv a t ives o f  a n -
hyd r o - S -hydroxy-8-D- 2 ' -d eoxyr ibo furano syl -7-oxo -I , 3 , 4 - thiadiazo lo [ 3 , 2-a] py-
r imid ine hydroxid e ,  p r epar ed in a s imi lar f a shion as above , ,.,ere d e s igned 
I as po t ential inhib i t o r s  o f  thymidyl a t e  synth e t a s e .  H-NMR sp e c t rum o f  the 
meso ionic thiazol ino pyr imidine nuc l eo s i d e  sugg es t ed that the a -a nom er had 
been obta ined exclu s ively . 
The m e s o  ionic imid azo thiazine nucleo s id e s , i . e .  d er iva t iv e s  o f  anhy -
dr o - 5 -hydroxy-l-D-r ibo fur ano syl-7 -oxo imid azo [ 2 , l -b ] thiaz inium hydroxide we r e  
d e s igned a s  po t ent ially us eful chemo therap eu t i c  agent s ,  since  they po s ses s ed 
s t r u c tural and i so s t er i c  s imil ar i ty wi th pur ine nuc l eo s id es . The nuc l eo -
s id e  �"a s  prepar ed by a cycl i z a t io n  r eaction bet�"een the tri-O-ace tyl -D-
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r ibo f ur ano syl imid a z o l e-2-thione and carbo n suboxid e .  The resul t ant meso -
ionic nuc l eo s id e  was found to b e  uns tabl e a t  room t emperature or  in a q u eo u s  
s o l u t ions . 
S everal meso ionic thiad i a z o l o pyr imid ine nuc l eo s i d es and the thiad i a -
zolopyr imid ine nucl eo s id e  wer e as sayed for  toxic i ty t o  L 1 2 1 0  c el l s  and 
H . Ep - 2  c el l s  in vitro and lympho id l eukemia  L1 21 0 in v ivo (as  t h e  t r i - O -
a c e t a t e s ) . The neg a t iv e  r esul t s  o b t ained from the s t udy could b e int er -
p r e t ed in s everal way s . 
1 .  The anom er ic mixtur e o f  the thiad iazolopyr imidine nu c l eo s id e  may no t 
be d eacyl a t ed to  the f r e e  nuc l eo s id e ,  wh ich ,,,o uld be neces s ary befo r e  pho s -
pho ryl a t ion o ccurr ed in v ivo to  a f fo r d  t h e  corr espond ing nuc l eo t id e . 
2 .  The thiad i a zolopyr imid ine nuc l eo sid e may no t be a subs tr a t e  for  the 
enzyme ca talyz ed pho sphoryl a t i o n  ev en af t er succes s f ul d eacyla t io n  in v ivo . 
3 .  2-Amino -l , 3 , 4-thiad iazo l e  ( 2-ATD ) may f o rm the N3 -nucleo tid e ,  wh i ch 
co uld b e  the metabo l i t e  r esponsibl e for i t s  ant ineoplas t ic ac t ivity . 
4 .  2-ATD i t s e l f  may no t be r ibo syl a t ed f ir s t  and subs equently p ho sphory� 
l a t ed to the corr espond ing 2 -ATD mo nonucl eo t id e . Ra ther , 2-ATD m a y  b e  d i-
r e c t ly r ibo pho s phoryl a t ed via th e enzyme pho sphor ibo syl pyro pho spha t e  t rans-
f eras e to the nucl eo t id e .  
Even i f  the meso ionic thiad iazolopyr imid ine nucl eo s ides  und er go r ap id 
r ing-op ening in vivo and s erve a s  prod r ug s , the l a ck o f  cy to tox i c i ty ob-
s erved again s t  L 1 2 l 0  c el l s  and H . Ep - 2  cel l s  in cul tur e  may be a t tr ibu t ed t o  
inef f e c t ive in vivo deacyla t io n  and pho sphoryl a t ion . Henc e ,  i t  wo uld b e  
t o o  early to c o nclud e  whe ther or no t the thiad i a zolo pyr imid ine nucl eo-s id e 
, 
,,,a s the s truc tural me tabo l i t e  o f  2 -ATD , whi ch wa s formed in v ivo by an ex -
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chang e r ea c t io n  w i th NAD ( s e e  S ec t io n  I I IB) . 
Futur e e f f o r t s  should b e  d ir ec t ed toward s  t h e  synthes i s  o f  nu c l eo t i d e s  
o f  t h e  abo v e  m en t io n e d  thiad i a zo lo py r imid ine nuc l eo s i d es ,  a nd d i f f er en t  
b l o cking gr o up s  s h o u l d  b e  u t i l i z ed , wh i ch coul d  be r emov ed und er conditions 
tha t d o  no t d e s t a b i l i z e  t h e  r e sul tant n u c l eo s id es and / o r  nucl eo t id e s . 
S inc e the m e s o  i o n i c  t hi a z o l ino pyr im i d ine nuc l eo s id e  was o b t a ined ex ­
c l u s iv ely a s  t h e  a anom er , i t wa s no t s ubmi t t ed f o r  b i o l o g i c a l  evaluat ion 
as a p o t en t i al ant in eo pl a s t i c a g e n t . I t  i s  q u i t e  p r o b abl e tha t dur ing t h e  
r ibo syl a t io n  and acyl a t io n  p r o c ed u r e s , t h e  t,.;o anomer s ,.er e o b t a ined but 
c o u l d  no t be s ep a r a t ed o n  a c c o un t  o f id en t i c a l  Rf values . Ano ther po s s i ­
b i l i t y  i s  tha t d ur ing t h e  c y c l i z a t io n  r ea c t io n a t  l 6 00 C t o  af ford t h e  m e s o ­
i o n i c  thi a z o l inopyr im id ine nuc l eo s id e , the nu c l eo s i d e  may und e r g o  therma l 
m u t a r o t a t io n  to y i e l d  the thermod ynam i c a l l y  mo r e  s t abl e anomer , which in; 
thi s c a s e , i s  t h e  a a nomer , Al t erna t ive m e t ho d s  should be f o und for the 
syn th e s i s  o f  the B anom er . 
The m e s o  i o n i c  im id a z o t hi a z ine nuc l eo s id e , unsub s t i t u t e d  at the C6-
p o s i t io n , .,Ta S f o u nd to b e  uns t a b l e  bo th a t  r o om t emp e r a tur e and in the 
p r e s e n c e  of s o l v ent s and mo i s t ur e , and und erwent rap id r ing -o p ening to a f ­
f o r d  the imid a zo l e - 2 - t h i o n e  nuc l eo s id e . As a c o n s e q uenc e i t  ,.;a s no t sub­
m i t t ed f o r  eval u a t io n  o f  i t s  p o t en t ial an t in e o p l a s t i c  pr o p er t i e s . I t  i s  
po s s ib l e t h a t  t h e  m e s o  io nic imi d a z o t h i a z ine nuc l eo s id e  may exhib i t  in­
c r e a s ed s tabil i t y  a t  r o om t emp erature and t o  s o lv en t s  if s ubs t i t u t ed at the 
C 6-po s i t io n  ,.;i th , f o r  examp l e , sma l l  a l kyl gr o up s . I n c r ea s ed s t ab i l i ty may 
r esul t from el ec t r o n i c  and /o r  s t er ic f a c t o r s  of the C6-substituent , since 
the meso io nic im id a z o thi a z i n e s  s ub s t i t ut ed at the C 6-po s i t io n  wer e found' to 
b e  mo r e  s t abl e t han the unsubstituted imid a zo t h i a z in e . 
Th e a r e a  o f  c a n c e r  chemo therapy invo lve s a cons tant s tr u g g l e  in an 
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a t t emp t t o  d e s ign and synthes ize compounds t h a t  a r e  bo t h  selec t ive i n  t h e i r  
inh ib i t io n  o f  r ap id ly growing tumo r  c el l s  and nontoxic to  normal c el l s .  
For many d e cad es , a t t emp t s  have b e en mad e to inhib i t key enz)�a t i c  p a thwa y s 
in the bo dy wi t h  the ul t ima t e  goal o f  inh ib i t ing DNA b io s ynth e s i s . The 
meso ionic nuc l eo s id e s  r ep r e s en t a novel c l a s s  o f  mo d i f i ed nuc l eo s i d e s , and 
even though r e s ear ch in this area is st i l l  in i t s  inf ancy , the s e  novel 
me s o  ionic nu c l eo s id e s  o f f er great  po t en t ial  for futur e d e s ig n  and synthe s i s  
o f  compo und s with a n  int er e s t ing chemo therapeut i c  pro f il e . 
VI . EXPERIHENTAL SECTION 
A. Chemical . Proton magnetic resonance ( lH-NHR) = ?ectra wer e  recorded 
on a Perk in-Elme r R-24 high re solut ion spectropho : :':>.=: t er and a JEOL FX 
9 0Q Four ier Transfo rm spec tropho tomet er ( d e n o t ed = :  :on a s t e r isk) , and 
chemic al shi f t s  are r epo r ted relat ive to tetrame t:-_�:- =- s il ane (He4 S i ) . In­
f r ared ( IR) spectra were o bta ined on a Perkin-Ele:e. :- 7.. 57 spec t r o pho to­
meter and ma s s  sp ectra ,,,ere d e t e rmined u s ing a Fi: :. :'; an 4 000- se ries  GC /MS 
data sys t em .  Ult rav io let (UV) s pec t ra were obtai::� � on a Beclunan Yill del  
2 5  spectropho tomet er , and r e sults are exp r e s sed c. 3  -, 1!lax in nan ometer s . 
El emental analy s e s  were perf o rmed by Atlant ic Mic :- : :" =. :' , Inc . , Atlanta , 
GA and d e t e rmined value s are \"lithin 0 . 4 % o f  theo re. :: :' :al values . All 
melt ing po int s ,.,ere determine d on a Thoma s-Ho over :::- e. : t ing po int appara­
tus and are uncorrected . FAB spectrum w a s  p e r f or::e. ':'  ay Dr . C .  Shramm , 
University o f  Ar izona . 
Column chromat ographic s eparat ions ,,,ere p erfo =-=-=d on activated 
s il ica gel , me sh s i z e  60- 2 0 0 , Davison Chemic al Cor::: . ,  Balt imore , Maryl and . 
Thin layer chromatography ua s performed on thin-lc.::- e. =-- c hroma t o g r aphy 
pl a te s ,  pre c oated with s i l ica gel GHLF , thickne s s  2:·� microns , Analtech , 
Newark , Dela,,,are .  The visual iza t ion of products 1.:: ::-::r in-l ayer chroma­
tograms vJaS accompl ished by UV abso rbanc e , £ol lo\o"2.c :- y cha rr ing with 40% 
H2S04 , whereb y sugars could be detected . 
2- (n-Propylamino ) thiazole (21) .  Sod iun b is ( 2-::Jl,= ::hoxyethoxy ) alumi­
nium hydride ( " Redal " )  ( 1 1 . 1 8 mL , 38 . 4  mmo l) in t oJ'--=: 2:G.e (2 5 mL) 'vas 
added dropH i s e  to  a s t irred susp en s io n of ar.dde 66 U:: . Og . 1 2 . 8  mmo l) in 
t oluene ( 65 mL) under a nitrogen atmo s phere at OOC .  The amide 6 6  "las 
p rep ared from 2-aminoth iaz ole ( 1 7 6 ) . Af ter hea t ing the react ion mix tur e  
at r e flux for 3h ,  and s tirring a t  ro om tempera ture overn i ght ( 12h) , aque-
o 
ous NaOH ( 20%) was added dropwise a t  0 C ,  unt i l  hydro gen evo lu t ion 
ceased . The reaction mixture was s tirred for an addit ional 2h , fil ter e d  
and t h e  f il trate ,vas dried (NaZS 04) ' Removal o f  the s olvent in v a c u o  
o 
gave a s emiso lid . Dis t i l la t ion ( Kugelrohr , bp 4 0- 4 1  C / 0 . 25 mm) gave 1 . 7 
o 
g ( 9 3% ) o f  !i2 which s o l idified  to  a p al e  yello>v s ol id ; mp 4 5 - l18  C .  IR 
-1 1 (Nuj o l) : 3 20 0 (NH) em ; rl-'NMR (CDC13) :  0 7 . 2  ( b r  1 ,  NH) , 7 . 1 ( d , 1 ,  
arom H) , 6 . 5 ( d ,  1 ,  arom H) , 3 . 2 ( t ,  Z ,  NCH2) ,  1 . 7 ( m ,  Z , CHZ) ' 1 . 0 
( t ,  3 ,  CH3) .  The crude p roduc t  was used dire c t ly in the prepar a t ion o f  
the mes o i onic comp ound � after Kugelrohr dis t il la t ion . 
Anhydro- 6 ,  8-di-n-propyl-5....:hydroxy..:.7"":oxo th iazolo [ 3 . 2-·a }  pyr imid in ium _ 
Hydroxide . ( 68) . Z- (n-P ropylamino) thiazo le (!i2; 0 . 1 0 g ,  0 . 7 romo l) and 
b is ( 2 , 4 , 6-trichlo rophenyl ) n-propyl malonate (63 )  ( 0 . 3 5 g ,  0 . 7 romo l) were 
o heated neat at 160 C ,  under a s tream o f  nitro gen , unt il a clear melt re-
suI ted (� 3 min) . When coo l ,  the resul tant  yellow oil was tri tura ted  
vli th anhy drous e ther ( 20 mL) . The crude s olid  vlaS recrys tallized  f rom 
o 
E tOAc to y ield 0 . 0 8 g ( 45%)  o f  white crys tals , mp 128-1 30 C ;  I R  (Nuj o1) : 
-1 1 1620  cm ( C=O) ; H-NMR ( CDC13) : Q B . 13 ( d ,  1 ,  arom H) , 7 . 3  ( d ,  1 ,  arom 
H) ,  4 . 25 ( t: ,  2 , C 6-CH2) , 2 . 7 ( t , 2 , N-CH2 ) , 2 . 0 (m , 4 ,  CH2) ,  1 . 25  ( t , 6 ,  
CH3) ·  
Anal . Calcd for C 12H16N20Z S :  C ,  . 5 7 . 1 2 ; H ,  6 . 39 ;  N ,  1 1 . 10 .  Found : 
C ,  5 6 . 9 5 ;  n ,  6 . 4 3 ;  N ,  11 . 05 .  
1..:.Benzoy1 th io s emicarbazide ( 73 ) . The t i t le comp ound ; 22, wa s pre-
p ared according to the me thod of  Hoggarth ( lBO) . Finely pO\\ldered thio-
s emica.rb az ide (�; 9 . 0  g ,  0 . 1  mo l) and benzoyl chloride ' ( BO ;  14 . 0  g ,  
1 4 3  
o 
0 . 1 mol) were mixed t o ge t h er an d c o o l e d  to 0 C ( ice-b ath) . The mix t ur e  
vlas caut ious ly �varmed t o , a n d  h e l d  a t , 1000C fo r 1h , c o o l e d  to ro om tem-
p e r a t ure and a 1 l mve d t o  s t i r  a t  r oom t emp erature overnight ( 12h) . F il-
trat ion gave a p ale yel l mv s o l i d  wh ich vlas recrys tall i z ed f r om ho t 9S% 
E t OH to y ie l d  whi t e  cry s ta ls , whi ch were recrys t a ll i z e d f r om ho t H20 to 
a f f o rd 6 . 0  g ( 30%) of c ry s t al l ine 113 mp 198-201oC [ l i t . ( 180) mp 1 9 So C ] . 
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2":'Amino - S":'pheny l- l ,  3 ,  4- thiadia z o l e  (1!!) . l-B en z oy l thios emi c ar b a z ide 
(22; 2 . 0  g , 0 . 0 1 mol ) was added to 8 S %  H3Po 4 ( 2 0 mL) over a 10-min p e r-­
i o d , an d the mix ture was then s ti r r e d  at l 2 0
0
C f o r  3 0 min . The co ol e d  
so lu tion w a s  d iluted with c o ld H20 to 1 0 0  mL ;  t h e  whi te s o l i d  th a t  p re­
c ip i ta t e d  was removed by f i l t r a t ion . The f i l t ra t e  was tr e a t e d  w i th NH4 0H 
( 1 0 0  fiL) t o  a f ford a cream- c o lo r e d  s o l i d  that wa s re cry s tal l i z e d  f rom 
9 S %  E tOH t o  y iel d 300 mg ( 2 0 % ) o f  7 /+ as c olo r le s s  s quare crys t a l s , mp 
o 
2 2 0 - 2 24 C [ l i t . ( 18 0 )  mp 22 4°C ] . 
2-Ac e t amido - S-phenyl - l , 3 , 4 ..:. th iadiazo le (]2) . A mix tur e o f  2-amino -
S-pheny l- l , 3 , 4 - thiadi a z o le (1!!..; 300 mg , l o S  mmol ) , Ac 20 ( 3 . 6  mL) an d 
pyri dine 0 . 0  mL) was he ated a t  r e flux for 2h , and c o o le d  to roo m t em-
p er a t ure . The res ul t ing crys ta ls were c o l l e c t e d  by fil t r a t ion and washed 
wi th MeOH to af f o rd 2 7 0  mg ( 8 0%) of wh i t e  needles 11; mp 2 7 8- 2 8 2 o C [ lit . 
( 181)  fiP 2 7 8-2 80oC] . 
2-E thyl amin o-5-phenyl-l , 3 , 4- t h iad i a zo le ( 7 1) . Me tho d A :  C oncen-
t r a t e d  HCl ( O . OS mL) was ad ded t o  a s o l ut ion o f  4 - e thy l-3 - thi os emicarba-
zide (�; 1 . 2  g ,  0 . 01 mo l) and trime thyl or tho b e n z o a t e  (1Q; 3 . 6 g ,  0 . 01 
mo l) :i.n 9 S %  E tOH ( IS mL) . The react ion mix ture was s t ir r e d  a t  ro om t eni-
perature for 1 .  5h . h eat e d  at r e f lux f o r  1 .  5h , co ole d and the s o lven t  ,,,as 
evap orated und er vacuum to near dryness to af f o rd a white so lid . The 
cru d e  p roduct was co l l e c t e d  by f il tration and �va s �vashed with p e tro l eum 
eth er ; recrys talli z ation from 9 5% E t OH yiel ded 0 . 6 5 g ( 3 0% )  o f  7 1  a s  
o 1 white crys ta ls ; mp 1 7 3- 175 C .  Infrared an d H-1TMR sp e c tra w e r e  i den-
tic al ,.,ith those obtained in Metho d B .  
o 
Mixed mp = 1 7 3 -1 74 C .  






S :  C , 58 . 4 9 ;  H ,  5 . 4 1 ; N ,  2 0 . 48 ,  Fo und : 
C ,  58 . 54 ; H ,  5. 45 ; N, 20. 45. 
Metho d B .  A s olution of 2-a c e t amido - 5 -pheny l- l , 3 , 4- th iad i azol e  
(22; 200 mg , 1 .  0 romol) in THF ( 15 mL) vTa S adde d  dr op\.,ise t o  a s t irred 
suspens io n of lith ium aluminium hyd r ide ( 80 mg , 2 . 0  mmol) in 1nF (15 mL) 
o 
at 0 C ,  and th e mixture was then heated a t  reflux fo r 3h . Success ively , 
H2 0 ( 1  mL» ) 15% NaOH ( 1 . 5 mL) , H2 0 ( 3  mL) ,.,er e added dropwise a t  O
OC to 
the react ion mixture , until evo lution of hydrogen ceas ed . The m ixture 
wa s filtere d ,  and filtrate Ha s dried (HgSOI.) . Remova l of th e s o lvent 
in vacuo gave a white G olid , which upon re crys talliz a t ion from 95% E tOH 
o 
a f f orded 9 0  mg ( 40%) of 21. as white cry s t al s ; mp l 7 3 -l7Lf C ;  IR (KBr) : 
3 2 0 0  cm-1 (NH) ; lH_NMR ( CDC13) :  0 7 . 9 - 7 . 5 (m , 5 , arom H) , 7 . 6 ( br s ,  1 ,  
111) 3 . 5  ( q , 2 , CH2) , 1 . 3 (t, 3 , CH3 ) . 
Anhydro� 2-phE7nyl- 6 .  8 -die thyl- 5-hydroxy- 7-oxo -l., 3 , If - thiad i a z o  10 
[3, 2-a] pyrimidinium Hydroxide (!.§..) .  b is (2 , 4 , 6-Trichlorophenyl ) e thyl 
malona te (�2 ; 0 . 3 9 g ,  0 . 8 mmo l) and 2-e thylamino-5-phenyl-l , 3 , 4 - thia-
o 
diadiazole (11.; 0 . 2  g ,  0 . 8  mmol) Here heated in an oil  b a th ( 16 0  C) un -
til a clear melt resulted ( 5  min) . A s lo\v s tream of ni trogen was p a s s ed 
over the reaction mix ture during the heating perio d to aid in the r e -
mova1 o f  2 , 4 ,  6-trichlorophenol . When coo l ,  the res ul tant res idue \vas 
triturated with anhydrous e ther ( 20 rnL )  until crys tallization o ccurred . 
The s olid was c ollected by fi l t ration and recrys taJ.l i ze d  from iProH to 
o 
afford 0 . 2 7 g ( 9 8% )  o f  7 6  a s  pale yel lo\v cry stals ; mp 2 3 3 -2 35 C ;  IR 
-1 . 
. . 1 
(KBr) : 168 5 , 164 5 cm ( C= O ) . H ..... NMR ( CDC13) : 0 8 . 0- 7 . 6  (m , 5 ,  a rom 
1 4 5  
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H) , 4 . 2 5 ( q ,  2 , CH2 ) ,  2 . 6  ( q , 2 , NCH2) , 1 . 6  ( t , 3 , CH3) , 1 . 1 ( t ,  3 ,  NCR3) . 
Anal . calcd for C15H15N3S 02 : C ,  5 9 . 78 ;  H ,  5 . 02 ;  N ,  1 3 . 9 4 .  Found : 
C , 5 9 . 38 ; H ,  5 . 0 1 ;  N ,  1 3 . 7 7 . 
b i s  ( 2 ,  4 ,  6-Tri chlorophenyl) mal onate e s ter s . 6 1 , g, �. Comp ounds 
6 1 , g and � were p repared accor d ing to the p ro cedur e  of Kap p e  et a l  
( 33) . A mixture o f  malonic acid , e thylmalonic a c id , or n-p rop ylma lon i c  
acid ( 0 . 12 mo l) , trichloropheno l ( 6 0 ;  0 . 2 4 mo l) , and POC13 ( 0 . 12  mol) 
o 
,"er e  heated at 90  C for 6h . On coo ling , the reac t i on mixture w a s  puur e d  
o n  ice , and the s olid was ext rac ted with e ther . The e thereal l ayer "la S  
dried (Na2S04) and evapora te d  to  drynes s t o  give e ither c rude 6 1 ,  6 2  or 
6 3 . The crude p roducts were re cry s t al l i zed from t oluene to  yie ld cry s -
talline c omp ounds : 
o ° ° �:I.:., mp 15 0 C [ l i t . ( 9 ) mp 1 5 1 - 1 5 2  C ] ; 6 2 , mp 101 C 
[ l i t . ( 9 )  mp 102
o
C ] ; 6 3 , mp 7 8 - 8 10 C [ l it . ( 9) mp 7 4-76°C] . I t  'va s 
de t e rm ined that the se malona t e  es ters unden"en t spontaneous hydrolys is 
up on s tanding for s ever al we eks to s everal months . B e c ause o f  th is un-
exp e c t e d  finding , all cycli zation reac tions emp loying the s e  es t ers 
u t i l i zed e i th er f reshly p rep ared e s ters , or es ters whose ident i ty wa s 
f i r s t  confirmed by mp and / o r  thin laye r chroma to graphy . 
2 - ( D- Rib o furan� sylamino ) -1 , 3 , 4 - thiad ia zo l e  ( 8 2 ) . An anomeric mix-
ture of 2- ( 2  t , 3 '  , 5 '  - tri-O-acetyl-D-rib o furanosyl amino ) -1 , 3  , ll - th iad ia-
zo le (�; 0 . 2  g,  0 . 55 mmo l) was d is s o lved in anhydro.l1 s MeOH ( 20 mL) c on­
taining ��E t 2 ( 20 �L) ,  and the rea ct ion mixture was s t irred a t  OOC for 
4h .  Evapor ation o f  the s o lvent under reduced p re s s ure and tritur a t ion 
o f  the resultan t  mixture with anhydrous ether gave a s olid . Re crys tal� 
l i z a t ion f rom MeOH afforded 0 . 1  g ( 87%) of  8 2  as a cream-c olored so lid ; 
mp 95-99
0
C ;  I R  (neat) : 3300 cm� l ( OH) . 
5 . 3 5 ;  N ,  16 . 5 5 .  Found : e ,  3 5 . 6 4 ; H ,  5 . 6 1 ;  N ,  16 . 2 2 .  
a and 8 -2"': (2 ' , 3 ' , 5 ' -Tr i-0-acetyl-D-ribo furanos'y lamino ) -1 , 3 , 4- thia-
di azo le . (83a) , (§l§) .  A s o lut ion of  D-r ib o s e  ( 8 1 ; 3 . 7 5 g, 0 . 0 2 5  mol ) 
and 2-amino- I , 3 , 4-thiadiazole (12; 2 . 75 g ,  0 . 02 5  mo �) in MeOH ( 4  mL) and 
conc . Hel ( 0 . 25 mL) \vas warmed on a s team bath f or 1.5 min to a f f or d  a 
clear ,  amber-co lored s olution . Heating was cont inue-d until mo s t  o f  the 
HeOH evapo rated ( 2h) to leave b ehind a b rmvn visc ous res idue . The re s i-
due \va s d i s s o lved in H
2
0 ( 2 5  mL) , and th e aqueous s o,lut ion was ex t r ac ted 
with E tOAc ( 3x15 mL) t o  remove unreacted 2-amino-l , 3 � 4-th iad iazo le from 
the aqueous phas e .  The aqueous so lu t ion was evapora �ed to d ryne ss und e r  
reduced p res sure , and the resul t ing syr up \Vas dried tunder high vacuum to  
yield  5 . 8 g of  a foamy yello\V s olid , g. This  materi al wa s a cylated 
wi thout  further purification . A s o lu tion o f  2- ( D-ribo furano sy lamino ) -
1 , 3 , 4- th iadiazo le ( 82 ) , NE t 3 ( 2 5  mL , 0 . 1 75 mo l) and AC20 ( 25 mL) \Vas 
s ti rred at 100e for 2h to af ford a c lear br own s olut.:ion ,  tha t w a s  then 
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s t irred at ro om temp erature for  an addit ional hour to g ive a brown opaque 
so lu tion . The react ion mixture was d iluted with CHCJ_3 ( 2 5  mL) , \vashed 
with H20 ( 2 x 50 mL) , then wi th aqueous NaHe03 ( 5%) ( 25  mL) and again 
with H2 0 ( 2 5  mL) . The organ i c  phase \Vas d r ie d  (HgS O,-;. ) , and the solvent 
\vas removed under reduced pressure . TLe ( E t OAc) indicated the p r e s ence 
of the a.,... anomer , Rf : 0 . 5 ,  and the 8 -anomer , Rf : 0 . 4 .  
Purif ication and ' sep aration o f  the anomers \va s achieved by c olumn 
chromatography ( co lumn 5 0x7 cm , hO g silica gel)  wit:h E tOAc a s  the 
e luan t . The comb ined frac t ions c ontaining e i th er 8S3 q  or ' 833 'vere con--- -
cen trated t o  d ryness under reduced pressure to give crys talline s ol i d s . 
Recrystallization f rom EtOAc a ff orded 1 .  S g ( 32%) o:\t 83a ; mp l8 3-l8So C ,  
. 0 
and 0 . 9 4 g ( 24% ) o f  � mp l48.,..lSl e .  
83 a :  IR (KB r ) : 3240  (NH) , 1750  ( C�O)  em 
- 1  1 * 
H-NHR ( CDC13) :  <5 8 . 5  
( s , 1 ,  ar om H) , ( 6 . 7 9 br s ,  1 ,  NH) , 5 . 72 ( t , 1 , r ib os e ) , 5 . 3 8 ( d , J 
9H z ,  H- 1 ' ) ,  5 . 17 ( d ,  1 ,  r ib o s e ) ,  4 . 9 8 (m , 1 , ribos e) , 3 . 8 7 (m , 2 ,  
r ib o s e ) , 2 . 2 0 ( s ,  3 ,  CH3) ,  2 . 05 ( s , 6 ,  013) ; mas s sp e c t rum , m / e  3 5 9 
(M+) .  
Anal . c a1 c d  for C 13H17N3 S 0 7 :  C ,  4 3 . 4 5 ; H ,  4 . 7 7 ;  N ,  1 1 . 69 .  Foun d : 
C , 4 3 . 2 6 ;  H ,  4 . 8 4 ;  N ,  11 . 62 .  
IR (KB r) : 3240 (NH) , 17 5 0 ( C�0)  
.,.. 1 
e m  
1 ,,( 
-H-NNR ( CDC1 3 ) : <5 8 . 5  
( 5 , 1 ,  arom H) , 6 . 7 2 ( br s ,  1 ,  NH) , 5 . 6  ( d ,  2 ,  r ib o se ) , 5 . 2 6 ( d , J 
, 
2 . 2  Hz , 1 ,  H-1 ) ,  5 . 2 3 ( t ,  1 ,  r ibose) , 3 . 9 (m , 1 ,  r ibo s e ) , 3 . 8  (m ,  1 ,  
rib o s e )  2 . 2  ( s ,  3 ,  CH3) ,  2 . 1  ( s ,  3 , CH3 ) 2 . 05 ( s , 3 ,  CH3 )  , mas s s p e c­
+ 
trum , m / e  359 (M ) . 
Anal . ca1cd f o r  C13H1 7N3 S 0 7 ' 0 . 5  H20 : C ,  42 . 3 9 ;  H ,  4 . 89 ; N ,  1 1 . 41 .  
Found : C ,  4 2 . 6 1 ;  H ,  4 . 7 5 ;  N , 11 . 4 6 .  
ex arid S �Arihydr<::HS� e thyl-8- ( 2 ' , 3 '  , 5  t � tri-0-acety1-·D-r ib o furan osy1 ) -
5-hydroxy- 7-·oxo - 1 , 3 ,  4-thiadiazo 10J3 , 2-a ] pyr imid in ium Hyd roxid e ( 9 l a ) , 
( 91S ) . b if�- ( 2 , 4 ,  6 - Tr ich1o r opheny 1 )  e thy 1ma10nat e (g) ( 1. 3  g ,  2 . 8  mIllo1) 
and an anome ri c mix ture o f  2 - ( 2 ' , 3 ' , 5 ' - tri-0-a ce t-1-D-ribo furano sy 1-
amino) -1 , 3 , 4-th iad ia zol e (�) ( 1 . 0 g ,  2 . 8 mmo1) ,vere he a t ed on a n  o i l  
o 
ba th ( 1 6 0  C)  unt il a c le a r  me l t  r e s u l t e d  ( 15 min) . A s low s tream o f  
n i t ro gen was p a s s ed thro ugh the re act ion mixture dur ing the heating 
p e r i o d , t o  a i d  in the removal of 2 , 4 , 6 - t r ich 10 ro pheno l .  When c oo l , the 
r e s u l tan t y e ll ow-b rown gummy res idue was t r i turated '-lith anhydro us e the r 
(10  mL) un t il crystal li zat ion oc curred , The resu ltant crude y e 1low-
brmvn so lid 'vas co ll e c t e d  by filtration . TLC ( E tOAc) indica ted the p re-
sence of the a-anomer , Rf :  0 . 12 ,  and the (3 -anomer , Rf : 0 . 05 .  
Purif icat ion and s ep arat ion o f  . the anomers ,vas a chieved by co lumn 
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c hr omat ography , ( c olumn 50 x 7 cm , 40 g s i l i c a  g e l )  f i r s t  w i t h  E tOA c a s  
the e luant t o  remove unr eac t ed ma lona t e  e s ter g ,  f o 1 1 mve d b y  a 1 :  1 
EtOAc /NeOH mixt ure to e lu t e  9 1 0.  and 9 18 separately . The comb in e d  f r a c -
t ions conta in ing e i ther 9 1 c.: o r  9 18 Here evap or a t e d  t o  dryne s s under r e -
duc e d  p r e s sure to g ive c ry s t al l ine s o l id s . 
1 iz ed from E t OAc to a f f ord 0 . 65 g ( 60% )  o f  
( KBr ) : 1 6 25 ( C=O) , 1 740 ( e s t e r  C=O ) cm�
l
; 
Comp ound 9 1 0. wa s rec rys t a1 -
o 
produc t , mp 195-1 9 7  C .  IR 
1 ;e H-NHR ( CDCl 3 ) :  15 9 . 2  ( s , 1 ,  
arom H) , 6 . 7 ( d , 1 ,  H� I ' , J = 1 0 Hz) , 5 . B ( t , 1 , r ib o s e ) ,  5 . 3 (d , 2 ,  
r ib o se )  4 . 2  (m , 2 ,  rib o s e ) ,  2 . 5 ( q , 2 , CH2 ) ,  2 . 2  ( s ,  3 , C1I3) , 2 . 0 ( s , 3 ,  
CH3 ) , 1 . 9 ( s , 3 ,  CH3 ) , 1 . 1  ( t , 3 ,  CH3 ) ; ma ss s p e c trum , m l e 4 5 5  (}l+) . 
Anal . calcd for ClBH2 1N30 9S :  C ,  4 7 . 4 6 ; H, 4 . 65 ; N ,  9 . 2 3 .  F ound : 
C ,  4 7 . 5 B ; H ,  t • •  69 ; N ,  9 . 1 7 . 
Compound 21§.... via S  fur ther pur i f ie d  by c o lumn chromat ography t o  afford  0 . 5 0 
o 
g ( 39 % )  o f  9 18 , mp 1 55- 1 5 7  C .  IR (KBr ) : 1 62 5  ( C=O) , 1 74 0  ( es t er C= O )  
- 1  1 * cm Ih·:NMR (CDC1 3 ) :  15 9 . 4 ( s ,  I ,  arom H) , 6 . 5  ( s ,  1 ,  H.,.. I ' ) ,  5 . 7  
( t , 1 ,  r ib o s e ) , 5 . 4 (d ,  2 ,  r ib o s e ) , 4 . 2 (m , 2 ,  ribose) , 2 . 4 ( q ,  2 , CHZ ) '  
2 . 1  ( s , 3 ,  CH3 ) , 1 . 9  ( s ,  3 ,  CH3) , 1 . 8  ( s , 3 ,  CH3) , 1 . Z  C t , 
3 , CH3) ; mas s  
+ s p e c t rum , m / e  4 5 6  (N + 1 ) . 
Anal . calcd for C I BH2 1N30 9 S ,  0 , 5  H20 : C ,  44 . B 1 ;  H ,  5 . 00 ;  N ,  8 . 7 0 
Found : C ,  4 4 . 7 6 ; H ,  4 . 7 0 ;  N ,  8 . 5 3 .  
Dibromomalonyl d ichl o r id e  (.2.�) .  Dib romomalonyl dichl o r i d e  ( 9 8 )  wa s 
p r e p ared from d ibromomalon ic ac id (22) ,  which wa s p r epared accord ing t o  
the method o f  Te ichman (2 1 3 )  f rom ma lonic acid (�) . B r omine ( 1 1  mL ) 
\va s add e d  d ropwise t o  an irra d ia t e d  ( 2 0 0  wa t t  lamp) solut ion o f  malonic 
ac id (9 6 ; 10 . 4  g ,  0 . 1  mo l ) in HCOOH ( 1 5 . 3 mL) a t  room tempera ture . The 
o 
reac t ion mixture wa s then s t ir red a t  t. O C for I h ,  and at ro om t emp era-
ture o vernigh t (1 2h) . The re sul t ing sol id mass wa s col l e c t e d  by f i1 tra� 
1 4 9 
t ion and wa s dr ied over so lid KOH in a vacuum de. s s ica tor to y ield 1 6 . 6  g 
o 0 
( 6 0 % )  o f  c rude ac id 22, mp 1 3 7� 1 4 1  C f l it . ( 2 13)  mp 14 7-1 4 8  C ] .  Thi s  
p r oduct was us ed \vithou t  fur th er pur i f ic a t ion . 
Dibromoma lony l  d ich l or ide ( 98 )  was prep ared from !!J..., accord ing to 
the p ro cedure o f  S t audinger e t  a 1  ( 2 10 , 2 11 ) . P C 15 (9 . 4  g)  wa s added 
caut ious ly to  a s olut ion o f !!J... ( 7 . 0 g,  0 . 0 2  mo l) in anhydrous e ther 
( 5 0  mL) at room temp erature and the reaction mixture "la S heat e d  a t  re-
flux for 2h . The react ion mixture wa s d is t illed under vacuum ( bp 70-
7s
o C/ ls mm) t o  y ie ld 7 . 4  g ( 9 2% )  o f  9 8  [ lit .  ( 2 10 , 2 11) bp 7 0-80
o
C / I smm} . 
Anhydro-8-e.thyl-s-hydr oxy..:. 7 ":' oxo..:.1 , 3 , 4- thiad iaz o lo [ 3 , 2-a ] py r imid inium 
Hydroxide ( 101) . D ibromoma1 onyl dichlor ide ( 9 8 )  ( 3 . 0  g ,  0 . 0 1 mol )  in 
anhydrous e.ther ( 30 mL) \va s added dropwis e on to  zinc  shavings ( 2 . 0  g) 
under a nitrogen a tmosphe.re at such a rate that the s t irred solution 
b oiled r ap j.d ly . The e s cap ing vapors o f  c arb on sub oxide (22,) ,ver e bub­
bled int o  a. s o lut ion of 2 - e thy lamino- 1 ,  3 , 4 - thiadiaz o le ( 100)  ( 0 . OS g , 
0 . 3 8 romo l) in anhydrous ether ( 5 mL) t o  a f f ord an a lmos t  ins tant aneous 
yield o f  a thick ,vh i t e  p recip itate . The solid ,vas collected by f i l tra-
t ion and recrys tallized from CH3CN to a f ford 0 . 0 7 g ( 9 2%)  of 101 as 
o 0 
'vh i t e  cry s ta ls ) mp 20 8- 2 1 0  C [ l i t . (lsl )mp 2 0 8-209 C ] . 
2- (D-Ribo furanosylamino) t:h iazole ( 155 )  and 2"';'(2  t , 3  t , 5  t -Tr i-0-acety1-
D-r ib ofur anosy1amino) thia zole ( 8 4 ) . The t itle comp ounds 1 5 5  and 84  ",ere 
p repared by the method o f  S chubert et a1 ( 195) . 
Anhydro-8- ( 2 ' , 3 ' , s t -t ri-0-acetyl-D-r ibo ftirano syl) ,.;.5-hydroxy-7":'oxo-
thiazole [ 3 . 2-8. ] pyrimidinium Hydroxide (�) , ( 102S) • Carb on sub oxid e , 
. (9 9 )  wa S generated in s itu as desc ribed f or comp ound 101 and was bubb led 
into  a s olu t ion of 84 ( 6 0 0  mg , 1 . 6 mmol) in E tOAc (20 mL) f or a period 
o f  app roximate ly 30 min . A ,vhite precip itate f ormed s lowly ( 20 min) 
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up on s tanding . This s o l id mater ial was co lle c t e d  by f il tr a t ion t o  a f -
ford an anomeric mix ture of  102 . Pur i f i cat ion and sep aration o f  the 
anomers  "JaS achieved by c olumn chr omat ography ( co lumn 2 5x7 cm , 30 g 
s i lica ge l , )  firs t with E tOAc f ol loHed by 1 : 1  E tOAc /MieOH mix tur e to  
e lu t e  102a and 1028 s eparat e ly . The comb ined fra c t ions con t a in ing e i th-
er 1 0 2 a  or 1023 were evap orated to dryness und er reduced pres sure to 
o 0 
affor d  200 mg ( 31%) o f  102 ; mp 2 3 0 - 2 3 1  C [ l i t . ( 1 95)  T!lp 2 32-2 3 4  C ]  and 
o 0 
2 6 0  mg ( 3 8%)  o f  102 , mp 2 38-2 3 9  C [ l it .  ( 19 5 )  mp 23 6- 2 3 8  C] . Thes e pro-
duc t s  co-chromatographed with au then t i c  s amp les  of  l02 a  and 1023 ( TL C  
p la tes , s ilica gel GHLF , 2 5 0  microns ; e luant , E tOAc 1:�)2a , Rf : 0 . 2 2 ;  
10� , Rf : 0 . 10) . 
Anhydro-8-D-rib o furanosyl-5";'hydroxy";' 7-oxo - thiazoJLo [ 3 , 2-a ]pyrimidi-
nium Hydroxide ( 15 6a» ( 1 5 68 ) . The t i t le comp ounds l S_6a and 1563 W'ere 
prep ared by depro te c t ion o f  102a and 1028 respec t ive ly , W'i th HeOH/HNE t 2 , 
follmving the general pro cedure o f  S chuber t e t  al ( 1 95 ) . 
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a and S -Anhydr o-8-�_�).2�.:-tri-_0_-:-_<-!.��_t-D-riQ.Q.E1:l�_?..nos-.Y1l::::2-1"!y�ro..xy -
7-oxo- l , 3  , 4-thiad iaz o lo [3 . 2 . - a] pyr im id in ium Hyd r o x i d e .. ( 9 2(1 )  , � S ) .  Car-
b on sub oxide ,  generated as  des c r ibed for comp ound 1 0 l. ., an d was b ubble d 
in to a s olut ion o f  an anomeric mixture o f  2- ( 2 ' , 3 '  , S ' -- tr i-O-ace ty l-D-
r ib ofuranosylamino ) 1 , 3 , 4- thiadiaz ole (.§l; If 00  mg , 1.0 mmol) in E tOAc 
( 3 0  mL) for a period of ap proximat e ly 40 min . A \vhite precip it at e ,  
formed af ter 3 0  min , \va s collected b y  f iltra t ion t o  afford an anomer i c  
mixture o f  9 2 . TLC (EtOAc) indicated the p re s ence o f  the a - anomer , Rf : 
0 . 09 ,  and the B .,-anomer , Rf : 0 . 05 .  Pur i f icat ion and s ep arat ion o f  the 
anomers vTaS achieved by c olumn chromat o graphy ( co lumm. 2 Sx7 cm , 30 g 
s i lica gel) fir s t  with E tOAc fo llowed by 1 : 1 E tOAc /MeOH mixture t o  
elut e 9 2a and 9 �  s ep arately . The c omb ine d  f ract ion s containing e i ther 
9 2 0.  or  9 28_ \vere evaporated  to drynes s  under reduced pres sure t o  give 
crys t al l ine s olids . Compound 920. was purifie d  by preparat ive TLC ( s ili-
ca gel p la t e , 1 0 0 0  microns ; eluan t , E tOAc) , to yield 100 mg ( 2 3% )  o f  9 20. 
o 
as wh ite crystals ; mp 1 70-1 7 2  C ;  IR (KBr) : 1 7 5 5  ( ester C=O) , 1 6 5 0  (C=O)  
cm-l ; \r-NMR* ( CDC13) :  <$ 8 . 9  ( s , 1 , arom H) , 6 . 65 ( d ,  1 ,  H-l ' , J = 10 
Hz) , 5 . 7  (br ,  s ,  1 , ribose) , 5 . 3  ( dd , 2 ,  ribose) ,  5 . 1  ( s , 1 ,  6H) , 4 . 2  
(m ,  2 ,  r ibose) , 2 . 2 ( s , 3 , CH3 ) , 2 . 0 ( s , 3 , CH3) .  1 . 9  ( s , 3 ,  CH3 ) . 
Comp ound �� was recrystallized from EtOAc to afford 150 mg ( 3 5% )  of 
o 
white crys tals ; mp 2 0 7- 2 1 0  C ;  IR (KBr) : 1 7 5 0  (es ter C=O) , 1 6 5 0  ( C=O) 
-1 1 * cm H-IDfR (CDC13 ) :  IS 8 . 9 ( s , 1 , a rom H) , 6 . 3 ( s ,  1 ,  H-l ' , J = 1 . 5 
Hz) , 5 . 6  ( br . s ,  1 ,  ribose) , 5 . 3  ( d , 2 ,  ribose) , 5 . 1 ( s , 1 ,  6H) , 4 . 2  
(m,  2 , ribose) , 1 . 9 9 ( s ,  3 , CH3 ) , 1 . 90 ( s , 3 , CH 3) , 1 . 8 (s , 
3 , CH3 ) . 
Anal . calcd for C1 6H1 7N309S  0 . 5 H2 0 :  C ,  l�4 . 03 ;  N ,  4 . 15 ;  N ,  9 . 62 .  
Found :  C ,  43 . 9 0 ;  H , 3 . 9 5 ;  1'1 ,  9 . 9 3 .  
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l-Ethyl- l-n�-thiadiazolo-2"':yl-) urea ( 107 ) . Phenoxycarbonyl iso cy­
anate ( 105 ; 500 mg , 3 . 0 mmol) in anhy d r o u s  E tOAc ( 10 mL) under a nitro-
gen atmosphere , was added to  a solution o f  2-e thyamino-l , 3 , 4-thiadiazole 
( 100 ; 3 40 mg , 2 . 6 mmol) in anhydrous E tOAc ( 10 mL) over a perio d of 15 
min .  The reaction mixture was s t irred at  room temp erature for 2h , and 
then heated at reflux for 411 . The crude pr oduct i . e .  Anhydro-8-ethyl-
5-hydroxy-7-oxo-l , 3 , 4- thiadiazolo [ 3 , 2a ] -s-triaz inium hydroxide ( 10 6 )  
o 
ob tained on c oo l ing was f il t ered ; crude mp 145-150 C [ li t  ( 15 9) mp 145-
146
o
C] ; IR (Nuj ol) : - 1  1 6 6 0 , 1 75 0  (C=O) cm • The crude pro duct contain-
ing � could no t be recrystallized from gl acial A cOH as reported . Upon 
concentration of the mother liquor under reduced p ressure , a white s o l i d 
vTa S  obtained which was identif ied to be l.-ethyl-l- ( 1 , 3  , 4-thiadizol- 2-y1) 
0 0 . . urea ( 10 7 ) ; mp 173- 1 7 5  C [ lit ( 15 9 )  mp 173-174 C ]  IR (NuJ ol) : 3 3 0 0  (NH) , 
1 6 6 0 ( C=O) em- I ;  lH_NMR ( DMSO-d 6 ) :  0 9 . 2  ( s ,  I ,  ar om H) , 8 . 2  ( br . s ,  
Z , NH ) , 4 . 15 ( q ,  2 , CHZ) , 1 . 2 ( t ,  3 , CH3) '  
Anhyd ro-:-6-e thyl-8- (3 '  , 5 '  - d i-0-acetyl-a-D-2 ' -deoxyr ib o furano syl) - 5 -
hydroxy- 7- oxo-2 , 3- d ihydro thiazo lo [  3 ,  2-a J  pyr im id in i um Hydroxid e ( l 1 Za) . 
A s o lut ion of  2 ' -deoxy r ib o s e  ( 10 9 ; 4 . 0  g ,  0 . 0 3 mol) , and 2-amin o t h ia­
z o l ine ( 108 ; 3 . 0  g , 0 . 03 mo l ) , in MeOH ( 6  mL) and conc . HC l ( 0 . 1 mL) 
Has �V'armed on a s team b a t h  f o r  2h to y ield a ye lloH syrup . The syrup 
Has dried under high vacuum to give a cream-co lored f oamy so lid which 
\V'as acy la t ed Hithou t  further p ur i f i cation . A solu t ion o f  2- ( 2 '  - de o xy ­
D-r ib ofuranosylamino) th ia z o l ine ( 110 ) , NE t3 ( 3 0  mL) and Ac20 ( 3 0  mL) 
Has s tirred at room temp erature for 30 min to give a brmffi s o lu t ion . 
The react io n  mixture \V'as d i luted \V'i th CHC13 ( 8 0 mL) Hashed \vith H2 0 
{ 2  x 4 0  mL) , aque ous NaHe03 ( 5% ,  2 x 40 mL) and H2 0 ( 4 0 mL) . The o r­
gan ic phase Ha s dried (HgS 04 ) and the s olvent \V'as removed unde r  reduced 
p res sure . Purificat ion and sep ara t ion o f  2 - ( 3 ' , 5 ' - d i-0-ac etyl -D-2 ' ­
de oxyr ib o f ur ano sylamino ) t h ia z o l in e ( I l l ) was achieved by co lumn chro ­
mat ography ( column 120 x 7 em , 1 2 0  g s ilica gel )  with E tOAc as the 
eluant . The comb ine d  frac t ions c ontaining the des ired nuc le os ide Here 
evap orated to dryne ss  under r educed pres sure to give an oil , vlhich \vas 
sub s equent ly utilized in the cyc lizat ion s tep wi thout fur ther purif ica­
t i on ( s ee Figure 34 ) , A second  frac t ion was is olated from the c olumn , 
which Ha s evap orated t o  dryness in vacuo t o  a f ford 5 0 0  mg ( 10% ) o f  
2-a ce tamido-2-thiazoline ( 11 5 )  as \V'hite  cry s ta ls ; mp 19 9-202 0C [ l i t  
( 15l) mp 198- 2 0 0
0
C ] . 
bis ( Z , 4 , 6-Tr ichlorophenyl) ethyl ma lonate ( 6 2 ; 0 , 9 8 g , 2 . 0  romo l) 
and 2- (3 ' , 5 ' -Di-0-acety l-D- 2 ' ,...d eoxyribo furanosylamino) thiazoline ( Ill 
0 . 5 8 g,  2 . 0  mrno l) were heated on an oil  bath ( 160°C) un t il a clear melt 
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r e sul ted ( 3  min) . Hhen c oo led , the resul tant ye l l oH gum was tr i tur ated 
wi th anhydr ous e ther ( 5 0  mL) unt il cry s tallizat ion oc cur red . Re cry s tal-
l i z a t ion from CH2C1 2 a f f o rded 0 . 0 8 g ( 10% ) o f  l 12a a s  \vh i te cry s tal s ; 
mp 2 0 3 - 2 04 °C IR (Neat) : 17 45 ( es t er C=O) , 1 63 5  ( C=O) , 1625 ( C=O) cm-1 ; 
, 
o 6 . 6  ( dd ,  1 , H-l ; ,  J '  = 4 H z , J "  = 5 H z ) , 5 . 5  (br . s ,  
1 ,  deoxyr ib o s e ) , 4 . 9  (m , 2 ,  deoxy r ib o se) , 4 . 3 (m , 3 ,  deoxyrib os e ) , 4 . 0  
( t ,  2 ,  CH2 ) ,  3 . 4  ( t ,  2 ,  CH2 ) , 2 . 3 ( q ,  2 ,  CH2 ) ,  2 . 1  ( s , 3 , CH 3) , 2 . 0  
( s ,  3 ,  CH3 ) ,  1 . 0 ( t ,  3 , CH3) . 
Ana l .  ca lc d f o r  C1 7H2 2N20 7 : C ,  5 1 . 2 ll ; H ,  5 . 5 6 ; N ,  7 . 03 .  F ound : 
C ,  SO . 9 6 ;  H ,  S . S 8 ;  N ,  6 . 9 9 .  
In one in s tance , the recry s t al l izat ion mo th er l iquor ( CH2 C 12 ) 
yielded 0 .. 04 g ( 10%)  o f  6-e thyl-7-hydroxy- 2 , 3 , 4 , 5 - t e trahydr othia z o l o  
[ 3 , 2-a] pyrimidin ium- S -one ( 114 ) a s  cre am c ry s tals ; mp 2 l 8- 2 2 0o C [ lit . 
( l S 3 )  mp 2 2 4 - 2 2 5 0C ]  Hhich co-chromat ographed with an au then t ic s amp l e . 
IR (KBr) : 1660 ( CS C=O) , 1630 ( C 7 C=O)  em- I ; 
lH_�� ( DMSO-d6) :  0 11 . 2  
( b r . s ,  1) , 4 . 45 ( t ,  2 ,  thiazoline CH2 ) , 3 . 5  ( t ,  2 ,  thiazo l ine  CH2) , 
2 . 4  ( q , 2 , CH2 ) , 1 . 1  ( t ,  3 ,  CH3) .  
Anhydr o- 6-e thyl- 8- (a-D- 2 ' -deoxyr ib o furano syl) -5-hydroxy- 7 -oxo - 2 , 3 , -
d ihydrothiazolo [ 3 , 2-a]pyrimidinium Hydr oxide ( 113a) . Me thod A :  Deoxy-
r ib os ide ;11 2 a ( 30 mg , 0 . 0 8  romo l) was dis s o lved in anhydrous  HeOH ( 3  mL) , 
c ontaining HNE t2 ( 12 mg) . The so lut ion was kep t at O
OC for 9 4 h ,  af ter 
which the s o lven t wa s evap orated in vacuo to  afford a Hhite s o lid . Re-
c rys tallizat ion from 2 ; 1  MeOH-E t OAc gave 2 0  mg ( 7S%) o f  l12a a s  whi te 
crystals ; mp l25-l3 0oC ;  I R  (KBr) : 3200-3 600  ( OH)  , 1 6 3S , 1 6 2 0  ( C=O)  em-1 
1 * H-NMR, (D;MSO-d6) ;  0' 6 . 4  ( dd ,  1 ,  H- l ' , J ' J I I  =- 10 . 0  Hz) ,  4 . 9  (br s ,  1 ,  
deoxyribo se)  4 . S  (m , 2 ,  deoxyribose) , 4 . 0 (m , 3 ,  deoxyrib os e ) , 3 . 7 3 
( t , 2 ,  thiaz oline CH2) ,  3 .70  ( t ,  2 ,  thiaz oline CH2 ) ,  3 . 4  ( s ,  HOD) , 2 . 1  
154  
( q ,  2 ,  cn 2 ) '  1 .  2 ( t ,  3 , CH 3)  . 
Ana l .  c a lc d  f or C 13H l SN 2 0 5 S 1 . 5  H2 0 :  C ,  4 5 . 7 3 ;  n ,  6 . 2 0 ;  N ,  8 . 2 0 .  
F ound : C ,  4 5 . 7 S ; H ,  5 . 9 5 ;  N ,  S . 1 5 .  
He thod R :  De oxy r i b o s ide ( 112a.) ( 220  mg , 5 5  mo l) 'va s d is s o lv e d  in 
an.hydrou s HeOtI ( 22 mL) c on ta in in g  HNE t 2 ( S O  mg) . The s o lu t ion Ha s 
s t irre d  at ro om t emp er a t ur e f or 3 6h and the s olvent Ha s evap o r a t e d  in 
vacuo to give a y e l l mv o i l , Hh ich y ield e d  a pale yel lm-l s ol id on t ri-
turat io n  Hith anhydrous e the r . The crude s ol i d  'vas purif ied b y  c o lumn 
c hr omatography ( 6  g s i l ica gel) f i r s t Hith E tOAc as the e luan t , f o l l OH-
ed by HeOH . The f r a c t ions con t a in ing the d e s i r e d  de oxyrib o s i d e  wer e 
evap o r a ted t o  d ryne s s  und e r  r e du c e d  p r es sure to afford 10 0 mg (58%) of 
1 
In f r ar e d  and H-NHR s p e c t r a  Her e  ident i c a l  H i t h  
tho s e  ob tained i n  He thod A .  
3-,.;t.le thyl-4-e thyl- l , 2 , 4 - tr i a z ole- 5 - th ione ( 2 2 3 )  ( 124) . 4-E thyl-3-
t h io s emicarb a z id e  (2.2.) ( 2 . 9 8 g, 0 . 0 2 5  mo l) , t r ie thy l o r t ho a c e t a t e  ( 1 7 5 )  
( 4 . 0 6 g ,  0 . 0 2 5  mo l )  and con e . H C l  ( 0 . 0 7  ml) 've re d is s olved in ab s olute 
E t OH ( 30 mL) and s t ir re d  at r oom temp era ture for lh , he a te d  a t  r e f lux 
f o r  lh and t h en c o o le d . Th e s o lven t Has r emove d in v acuo t o  y ie l d  a 
gl o s sy ma terial Hh ich Has r e crys t a ll i z e d  f r om 9 5 %  E tOH t o  y i e ld 0 . 64 g 
o 
( 2 0% )  o f  1 2 4  as cub ic c ry s t al s ; mp 1 2 5- 1 2 9  C .  IR ( CH C 13 ) :  2 9 5 0 , 1 5 8 0 , 
14 7 0 , 1 3 6 0 , 13 20 ... 1 cm 
CH3 ) , 1 . 4  ( t , 3 , CH3 ) . 
o 4 .  1 ( q , 2 ,  CH2) ,  2 . 4 ( s , 3 , 
Anal .  c a l c d  for C 5H 9N 3S :  C ,  4 1 . 9 4 ;  H ,  6 . 3 3 ;  N , 2 9 . 3 4 .  Found : 
C ,  41 . 9 2 ; H , 6 . 3 7 ,  N ,  2 9 . 3 3 .  
4'"".E thyl� 3 .... thio s emi carba z ide ( 69 ) . Hydra z ine ( 1 7 6) ( 1 . 6 g ,  0 . 05 
mo l) \'las added dropvl is e  to a cold s t ir r ing s ol u t ion o f  e thyl is o th i o -
cyana te (177) ( 4 . 3 6 g ,  0 . 0 5 mo l) i n  anhy drous e ther , and the r e a c t ion 
1 5 5  
mixture was then s tirred at  r oom t emp erature for lh . The re su l t ing p r e -
c ip i ta t e  vJaS collected , washed with p e tro leum e ther and re crys tall i zed 
from b enzene to y ield 4 . 5  g ( 75% ) o f  (�) as white  needles ; 
[ l it . ( 6 ) mp 8 2-84 °C ] .  
° 
mp 8 0 - 8 1  C 
Anhydro- l , 6-d ie thyl-5-hydroxy"':' 7-oxo-2-me thyl- l , 2 , 4- tr i a zo l o [ 2 , 1-b ] -
thia z inium Hydroxide ( 12 5 ) . b is- ( 2 , 4 , 6-Trichlorophenyl) e t hyl malona t e  
( 6 2 ; 0 . 8 g ,  1. 7 mmol) and 3-me thyl-4-e thyl-l , 2 , Lf- tr ia zole-5-thione ( 124 ; 
° 
0 . 25 g ,  1. 7 romol) were heated on an oil bath ( 1 2 5  C) , unt i l  a clear mel t  
resu lted ( 20 min) . When co oled , the r e s ul t an t  guwny res idue was tr i tu-
rated with anhydrous e ther ( 10  mL) , until  cry s t al l i zat ion occurred . The 
s olid was collected  by f i ltrat ion and recry s tal l i z ed from h o t  E tOAc t o  
a f f ord 0 . 1  g ( 2 5%)  o f  the mes oionic comp ound 1 2 5  a s  whi te crys tals ; mp 
203-2050C ; IR (Nuj 01) : 1640  ( C=O) em- I ;  \-·NMR ( CDC 13 ) :  0 Lf . 2 5  ( q , 2 ,  
C6-CH2 ) ,  2 . 85 ( s , 3 ,  CH3 ) ,  2 . 6 8 ( q , 2 , NCH2 ) , 1 . 4  ( t , 3 ,  C-CH3) , 1 . 2  
( t , 3 ,  NCH3 ) .  
An a l .  calcd for C I0H13N30 2 S :  C ,  5 0 . 19 ;  n ,  5 . 4 7 ;  N ,  1 7 . 5 6 .  Found : 
C ,  5 0 . 12 ;  H ,  5 . 4 9 ;  N ,  1 7 . 49 . 
Anhydro-1-me thyl- 6-ethyl-5-hydroxy- 7-oxo-imi dazo [ 2 , 1-b ] t h i a z in ium 
Hydroxid� ( 12 1) . b is ( 2 , 4 , 6-Trichloropheny1) ethy1 malonat e  (�; 0 . 4 3 g ,  
0 . 87 romol) and me thimazole ( 120 ;  0 . 1 g ,  0 . 8 7 mmo 1) Here heated on an 
o 
o i l  bath ( 160  C)  under a slmV' s tream o f  nitr ogen , unt il a c lear mel t  
re sulted ( 10 min) . Hhen coole d , the resultant res idue ,vas triturated 
with anhydrous e ther ( 10 mL) , until c ry s tal liza t ion occurred . The s o lid 
was co llected by tritura t ion and recrys tallized from E tOAc to a f ford 
0 . 18 ( 2 0% )  of the mes oionic c ompound 121 a s  white crys tals ; mp 194-l 9 6 o C 
o 1 1 . llit . (234) mp 19 4-19 5 C] .  IR (KB r) : 1 6 5 5 , 157 0  cm- ; H-};'MR 
1 5 6  
(DMSO-d6) :  0 8 . 1 5 (d , 1 ,  arom H) , 7 . 9  (d , 1 ,  arom H) ,  3 . 7 5 ( s ,  3 , NCH3) ,
 
2 . 4 5  (q , 2 ,  CH2 ) ,  1 . 0 ( t , 3 , CH3 ) . 
1- ( 2 ' ..tl '  , 5 ' -T ri-O-ace tyl-J3 -D- r ib ofur an o syl) [I , 5 - dihydro - imid a z o le-
2- thione ( 1 42.) . Th e t it l e  c omp oun d was p rep ared ac cord ing to the gen-
er al p ro c e dure o f  Imb a c h  et al ( 2 3 7 ) . A d ry , f ine ly p owde red mixture 
of imi da z o l i d ine- 2- thione ( 14 1 )  ( 1 . 0  g, 9 . 8 rmno l ) , 1 , 2 , 3 , 5 - t e tra-0-
acetyl-{3 -D-rib ofuranos e  ( l3 8) ( 3 . 3  g, 9 . 8  mmo l) , and tw"ic e-sl.lb l imed 
o 
i o d ine ( 0 . 05 g) \vas fu s e d  f o r  2 0  min at 1 8 0  C in a p ear- shap e d  f l a s k  
und er redu c ed p ressure ( 5 5  mm Hg ; w a t e r  as p irat or) . S ep a r a t ion and 
p u r i f i c a t ion o f  the nuc l e o s ide 142 wa s achi eve d by c olumn chr oma to-
gr aphy ( c olumn 5 0 x 7 cm , 40 g s i l i c a  gel) f ir s t  Hith eHC13 an d then 
"l ith 9 : 1 CHC13 / CH3 COCH3 mixture . The fr ac t i on s c ontaining the de s ir e d  
c omp oun d were evap o ra t e d  under reduced p re s s ur e  t o  a fford an o i l . C on-
t inue d  drying under high vacuum r e s u l ted in 30 0 mg ( 8%) of the hy gr o-
s c o p i c  s o l i d  142 . IR ( Nuj o l ) : 33 60  (NH) , 1740 ( e s t e r  C=O) cm-l ; 
�-};"'MR ( CDC13 ) :  0 1 1 . 2 ( br s ,  1 ,  NH) , 6 . 8  ( t .  1. ribose) , 6 . 7 ( d ,  2 ,  
r ib o s e ) , 6 . 4  ( d ,  1 ,  H- l ' ) , 5 . 4 (m,  2 , r ib o s e ) , 3 . 8- 3 . 9 (m , 4 ,  imidazo-
l i d ine H) , 2 . 1- 2 . 3  ( t ,  9 ,  CH3 ) . UV ( 9 5% E tOH) : A max 2 45 nm , mas s 
+ 
s p e c t rum , m/e 3 6 0  (N ) . 
Ana l .  calcd f or C14H20N20 7S :  C ,  4 6 . 7 0 ; H , 5 . 60 ;  1'1 , 7 . 7 8 .  Fo und : 
C , 4 6 . 5 6 ;  H ,  5 . 70 ;  N ,  7 . 8 5 . 
rmi da z o l ine-2- thione ( 1 3 0 ) . The t it le c omp ound was p r ep ar ed 
according t o  the method of Harbva ld ( 2 3 8) . Aminoace ta ldehyde d i e thyl-
ace ta l · (ill; 4 . 8  g ,  3 6 . 0  mmol )  ,vas d is so lved in H 2 0 ( 20 mL) and the pH 
o f  th is s olution was adj u s ted to ca . 5 , 0  by ad d i t ion of HCl . Po tass ium 
iso thio cyanat e  ( 144 ; 3 . 6 g ,  3 6 . 0 mmo l )  in H20 ( 2 0 mL) 'vas added t o  this 
s o lu t ion and the resul t an t mix ture was s tirred for lh . The s o lu t i on 
was evap o r a t e d  unde r  reduced p re s sure t o  a f fo r d  a s ticky r e s i d u e . 
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P o t as s ium chloride , precipi tated by the add it ion o f  ab s o lu t e  E tOH ( 2 5 
mL) , �vas removed by f iltration , and the result ing s o lut ion \Vas hea t e d  
on an oil  b a t h  ( 1450C)  unt il a s o lid began to  f o rm .  This res idue Has 
s t irred at: room t emp erature overnigh t  ( 12h) . The s o l i d  mate r ia l  w a s  
collected by filtrat ion to a f ford 2 . 5  g ( 6 7% )  of l30 a s  a c ream- c o lored 
so lid ; mp 220- 2 22 0C [ lit . ( 2 3 8 )  mp 2 22-2 2 6
°
C ] . Comp ound 1 3 0  H a s  used  
in s ub sequen t reactions without further purif ica t i on . 
1- ( 2  t , 3 '  , 5 '  �Tri�O�a ce tyl-e -D-rib o furano syl) imi da:;:ole-2-thione 
(2:..39 ) • Comp ound 1 3 9  was p rep ared by t h e  method o f  Imb ach e t  a l  ( 2 3 7) . 
A f inely p owdered mixture o f  imidazole-2- thione (130 ; L O g ,  9 . 8  mrnol) , 
l , 2 , 3 , 5- t e tra-0-ac e tyl-l3 -D-ribofuranose  ( 138 ; 3 . 3 g .  9 . 8 mrno 1) , and 
t,.ice sub l imed iodine ( 0 . 5 g)  was fu s e d  in a p ear-shaped  f la sk f o r  20 
o 
min a t  180 C under vacuum ( 12 n� Hg) . S e p ara t ion and purifica t ion o f  
the d e s ired nucleos ide 13 9 was achieved b y  column chromatography ( co l-
umn 5 0  x '7 cm, 4 0  g s i lica gel)  f ir s t  vlith CHC1 3 and then with 9 : 1  
CHC 13 /CH3 COCH3 mixture . The frac t i ons containing th e des ired nuc leo-
side were evap orated under reduced p r e s sure to af ford an o iL C on t inued 
drying o f  the o i l  in vacuo overnigh t  gave 0 . 4 g ,  ( 11%) of 139  a s  a 
hygr o s cop i c  p ink-co lored sol id , mp 5 0- 5 5
0
C [ lit . ( 2 3 7 )  reported  as an 
o i l ] ; IR (neat) :
· 
3300  (NH) , 1750  ( e s t e r  C=O) cm-l ; IH-NHR ( CDC13) :  0 
11 . 6  ( brs , 1 ,  NH) , 7 . 5  (brs , 2 ,  arom H) , 7 . 0  ( t ,  1 ,  rib o s e ) , 6 . 8  ( d ,  2 ,  
r ib os e ) , 6 . 5  ( d , 1 , H-1 ' ) , 5 . 5  (m ,  2 , ribose)  2 . 1-2 . 2  ( t , 9 ,  CH3) , UV 
I. 
( 9 5% E tOH) : A max [ lit  ( 23 7 )  UV ( 9 5%EtOH) : A max 2 6 6  (c  1 . 5 x 10  ) ; 2 68 
( c  1 . 1 3 x 10
7
) ,  mas s spectrum � m/ e 3 5 8  (H+) . Compound 139 was used in 
the sub sequent cyc1izatio n  react ion without fur ther p uri f i ca t ion .  
Anhydro- 7-ben zyl-6-hydroxy-8-oxo"; pyrimid ino [ 2 , l-:-b ] thia z inium 
Hydroxide. (1.2 8) . Benzy1ma1ony1 di chlo r ide ( 12 6 ;  0 . 2 5 g ,  1 .  0 mmo 1) wa s 
1 5 8  
added dropwise t o  a s t irred s olution o f  2-mer cap topyr imidine ( 1 2 7 ;  0 . 1  
g ,  1 . 0 mmo l) in xylene ( 70 mL) already heated t o  ref lux . The yel low 
s olution turned br igh t red as the d ichl or ide ,va s  adde d . Af ter hea t ing 
at r e flux fo r 20 min , the s o lu t ion was coo led and a f ine orange - co lored 
s olid  p r e c ip it ated , which wa s colle cted by filtration . Re cry s talliza-
t ion o f  th is solid  material wi th ho t xylene gave 0 . 1 9 g ( 7 0%)  o f o range 
cry s tals ; mp 1 9 5-200
o
C ( d) [ l it . ( if 1)  mp 2 0 2 0C ( d) ] .  
Anhyd ro- l-me thyl-- 6-b en zyl-5-hydroxy- 7-oxo- imidazo [ 2 ,  I-b ) thia z in ium 
Hydroxide ( 12 9 ) . Prepara t ion of the t it le comp ound emp loyed a method 
anal ogous to that us ed by Kappe  et  al ( if 1) for the synthes is of 12 8 .  
Benzylmal o nyl d ichl o r ide  ( 12 3 ; 0 . 2 5 g ,  1 . 0  mmol) ,vas added drop'\vise to 
a s t irred s olu tion o f  methimazole ( 120 ; 0 . 1 g ,  1 . 0  m ol)  in CHC 13 ( 1 . 5  
o 
mL ) a t  20 C .  The resul t ing react ion mixture ,vas s t ir red for  20 min 
under a nitrogen atmosphere . The wh i te p re c ip i tate ob tained ,va s 
collec ted by filtration , washed. " ith CHC13 ( 10 mL) and recrys tall ized 
fr om MeOH to af ford 0 . 0 6 g ( 2 2%)  of  12 9 as ,<,hite  nee d le s ; mp l8 4-l8 6°C 
[ lit . ( 2 34)  mp l85-l 8 6°C] . 
Anhydro-l-me thyl- 5-hydroxy- 7-oxo-imidazo [ 2 , 1-b } thiaz inium Hydrox-
ide ( 12 2 ) . Carbon sub oxide (.22.) ,vas generated in s it u  as des cr ibed for 
comp ound 10 1 and was bubb led into a s o lu t ion o f  me thimazole ( 12 0 ; 0 . 1 
g ,  0 . 8  mmol) in ben z ene ( 10 mL) for a p e r i od of  appr oximately 15 min . 
The '('ihite precip itate that formed was co llected by filtra t ion to  a f fo rd 
o 0 
0 . 13 g ( 88% ) of  122 , mp 188-189  C [ lit . ( 7) mp 188-189 C ) . IR ( KB r ) : 
1 69 0 , 1 6 35 (C;"'O) em- I ; �-NHR (DMSO-d6) :  <5 8 . 35 (d , 1 ,  ar om H) , 8 . 1  
( d ,  1 ,  arom H) 5 . 1  ( s , 1 ,  6H) , 3 . 6  ( s ,  3 ,  CH3 ) ;  UV (HeOH) : A max 2 6 0  
7 8 + 
( E:  6 . 85 -x 10 ) , 209  ( c 1 . 32 x 10 ) :  mas s spectrum ,  mle 182 (M ) . 
7";Hyd roxy- (SH) - imidcizo [ 2  , 1";bJ thiaz inium-5-one ( 1 2 3 ) . Carbon sub-
159 
ox ide (22.) was gener ated in s i tu as described for comp ound 101 and ,.,a s 
bubbled into a s olut ion o f  imidazol ine- 2- th i one ( l 3 0 )  ( 0 . 1 g ,  0 . 001 
mo l )  i n  CH3CN ( 30 rnL ) , f o r  a p eriod of app roximately 3 0  min . The 
cream-colored s o l id obta ined ",as co lle cted b y  f i l tr a t ion t o  a f f or d  0 . 1 2 
o 
g ( 7 1% ) o f  12 3 ; mp 170- 175 C (d) . The compound ,.,a s f ound to be ther-
mally un s table ; this pre cluded its recrys tall i z a t ion . The erude p r o d u c t  
,,,a s s t irred i n  CH3CN a t  r o om temperature for 12h , a n d  t h e  ,,]hit e so l id 
wa s colle cted by filtrat ion , mp l71f-1 750C (d) ; IR (KB,x-) : 1680 , ( C5 
C=O) , 1 6 20 ( C 7 C=O) em- I ; IH-NMR (DMSO-d6 ) :  IS 1 1 . 75 (br . s ,  1 , -OH) , 
8 . 2  ( d , 1 ,  arom H) , 7 . 9  ( d ,  1 ,  arom H) , 5 . 0  ( s , 1 ,  6H) ; UV (NeOH) : A 
max 2 8 9  ( E: 1 . 92 x 10
7
) ,  2 2 8  ( E  2 . 5 3  x 1 0 7 ) .  
An a l .  caled. for C 6H4N202S . 0 . 25 H20 : C ,  4 1 . 7 9 ;  H ,  2 . 4 8 ;  N ,  16 . 2 t+ 
Found : C ,  4 1 . 7 4 ; H ,  2 . 5 9 ; N ,  16 . 19 .  
Anhydr o- l- ( 2 ' , 3 ' , 5 ' - t r i- 0-ac etyl-S ,..,D-rib o furan os.yl ) - 5-hydr oxy- 7 -
oxo - imida zo [2 ,}-b] th iazirdum Hydroxide ( 14 5b ) . Carbon sub oxide "Ja S  
generated in situ as des c r ib ed f or comp ound 101  and "ras b ubb l e d  i n t o  a 
s o lu t i on of 1- ( 2 ' , 3 ' , 5 ' - t r i- O- ace tyl -S -D-r ib o furano s yl ) imid a z o l e - 2 -
o 
thione ( 139 ; 0 . 1  g ,  0 . 2 7  mmo l )  in ben zene ( 1 0  mL) co ol e d  to 0 C ( ice-
bath) f o r  a p e r i o d  o f  app roximately 4 0  min . A ",hit e fluf fy p re c ip i ta te 
was obtained which ",a s colle c ted by filtrat ion to a f ford 0 . 08 g ,  ( 6 6 % )  
o o f  crude l4 5b , mp 140-141 C .  The comp ound could not be recrys ta ll i zed 
with eithe r ho t or cold s olven t s , and app arently underwent a relat ively 
rap id ring-op en ing at ro om temperature . I R  ( KB r) o f  crude produ c t : 
1750 (es ter C=O) , 1 6 3 5  (C=O) em- I ;  �-NMR (CDCI3) : IS 7 . 7 ( d , 1 ,  ar om H) , 
7 . 5  (d ,  1 ,  arom II) 6 . 6  C d ,  1 ,  H-I t ) ,  6 . 12 C d , 1 , r ib ose) , 5 . 6 5 (m, 2 , 
ribo s e) ,  5 , 3 5 ( s ,  1 ,  6H) , 4 . 7 5--:4 . 6  (m , 2 ,  ribo s e) , 2 . 3-2 . 1 ( t , 9 ,  eH3) . 
1�Aeetyl-3�me thyl imi d a z o l irie-2�thi6ne ( 149 ) Me tl10d A. The t i t le 
1 6 0  
comp ound l!f 9  was p rep ared according t o  the me tho d o f  S imon e t  a1 ( 2 41) . 
AC 2 0 ( 1 . 0  g ,  0 . 01 mo l )  was added to a so lu t ion o f  methimazole ( 12 0 ; 1 : 1 
g ,  0 . 01 mo l) in pyridine ( 15 mL) and the reac t ion mix ture \"as hea ted a t  
reflux f o r  2h ( o il-ba th) . The s olven t  ,,,as removed by evap ora t i on und er 
reduced p re ssure and a white s o l id was ob tained up on dry ing under high 
va cuum ove rnight ( 1 2h) ; mp 70- noC [ li t  ( 2 4 1) mp n-7lfoC ] . 
He thod B .  Ac2 0 ( 1 , 0 g ,  0 . 01 mo l) was added to a s olut ion o f  me th­
imaz ole ( 1 20 ; 1 : 1 g ,  0 . 01 mo l) in NEt 3 ( 10 mL) , and the react ion mix-
ture was heated at r e flux f o r  2h ( o il-bath) . The solvent  'Vla S removed 
under  p re s s ure and the resul tant wass wa s dr ied under h igh vacuum over-
nigh t (1 2h) to afford a white s o l id . Pur i f ica tion of  the c ompound \Vas 
ach i eved by co lumn chromatography ( c olumn 25 x 4 cm , 6 g s il ica gel)  
firs t with C6H6 ' fo ll owed by 1 : 1  C6H6/EtOAc mix ture . The frac t io n s  
c on ta ining the des ired c ompound were evapor a t ed to drynes s under re­
duced p re s sure to affo rd 400 mg ( 2 5% ) of a ,.,hite so l id , mp 70- noC 
. 0 
[ lH .  ( 2 41 ) mp 12-74  C ] . 
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B .  B ioas say .  
The mes oion ic xan thine ana logs �, li ,  l57- l 7 Lf \-le r e  eva lu;l ted as  
inh ib itors of adenosine b inding a t  the Al inhib itory s it e  by Daly e t  al 
at Nat ional Ins t i tute of Health , Be thes da , Mary land . The thiad iazo lo ­
pyr imidine nucleos ide §l ( an omer ic mixture) and the mes o ionic thiad ia­
z o lopyrimidine nu cleo s ides 9la and 9 18  Here as sayed for toxic i ty to 
Ll2 l 0  cells  and H . Ep-2  cells in cul ture , by Bennet t  e t  aI ,  at S o u the rn 
Res e arch Ins titu te , Alab ama . The thiazolopyrimidine nucleos i d e  8 4  and 
the thiadiazolopyr imid ine nucleos ide 83 (anomer i c  mixture ) He re tes t e d  
agains t lympho id leukemia L1 2l0 by Dr . van ' t Rie t and Dr . Wamp ler a t  
t h e  Med ical Co llege o f  V irgin ia , VCU , Richmond . The thiad iazo lopyrimi­
dine nucleo side 83a-tB and the thi a zolopyr imidine nuc l e o s ides , a s  the 
tr�-O-acet.y l derivat ive , 155 and as the dep ro t. e cted  156S Here eva luated 
agains t lymphoid leukemia L12 l0 at the Nat.ional Can c e r  Ins titu t e , 
B ethesda , Maryland . 
B inding o f  [3 H ] N6-Cycl ohexylad enos ine ( 243) : 
B rains \vere dis s e c ted into specific  reg ions and homo gen i zed in 1 0  
vol umes o f  50  niH Tris · H Cl buf fer , pH 7 . 5 containing 0 . 1 wI CaC 12 ' 
Af ter cen trifugation at 10 , 000 g for 20 min , the p ellet Has res us p end­
ed , r ecentrifuged and f ina lly resuspended in 10 vo lumes of Tris ' HCl 
buf fer Hith 10 � g /ml of  adeno s ine deaminase . Af ter incuba t ion a t  2 50 
for 3 0  min ) the suspens ion vlas u s e d  for b inding assay s . 
;Fo r b inding as says a membrane s uspens ion from 10 mg (<;vet Hei ght)  




-cyc lohexy ladenos ine in  2 ml final vo lume Tris ' HCI 
buffer was incub ated for 12 0 min at 2 5
0 C .  Samp les \'le r e  then f i l t ered 
through Wha tman GF /B filters us ing a B rande l Ce1l Counter 
(Gaither sb urg , MD) and Hashed three times Hith 4 ml ice co ld Tr is ' HCl 
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buffer . '111e f il te r dis c s  ,.ere removed and radioac t iv i t y  de termined by 
l iquid sd.n t i1la t ion spe c tr ome try . Nonspe c i f ic b ind ing w a s  l e s s  t h an 
1 0 %  o f  t o tal b inding a s  de f ined with 1 0  �M 2-chloroadenos ine . B ind ing 
assay s  we re carried o u t  in t r ip l ic ate . Bind ing s i tes f o r  r 3H ] N6-cyc lo­
hexyladen o s ine in r at b r a in memb r anes exhib it a KD of ab ou t 1 nN and a 
dens ity o f  ab out 1 0  pmo l p e r  mg pro t e in . 
As say fo r An t ineoplastic  Ac t iv i ty .  
For d e termina t io n  o f  cy t o t oxic i ty o f  c and id a t e  d rugs 83a-+i3 , 9 l a , 
918 agains t L12l0 ce l l s in cul ture , 100 c e l l s  �.ere placed in a s cre\.­
cap tub e cont a ining 5 ml o f  Fis che r ' s medium ( Z4 6) "'i t.h 0 . 1 5% agar and 
to which has been added e i the r  no d rug ( c on t r o l s )  or the cand id a t e dru g  
a t  var ious c oncen t ra t ion . The screw-cap s  were lo os e ned an d the cul­
tur e s  \-rere inc ub ated at 3 7
°
C for 7 days in a humidified a tmosphe r e o f  
5% COZ ' The number o f  co lonies forme d  ,.as then counted v isually under 
a micr os cope . 
In o rd er to det ermine cytoxicity o f  candidate drugs §a-+i3 , 9 la , and 
918 aga in s t  H , Ep- 2  ce lls , app r oximat ely 100 c e l l s  from a s t ock culture 
of H , Ep-Z cells ,.ere p la c e d  in 4-ounce p r e s c r ip t ion b o t t l e s  con t a in ing 
10 ml of SRI- 1 4  med ium ( 2 4 7 ) for the contro ls an d f or the cul tur es in 
vh ich the candidate drug had been added a t  var ious c oncentra t ions . Af­
te r the cultures ""ere incub a t e d  at 3 7 °C for 7 - 1 0  days , the me dium vTaS 
de can te d ; and the cells adhering to the g la s s wer e "Ta shed �.;rith pho s ­
phat e-buf f e red 0 , 85% NaC l  solu t ion ( pH 7 . 0 ) ,  and the number of c o lon ies 
formed were then c ounted visually under a mi cr o s c op e , 
For . the in vivo tes t ing , the L12l0 leukemi a ,vas induced in DBA/ 2  
mice and 0 , 1  m l  of dilute d a s c i tic f luid ( 105 cells ) wa s adminis tered 
by the intr.aperi toneal rout e t o  female DBFl mi ce . Dos ing v ith the 
1 6 3  
potent ial ant itumor comp ounds 84�� and 83�B was s t ar t ed 2 4  hours 
la t e r . Cont r o l  l i f e  span ",'as 8-11 days . The Na t ional Cancer Ins ti­
t u t e ' s  protocol for s creening comp ound s  agains t leukemia  L1 2 1 0  was 
f o llowed ( 2 44) ; de t a i l s  are shown in App en d ix I .  
The nuc l e o sldes 8 3 �+B , 155  and l.2§P ,,,ere evalua t e d  again s t lymp­
h o id leukemia L1210 in female BDF 1 mice . S ix anima l s  ,,,ere used in each 
t e s  t and control group . The comp ounds ,,,ere adminis t e r ed by in trap e r i­
toneal route (aqueous suspen s i on) and dosage var ied from 11 . 2 5 mg / kg up 
t o  180  mg/kg . The mice were dosed daily for 5 d ays � c ontrol lif e sp an 
,"as 5 d ays . 
1 64 
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Ap p end ix I 
P r o to co l  f o r  s cr e ening compound s ag a ins t lympho id l eukemia L 1 2 l 0 . 
1 7 9  
Lymphoid Leukem ia L 1 21 0  Protocol 1 .1 00 
L1 21 0 :  Asci t i c  fl u id implanted i n  B D F ,  o r  C D F ,  mice. Treatment 
begins 24 hours after implant. Results expressed as a 
percen tage of control survival time. Under normal con ditions, 
the inocu lum site for primary screening is ip, the drug is 
a d m i nistered ip, and the parameter is mean survival time 
( test system code, 3LE21 ; see Appendix I and Appendix II). 
For testing other than plimary screen ing, the information 
in this Protocol may vary by i nstruction from DR&D. 
Origin of tumor line: induced in 1948 in spleen a n d  lymph 
nodes of m ice by painting skin with l\1CA.l 
ANI MALS ( see Protocol 8 )  
Propagation : DBA/2 mice (or BDFl o r  CDF1 
for one generation if DBA/2 are not avail­
able) . 
Testing: BDFI ( C57BL/6 x DBA/2) or CDF1 
(BALB/c x DBA/2 )  mice. 
Weight: Within a 3-g weight range, with a 
minimum weight of 18 g for males and 17 g 
for females. 
Sex: One sex used for all test and control 
animals in one experiment. 
EXPERI M ENT S I ZE (see Protocol 9)  
Gen era l Testing :  Six animals per test group. 
Control Groups : Number of animals varies 
according to number of test groups. 
TUMOR TRANSFER (see Proto(;ols 5 and 6)  
Implant : Inject ip. 
Size of Imp l ant : 0.1 ml of diluted ascitic fluid 
containing 105 cells. 
Time of Transfer for Propagation : Day 6 or 7. 
Time of Transfer for Testing: Day 6 or 7. 
TESTING SCH E D U LE (see Protocols 3 and 4) 
Day 0:  Implant tumor. Run bacterial cultures 
(see Protocol 7 ) . Determine solubil­
ities. Thaw solutions. Prepare ma­
terials. Run positive control in every 
odd-numbered experiment. Record 
survivors daily. 
Day 1:  Check cultures. Discard contaminated 
groups. Weigh and randomize animals 
(see "Protocol 10) . Treat as instructed. 
Day 2:  Recheck cultures. Discontinue testing 
if contaminated. ' 
' J  Natl Cancer Inst 13(5 )  : 1 328, 1953. 
Day 5 :  Weigh animals and record. Prepare 
fresh compound for subsequent test­
ing. 
Day 20:  If there are no survivors except those 
treated with positive control com­
pound, evaluate experiment. 
Day 30 : Kill all survivors and evaluate experi­
ment. 
QUALITY CO NTROL ( see Protocol 7 )  
AcceptabJe control survival time i s  8-1 1 days. 
Positive control compound is 5-fluorouracil 
(NSC-19893 ) : single dose = 200 mg/kg/ 
injection, intermittent dose = 60 mg/kg/ 
injection, and chronic dose = 20 mg/kg/ 
injection. T/C lower limit for positive con­
trol compound is � 135 % .  Check control 
deaths, no takes, etc. 
EVALUATION ( see Protocol 1 1 )  
Compute m ean animal weight o n  Days 1 and 5, 
and at the completion of testing compute 
T/C for all test groups \vith > 65 % survi­
vors on Day 5. A T/C value ::; 85 % indicates 
a toxic test. An initial T /C � 125 % is con­
sidered necessary to demonstrate activity. 
A reproduced TIC > 125 % is considered 
worthy of further study. For confirmed ac­
tivity a synthetic must have two multi-dose 
assays (each performed at a different lab­
oratory) that produce a T/C � 125 % ; a 
natural product must have two different 
samples that produce a TIC � 125 % in ' 
multi-dose assays. 
REPORTING 
O n  the final day of  testing, prepare final control 
and test reports and send for key-punching. 
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